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1. Introduction 
The purine nucleoside adenosine is consensually identified as a ma-
jor local regulator of tissue function especially when energy supply 
fails to meet cellular energy demand. Due to its ability to equalize 
energy intake to metabolic demand in the 1980s it earned the reputa-
tion of a “retaliatory metabolite”.1 
Adenosine is omnipresent, released from almost all cells, and gener-
ated in the extracellular space by breakdown of ATP through a series 
of ectoenzymes, including apyrase (CD39) and 5′-nucleotidase 
(CD73).2 The latter dephosphorylates extracellular AMP to adeno-
sine, regulating the limiting step for its formation. Extracellularly, 
adenosine concentration is kept in equilibrium by reuptake mecha-
nisms operated through the action of specific transporters. Then in-
side the cell it is phosphorylated to AMP by adenosine kinase or de-
graded to inosine by adenosine deaminase (ADA). Intracellularly, 
adenosine formation is dependent upon the hydrolysis of AMP by an 
intracellular 5-nucleotidase or hydrolysis of S-adenosyl-
homocysteine. It is estimated that the levels of adenosine in the in-
terstitial fluid are in the range 30-300 nM.3  
Adenosine concentrations increase under metabolically unfavorable 
conditions. Tissue hypoxia, for example, leads to an enhanced 
breakdown of ATP and the increased generation of adenosine. In 
addition to this route, the release of adenosine might be potentiated 
by hypoxia-dependent inhibition of the salvage enzyme adenosine 
kinase which rephosphorylates the nucleoside to AMP.4  
As adenosine is unstable and its half-life is limited by deamination or 
cellular reuptake, hypoxia-induced increase typically affects only lo-
cal adenosine receptor signaling. As adenosine is not released in a 
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transmitter or hormone-like fashion, it is likely to belong to the group 
of autacoids. 
Adenosine mediates its effects through activation of a family of four 
G-protein-coupled adenosine receptors (ARs), named A1, A2A, A2B 
and A3. These receptors differ in their affinity for adenosine, in the 
type of G proteins that they recruit, and finally in the downstream 
signaling pathways that are activated in the target cells. A1 and A3 
ARs display high and low affinity for adenosine, respectively, and are 
inhibitory toward regulation of adenylyl cyclase activity. By contrast, 
activation of high-affinity A2A and low-affinity A2B subtypes stimulates 
adenylyl cyclase leading to an increase of cyclic AMP (cAMP) levels. 
Early pharmacological evidence for the existence of ARs has been 
provided by specific antagonism by methylxanthines, caffeine, and 
theophylline of adenosine-induced effects in the heart and brain.5 
These receptors are widely distributed through the body, and their 
presence on basically every cell makes them an interesting target for 
the pharmacological intervention in many pathophysiological situa-
tions linked to an increase of adenosine levels. 
The first recorded report describing evidence for an ARs originates 
from 1976. Now, 30 years later, advances in understanding the role 
of adenosine and its receptors in physiology and pathophysiology as 
well as new developments in medicinal chemistry of these receptors 
have enabled researchers to identify potential therapeutic areas for 
drug development. 
With the combination of pharmacological data, using selective 
ligands and genetically modified mice, important progress has been 
made toward an understanding of the role of ARs in a variety of dis-
eases, such as inflammatory conditions, sepsis, heart attack, ische-
Chapter 1                                                                                       Introduction 
 
5 
mia-reperfusion injury, vascular injury, spinal cord injury, chronic ob-
structive pulmonary disease (COPD), asthma, diabetes, obesity, in-
flammatory bowel disease, retinopathy, and Parkinson’s Disease 
(PD). Nonselective AR antagonists are used to maintain wakefulness 
(caffeine) and, less commonly at present, treat bronchospasm (theo-
phylline, aminophylline, enprofylline). Currently a number of new se-
lective AR agonists and antagonists are in testing for a variety of new 
indications.  
 
1.1. A2A Adenosine Receptor 
1.1.1. Pharmacology 
The gene for the A2A AR has been cloned from several species in-
cluding dog,6 rat,7,8 human,9 guinea pig,10 and mouse11 and demon-
strated a high degree of homology among human, mouse, and rat.12 
The A2A AR stimulates adenylyl cyclase activity through the coupling 
with Gs proteins leading to activation of cAMP-dependent protein 
kinase A. This in turn phosphorylates and activates various recep-
tors, ion channels, phosphodiesterases, and phosphoproteins like 
CREB and DARPP-32.13-15 Activation of protein kinase C has been 
also reported in PC12 cells.16 In brain striatum the A2A subtype stimu-
lates Golf, another member of the Gs subfamily of G proteins.17 In ad-
dition A2A AR can interact with different types of Ca2+ channels to ei-
ther increase intracellular Ca2+ or decrease Ca2+ influx18,19 and is in-
volved like the other adenosine subtypes in the modulation of ERKs 
activity.20 
Due to a long carboxy terminal domain, the A2A AR shows a greater 
molecular weight (45 kDa) in comparison to the other subtypes (36-
37 kDa). The A2A AR C terminus has been defined as a crowded 
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place where different accessory proteins may interact such as D2-
dopamine receptors,21 R-actinin,22 ADP-ribosylation factor nucleotide 
site opener (ARNO),23 ubiquitin-specific protease (USP4),24 and 
translin-associated protein X (TRAX).25 The lack or presence of such 
different partners may explain conflicting results deriving by A2A ARs 
activation, e.g., neuroprotection versus neurotoxicity.26 
Within the brain A2A ARs are richly expressed in the striatum, nu-
cleus accumbens, and olfactory tubercle. A coexpression of A2A with 
D2 dopamine receptors has been reported in the GABAergic striato-
pallidal neurons where adenosine and dopamine agonists exert an-
tagonistic effects in the regulation of locomotor activity. Activation of 
A2A ARs in striatopallidal neurons decreases the affinity of D2 recep-
tors for dopamine, antagonizing the effects of D2 receptors (Fig.1). 
The negative interaction between A2A and D2 receptors is at the basis 
of the use of A2A antagonists as a novel therapeutic approach in the 
treatment of PD.27 In addition, A2A ARs may have an important role in 
the neurodegenerative process. Accordingly, a neuroprotective effect 
was demonstrated after caffeine intake or A2A AR inactivation against 
dopaminergic neurodegeneration in a neurotoxin model of PD.28 
Concomitantly, two large prospective epidemiological studies have 
strongly associated caffeine consumption to a reduced risk of devel-
oping PD.29,30 Last, the recent discovery that the A2A can form func-
tional heteromeric receptor complexes with other Gprotein- coupled 
receptors such as D2 and the mGlu5 receptors has also suggested 
new opportunities for the potential of A2A antagonists in PD.21 In the 
future development of bivalent ligands, able to activate D2 and block 
A2A ARs or antagonize both A2A and mGlu5 subtypes, would be a 
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promising strategy for the treatment of this neurodegenerative dis-
ease.31-33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Functional interactions between dopamine D2, adenosine A2A and me-
tabotropic glutamate 5 receptors in striatopallidal neurons.34 
In addition to the protection against striatal and nigral neuron loss by 
A2A antagonists, there are data also supporting their protective role 
outside the basal ganglia.35 Local injection of an A2A antagonist pre-
vents glutamate-dependent death of neurons in hippocampal cor-
tex36 and also reduced cortical damage in a variety of ischemic 
stroke models. In A2A knockout (KO) mice transient focal ischemia 
caused less neuronal damage in comparison to their wild-type (WT) 
littermates.37 Therefore, it seems that tonic activation of A2A ARs may 
be responsible for dangerous signal during injury, in contrast to the 
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neuroprotective effects induced by endogenous A1 activation. Re-
cently, selective inactivation or reconstitution of A2A ARs in bone-
marrow cells revealed their contribution to the development of 
ischemic brain injury.38 
The involvement of A2A ARs in neuroprotection is likely to be com-
plex as stimulation of this subtype also diminishes brain damage af-
ter excitotoxic and traumatic injury.39,40 
A2A-mediated protection has been reported against ischemia in the 
myocardia, kidney, and liver and in ischemia-reperfusion injury in the 
spinal cord.41-44 
High expression of A2A ARs has been found in platelets, leukocytes, 
vascular smooth muscle and endothelial cells with important implica-
tions in the regulation of inflammatory responses. It is now well es-
tablished that stimulation of the A2A AR in immune cells induces anti-
inflammatory effects, mostly due to its ability to increase cAMP lev-
els, which has strong immunosuppressive effects.45 Stimulation of 
A2A ARs inhibits neutrophil adherence to the endothelium, degranula-
tion of activated neutrophils and monocytes, plus superoxide anion 
generation. A2A ARs have been recently defined as sensors and ter-
minators of proinflammatory activities. The strongest evidence for the 
key role of A2A in inflammation derived by the elegant study of Ohta 
et al.46 using mice deficient in A2A ARs. In this model the lack of A2A 
subtype leads to increased tissue inflammation and damage, thus 
suggesting a negative and nonredundant regulatory role for the A2A 
AR. This model permits one to appreciate that adenosinergic regula-
tion of immune cells is fundamental in normal physiological control of 
inflammation in vivo in spite of the fact that other Gs-protein-coupled 
receptors and cAMP elevating ligands are present such as catheco-
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lamines, prostaglandins, dopamine, and histamine.45 Interestingly, 
the A2A AR has been demonstrated to be involved in promotion of 
wound healing and angiogenesis in healing wounds.47,48 
Moreover, it plays an active role in the pathogenesis of dermal fibro-
sis, suggesting a role for antagonists as novel therapeutic approach 
in the treatment and prevention of dermal fibrosis in diseases such 
as scleroderma.49 
 
1.1.2. A2A Adenosine Receptor Antagonists 
The discovery and development of potent and selective A2A AR an-
tagonists became, in the last 10 years, an attractive field of research 
to the discovery of new drugs for the treatment of neurodegenerative 
disorders, such as PD. 
Different compounds have been deeply investigated as A2A AR an-
tagonists, which could be classified in two great families: nitrogen 
polyheterocyclic systems and styrylxanthine derivatives. Table 1 
summarizes the examples of A2A AR antagonists reported in this sec-
tion. 
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Table 1. Affinity of AR antagonists at the A1, A2A, A2B and A3 ARs. 
°Ki values for ARs (nM) 
A2A antagonists 
A1 A2A A2B A3 
1, CGS-15943 3.5a 0.15b 71c 50.8d 
2, 8FBPTP *3.351 *1.251 *ND *ND 
3, SCH-58261 54955 1.155 >1000055 >1000055 
4, SCH-63390 35055 1.255 >1000055 >1000055 
5, SCH-442416 1,11154 0.04854 >1000054 >1000054 
7 25353 1.553 ND53 >1000053 
8 4,92755 4.6355 >1000055 >1000055 
9 13955 14055 >1000055 >1000055 
10 2,16055 0.2255 >1000055 >1000055 
11, SCH-BT2 36955 3.855 >1000055 >1000055 
12 ND 0.9459 ND ND 
13, SCH-420814 ND 1.160 ND ND 
14, KF-17837 >1000062 7162 ND 250062 
15, CSC *2800063 *5463 ND >1000063 
16, BS-DMPX *1200 *8.2 ND ND 
17, KW-6002 283066 3666 180066 >300066 
18, ST-1535 72 6.6 352 >1000 
°Binding experiments at recombinant hA1, A2A, A2B and A3 ARs, unless noted; *Binding 
experiments at rat brain (A1) and striatum (A2A) ARs; ND not determined. a Ongini, E.; 
Dionisotti, S.; Gessi, S.; Irenius, E.; Fredholm, B. B. Naunyn Schmiedebergs Arch. 
Phamacol. 1999, 359, 7. b Varani, K.; Gessi, S.; Dionisotti, S.; Ongini, E.; Borea, P. A. 
Br. J. Pharmacol. 1998, 123, 1723. c de Zwart, M.; Vollinga, R.; Beukers, M. W.; Slee-
gers, D. F.; von Frijtag Drabbe Kuenzel, J. K.; de Groote, M.; Ijzerman, A. P. Dru. Dev 
Res. 1999, 48, 95. d Klotz, K.-N.; Hessling, J.; Hegler, J.; Owaman, C.; Kull, B.; Fred-
holm, B. B.; Lohse, M.J. Naunyn Schmiedebergs Arch. Phamacol. 1998, 357, 1. 
 
1.1.3. Medicinal Chemistry 
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines (PTPs) 
9-Chloro-2-furan-2-yl-[1,2,4]triazolo[1,5-c]quinazolin-5-ylamine 
named CGS-15943 (1, Figure 2) represented the first potent but 
poorly selective antagonist for the A2A AR subtype.50 Bioisosteric re-
placement of the phenyl ring of CGS-15943 with an N7-substituted 
pyrazole led to the first example of an adenosine antagonist display-
ing the pyrazolo-triazolo-pyrimidine (PTP) core named 8FBPTP (2, 
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8-(4-fluorobenzyl)-2-(2-furyl)-8H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-
c]pyrimidin-5-amine, Figure 2).51 Some structural features of this 
compound highlighted the essential requirements for the A2A affinity, 
i.e., the furyl moiety and the free amino group at the 5- position. 
Starting from these observations Baraldi et al.52,53 focused their in-
terest on the pattern of substitution on the pyrazolo preserving the 
other structural elements. 
Figure 2. Structural relationships between CGS15943 and 8FBPTP (the first 
A2A AR antagonist) 
2, 8FBPTP1, CGS15493
N N
N
N O
NH2
Cl
N N
N
N
N
N
O
NH2
F
 
Several alkyl, aryl, and phenylalkyl substituents have been intro-
duced at both the N7 and the N8 positions. The biological data de-
rived from the molecules obtained, indicated that the best radicals 
were phenylalkyl chains and among these it was possible to discern 
the length of the spacer introduced between the phenyl ring and the 
pyrazolo nitrogen that was optimized in two or three carbon atoms. 
Two selected compounds of this family named SCH-58261 (3, Figure 
3, 5-amino- 7-(β-phenylethyl)2-(2-furyl)-pyrazolo[4,3-e][1,2,4]triazolo- 
[1,5-c]pyrimidine) and SCH- 63390 (4, Figure 3, 5-amino-7-(3- 
phenylpropyl)2-(2-furyl)-pyrazolo[4,3-e][1,2,4]triazolo[1,5-
c]pyrimidine)52,53 proved to be potent and selective A2A AR antago-
nists both in rat and human models. It was also noted that the N7 de-
rivatives were more selective for the A2A AR than the corresponding 
N8 derivatives. 53 
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From the family of SCH compounds, 5-amino-7-[3-(4- 
methoxyphenyl)propyl]-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-
c]pyrimidine (SCH-442416, 5, Figure 3) was selected for the devel-
opment of a new positron emission tomography (PET) ligand, whose 
chemical structure allows an easy introduction of a methyl group by 
direct O-alkylation of the phenolic function with [11C]CH3I under alka-
line conditions.54 The aim of this study was to use [11C]SCH 442416, 
(6, Figure 3) as a new ligand for the in vivo imaging of A2A ARs using 
PET. The in vitro binding in the brain and periphery, the good signal-
to-noise ratio observed between 5 and 15 min after injection, and the 
low occurrence of radioactive metabolites all suggested that 
[11C]SCH-442416 was applicable as the first non-xanthine ligand 
suitable for the in vivo imaging of A2A ARs using PET. In addition, the 
data obtained from the binding experiments showed a higher affinity 
of the title compound for hA2A vs rat ARs (0.048 vs 0.5 nM).54 
3, SCH-58261 4, SCH-63390
N
N
NN
N
N O
NH2
N
N
NN
N
N O
NH2
Figure 3.  A2A AR anatgonists (Pyrazolo-triazolo-pyrimidines).
6, [11C]SCH-442416
N
N
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5, SCH442416
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12, Analog related 
 to SCH-58261
N
N
NN
N
N
NNO
O
NH2
O
13, SCH-420814
Water-Soluble A2A Adenosine Receptor Antagonists 
The major restriction of the tricyclic adenosine antagonists was the 
low solubility in aqueous media that limited the pharmacological 
screening. Starting from this limit Baraldi et al.53-55 reported a second 
generation of pyrazolo-triazolo-pyrimidines bearing oxygenated sub-
stituents on the phenylalkyl chains at the 7-position (compounds 7-
10). The most interesting compounds are depicted in Figure 4. Com-
pound 7 displayed the best value of A2A AR affinity indicating that the 
4-hydroxy group positively influenced the receptor interaction but 
was not enough for reaching a good profile of water solubility.  
N
N
NN
N
N
NH2
N
N
NN
N
N
NH2
11, SCH-BT2
Figure 4.  Water-soluble A2A AR antagonists.
N N
N
N
N
NN
NH2
NO
7: R = OH
8: R = COOH
9: R = SO3H
10: R = NH2
R
S
O
O
NN
HCl
O
O
O
H3CO
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A water-soluble analogue of SCH-58261, named SCH-BT2 (11, Fig-
ure 4), was prepared by introduction of a 4-methyl-piperazine-1-
sulfonyl moiety at the para position of the phenyl ring. SCH-BT2 al-
tered neither motor behaviour nor produced postural asymmetry by 
itself. However, when infused concomitantly with levodopa (L-DOPA, 
capable of inducing modest controlateral rotational behavior), SCH-
BT2 significantly potentiated the number of contraversive rotations.56-58 
Very recently, a novel series of 3-substituted 8-furyl-[1,2,4]-
triazolo[1,5-i]purin-5-amine analogs related to SCH-58261 was re-
ported as A2A AR antagonists.59 Most of the N3- substituted aryl 
piperazine and piperidine analogs demonstrated in vivo A2A receptor 
binding affinity and A1 receptor selectivity profiles superior to those of 
SCH-58261. In these series compound 12, Figure 4, displayed both 
superior in vitro and promising in vivo profiles.  
Neustadt et al.60 recently reported the arylpiperazine derivatives of 
pyrazolo[4,3-e]triazolo[1,5-c]pyrimidines with antagonist activity on 
the A2A AR. Among these derivatives, SCH-420814 (13, Figure 4) 
demonstrated potent antagonist activity at the A2A AR. Structure-
activity relationship studies revealed additional compounds incorpo-
rating an aryl-piperazine side chain that also showed potent oral ac-
tivity in the haloperidol-induced catalepsy model in rats.  
 
Styrylxanthines 
1,3-Dipropyl-7-methyl-8-(3,4-dimethoxystyryl)-xanthine (14, KF-
17837, Figure 5) was the first A2A AR antagonist in this chemical 
class of compounds.61,62 The 3-chlorostyrylcaffeine 15 (CSC, Figure 
5) was identified as being less potent than KF17837 but with an in-
creased selectivity vs A1 AR subtype.63,64 
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Figure 5. A2A AR antagonists (styrylxantine).
N
N N
H
N OCH3
OCH3
O
O
14, KF-17837
N
N N
N
Cl
O
O
15, CSC
N
N N
N
Br
O
O
N
N N
H
N OCH3
OCH3
O
O
16, BS-DMPX 17, KW-6002
Introduction of a propargyl at the 1- position in combination with the 
8-styryl group in compound 16 (BS-DMPX, Figure 5) increased affin-
ity to the A2A AR with retention of selectivity.65 1,3-Diethyl-7-methyl-8-
(3,4-dimethoxystyryl)- xanthine 17 (KW-6002, also named istradefyl-
line, Figure 5) is an 8-styrylxanthine with high affinity for the rat stri-
atal A2A AR.66 Due to its high affinity and selectivity, a radiolabeled 
derivative, [11C]-KW-6002 labeled at the aromatic O-methyl position, 
was developed to be used in pharmacological testing to trace the A2A 
ARs in vivo.67,68 
 
 
 
 
 
 
 
 
 
 
 
9H-Purine derivatives 
Minetti et al., on the basis of the molecular modeling of a number of 
potent AR antagonists, designed and synthesized a number of 2-
alkyl-substituted purine derivatives as A2A AR antagonists.69 From 
them ST-1535 (2-n-butyl-9-methyl- 8-[1,2,3]triazol-2-yl-9H-purin-6-
ylamine 18, Figure 6), was the most interesting. 
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18, ST-1535
Figure 6. 9H-Purine derivative
 
1.1.4. Clinical Development and Patents 
PD is a progressive, incurable disorder with no definite preventive 
treatment, although drugs are available to alleviate the symptoms 
and/or slow down the progress of the disease. Current therapy is 
based on dopamine replacement therapy, the most common drug 
treatments being dopaminomimetic agents, including L-DOPA, a do-
pamine precursor, as well as direct or indirect dopamine receptor 
agonists. L-DOPA is the mainstay in the treatment of PD but, be-
cause of tolerance problems and a wide range of adverse reactions, 
including involuntary movements and vomiting, a strong demand for 
new therapies exists. Among the various strategies, A2A AR blockers 
are considered a potential approach to treatment of the disease.27, 70 
KW-6002, an adenosine A2A antagonist, is currently undergoing 
phase III clinical trials at Kyowa Hakko for the oral treatment of PD. 
As monotherapy or combination therapy with L-DOPA or dopamine 
agonists, it has been shown to improve the symptoms of the disease 
in a parkinsonian monkey model without increasing the incidence or 
severity of dopaminergic-related side effects or inducing or worsen-
ing dyskinesia. The company had been developing the drug for the 
treatment of depression, but phase II studies were discontinued. In 
mice and rats, KW-6002, like other A2A AR antagonists, dose-
dependently prevented reserpine and haloperidol-induced catalepsy, 
suggesting that it modulates dopaminergic neurotransmission.71,72 
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On the other hand, in D2 receptor knockout mice, which are a model 
of motor impairment that resembles PD, blockade of A2A ARs with 
KW-6002 rescued the behavioral parameters and reestablished al-
tered enkephalin and substance P expression, suggesting a non-
dopaminergic mechanism for the antiparkinsonian activity of KW-
6002.73 KW-6002 improved motor disability in experimental nonhu-
man primate parkinsonian models. Coadministration of KW-6002 and 
L-DOPA/benserazide potentiated the motor effects of levodopa 
(30%) without increasing the dyskinetic response.74,75 Recently low 
doses of KW-6002 coadministered with low doses of L-DOPA at-
tenuated the development of L-DOPA-induced dyskinesia as well as 
rotational responses to repeated L-DOPA in hemiparkinsonian mice. 
These results encourage consideration of future A2A antagonist trials 
in PD that are aimed at reducing the development rather than the 
expression of dyskinesia.76 Kyowa Hakko Kogyo has completed 
three phase III studies of KW-6002 in development for the treatment 
of PD (registration number [clinicaltrial.gov] 6002- EU-007, 6002-US-
013, or 6002-US-018). KW-6002 has a specific antagonistic effect on 
the A2A AR in the brain. The studies were conducted in PD patients 
with wearing-off phenomenon on treatment with L-DOPA alone or L-
DOPA administered concomitantly with other PD medications. Two 
studies were conducted in North America and one study was con-
ducted in 14 countries of the European Union and other regions. 
KW-6002 was administered for 12-16 weeks. The primary endpoint 
was the reduction in the percentage of awake time spent in the “off” 
state, which served as an indicator of the improvement in the wear-
ing-off phenomenon. One of the North American studies revealed a 
statistically significant reduction in the percentage of awake time 
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spent in the off state. The other North American study and the trial 
conducted in the European Union/other regions did not demonstrate 
a significant reduction in percentage of awake time per day spent in 
the off state compared with placebo patients but showed a significant 
improvement or a trend toward improvement in one of the secondary 
endpoints, the motor function score, assessed using the Unified 
Parkinson’s Disease Rating Scale subscore III. Kyowa Hakko in-
tended to submit a new drug application to the Food and Drug Ad-
ministration in the latter half of 2006. The long-term safety of KW-
6002 in patients who have completed 6002-EU-007, 6002-US-013, 
or 6002-US-018 studies has been assessed in an extension phase III 
study started in October 2004 (registration number [clinicaltrial.gov] 
6002-INT-001). Other open-label phase III studies of the continued 
safety of KW- 6002 for patients who completed the prior double-blind 
study 6002-INT-001 started in March 2005 (registration number 
[clinicaltrial.gov] 13711A) and in October 2005 (registration number 
[clinicaltrial.gov] 6002-US-025) and are currently recruiting patients. 
Phase II trials are also under way by the company for the treatment 
of restless legs syndrome (RLS). 
KW-6002 has been patented as a therapeutic agent for behavioral 
disorders,77 anxiety78 and higher brain dysfunction,79 in medicinal 
composition with dopaminergic agents, monoamine oxidase-B 
(MAO-B) inhibitors, or catechol-O-methyltransferase (COMT) inhibi-
tors for PD, RLS, and attention deficit hyperactivity disorder,80 in me-
dicinal composition with antidepressant agent such as the serotonin 
and/or norepinephrine reuptake inhibitors for depression81 and for 
disease accompanied by chronic muscle/skeleton pain82 and drug 
dependence.83 
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SCH-420814 is a selective, orally active A2A AR antagonist discov-
ered by scientists at Schering-Plough and currently under phase II 
investigation for PD.60 It reversed haloperidol-induced catalepsy in 
rats and potentiated L-DOPA induced turning behaviour in neuro-
toxin 6-hydroxydopamine (6-OHDA)-lesioned rats. Also, it was effec-
tive in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
monkey model of PD and several rodent models of depression. 
Pharmacokinetic profiling revealed oral availability of 57%, 41% and 
4% in rats, dogs, and cynomolgus monkeys, respectively. SCH-
420814 and SCH-412348 were tested in vivo in rats treated with the 
A2A agonist CGS-21680, which reduces locomotion. At doses rang-
ing from 0.1 to 1 mg/kg, both compounds dose-dependently reversed 
the effects of the A2A agonist 2-p-(2-carboxyethyl)phenethylamino-5’-
N-ethylcarboxamidoadenosine (CGS 21680). They also potentiated 
L-DOPA-induced turning behaviour in 6-OHDA-lesioned rats at the 
same dose ranges. These results suggest these agents may have 
potential in PD as well as in other conditions associated with reduced 
dopaminergic activity.60 
Both SCH-420814 and SCH-412348 have been patented for PD84 
and other involuntary movement disorders.85 Moreover, SCH 420814 
has been patented as a method for treating anxiety disorders includ-
ing panic disorder, agoraphobia, obsessive-compulsive disorders, 
social phobia, and posttraumatic stress disorder.78 
ST-1535 is an A2A AR antagonist in preclinical phase at Sigma-Tau. 
The compound displayed A2A AR antagonist activity in vivo as it in-
creased spontaneous motor activity in mice and was able to antago-
nize haloperidol-induced catalepsy at a dose of 10 mg/kg. It also ex-
hibited antidepressant activity in the mouse forced swim test. Poten-
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tially useful for the treatment of PD and other motor disorders, it was 
selected for in vivo characterization in animal models.86 ST- 1535 
(10, 20 and 40 mg/kg, per os (po)) when administered alone to 
MPTP-treated common marmosets produced a dose-related in-
crease in locomotor activity and tended to reverse motor disability. 
Treatment with a threshold dose of L-DOPA (2.5 mg/kg, po) pro-
duced an increase in locomotor activity and again tended to reverse 
motor disability.87,88 ST-1535, at oral doses of 5 and 10 mg/kg, an-
tagonizes catalepsy induced by intracerebroventricular administra-
tion of CGS 21680 in mice. Oral ST-1535, at 1.25 and 2.5 mg/kg, po-
tentiates L-DOPA effects in reducing haloperidol-induced cata-
lepsy.89 ST-1535 potentiates the effects of a threshold dose of L-
DOPA in unilaterally 6-OHDA-lesioned rats.88  
Subchronic (18 days, twice a day) ST-1535 (20 mg/kg ip) + L-DOPA 
(3 mg/kg ip) did not induce sensitization to turning behavior or ab-
normal involuntary movements during the course of treatment, indi-
cating a low dyskinetic potential of the drug; acute administration of 
ST-1535 (20 mg/kg ip) proved capable of reducing jaw tremors in a 
tacrine model of Parkinson’s disease tremor, thus representing a po-
tential new compound, with long-lasting activity, for the treatment of 
PD.90 ST-1535 has been patented for the treatment of PD and other 
motor disorders, Alzheimer’s disease, Huntington’s disease, Wilson’s 
disease, and neurodegenerative conditions including cerebral ische-
mia.91 
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1.2. A3 Adenosine Receptor 
1.2.1. Pharmacology 
The A3 AR is the only adenosine subtype cloned before its pharma-
cologic identification.92 It was originally isolated as an orphan recep-
tor from rat testis, having 40% sequence homology with canine A1 
and A2A subtypes.93 Homologs of the rat striatal A3 AR have been 
cloned from sheep and human. Interspecies differences in A3 AR 
structure are large, showing the rat A3 AR only 74% sequence ho-
mology with sheep and human. 
Table 2 . Distribution and therapeutical potential of A3 AR 
A3 ARs activation inhibits adenylyl cyclase activity by coupling with Gi 
proteins.94 In the rat mast cell line RBL- 2H3 and rat brain, A3 ARs 
stimulation activate phospholipase C through Gq proteins.95,96 The A3 
Organ and Tissue 101 A3 Agonist A3 Antagonist 
Heart 
Protection from myocardic 
ischemia, ischemic pre-
conditioning. 
 
Brain 
Cerebrovascular protection 
(chronic treatment), stroke 
prvenction. 
Cerebro-protective (acute 
treatment). 
Eyes  Therapy of glaucoma 
Inflammatory cells 
Antiasthmatic, antiinflam-
matory, immunosuppressi-
ve  
Antiasthmatic, antialergic.  
Tumor cells 
Combination therapy with 
classical chemoterapy 
agents 
Anticancer102 
Chapter 1                                                                                       Introduction 
 
22 
AR is widely distributed with its mRNA expressed in testis, lung, kid-
neys, placenta, heart, brain, spleen, liver, uterus, bladder, jejunum, 
proximal colon and eye of rat, sheep and humans (Table 2).92,97-100 
A dual role of A3 ARs has been reported in the brain. In particular, it 
seems that chronic preischemic administration of the agonist IB-
MECA induces a significant neuronal protection and reduction of the 
subsequent mortality, while acute administration of the drug results 
in a pronounced worsening of neuronal damage and postischemic 
mortality. 
Mice with functional deletions of the A3 AR (A3 AR-/-) reveal a num-
ber of CNS functions where the A3 ARs play a role, including no-
ciception, locomotion, behavioral depression and neuroprotection. 
Consistent with previous reports of the neuroprotective actions of A3 
AR agonists, A3 AR-/- mice show an increase in neurodegeneration 
in response to repeated episodes of hypoxia suggesting the possible 
use of A3 agonists in the treatment of ischemic, degenerative condi-
tions of the CNS.103 To date, much evidence supports that activation 
of A3 ARs is crucial for cardioprotection during and following ische-
miareperfusion and it is likely that a consistent part of the cardiopro-
tective effects exerted by adenosine, once largely attributed to the A1 
AR, may now in part be ascribed to A3 AR activation.104,105 The mo-
lecular mechanism of A3 AR cardioprotection has been attributed to 
regulation of ATPsensitive potassium channels. The cardioprotective 
effects of A3 ARs were also detected in mice overexpressing low lev-
els of A3 ARs without detectable adverse effects, while higher levels 
of A3 expression lead to the development of a dilated cardiomyopa-
thy.106 Similar data were observed in the case of A1 ARs overexpres-
sion.107 
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In addition to reducing injury in myocardial and vascular tissues, 
other beneficial actions at the inflammatory level have been attrib-
uted to the A3 subtype. For example, A3 ARs are expressed in hu-
man neutrophils where they are involved together with A2A in the re-
duction of superoxide anion generation108 and have been implicated 
in suppression of tumor necrosis factor alpha (TNFR) release in-
duced by endotoxin from human monocytes.109 Moreover, A3 activa-
tion seems to inhibit degranulation and superoxide anion production 
in human eosinophils.110 Transcript levels for the A3 subtype are ele-
vated in the lungs of asthma and COPD patients, where expression 
is localized to eosinophilic infiltrates. Similar evidence was observed 
in the lungs of ADA-deficient mice that exhibited adenosine-mediated 
lung disease. Treatment of ADA-deficient mice with MRS 1523, a se-
lective A3 antagonist, prevented airway eosinophilia and mucus pro-
duction. These results are in contrast to experiments performed in 
human eosinophils ex vivo, where chemotaxis was reduced by A3 AR 
activation, suggesting that significant differences exist between the 
impact of A3 signaling on eosinophil migration ex vivo and in the 
whole animal.111 The functional role of the A3 subtype in the patho-
genesis of asthma remains controversial and differences in the 
pharmacology of A3 subtype from different species render it difficult 
to understand whether an A3 AR agonist or antagonist is better for 
use in antiasthmatic therapies. A very interesting area of application 
of A3 ligands concerns cancer therapies. The possibility that A3 AR 
plays a role in the development of cancer has aroused considerable 
interest in recent years.112 A3 subtype has been described in the 
regulation of the cell cycle and both pro- and antiapoptotic effects 
have been reported depending on the level of receptor activation.113-116 
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A3 activation has been demonstrated to be involved in inhibition of 
tumor growth both in vitro and in vivo, leading to the development of 
A3 agonists in clinical trials for colon carcinoma. The molecular 
mechanisms involved in the anticancer effects induced by A3 ago-
nists included regulation of the WNT pathway.117 On the other hand, 
it has been reported that adenosine upregulates HIF-1R protein ex-
pression and vascular endothelial growth factor (VEGF) protein ac-
cumulation by activating A3 AR subtype in tumoral cells, suggesting a 
role for A3 subtype in the regulation of angiogenesis.118 Overexpres-
sion of the A3 subtype has been demonstrated in colon cancer tis-
sues obtained from patients undergoing surgery in comparison to 
normal mucosa. Overexpression in tissues was also reflected at the 
level of peripheral blood cells, rendering this adenosine subtype a 
possible marker for cancer detection.119 Similar data were also found 
in the case of arthritis, where A3 activation shows beneficial effects 
by suppression of TNFR production.120,121 Adenosine receptors have 
been implicated in many ocular and systemic ischemic diseases 
(e.g., retinal ischemia). The A3 KO mouse showed lower intracellular 
pressure, suggesting a role for A3 antagonists in the therapy of glau-
coma.122,123 
 
1.2.2. A3 Adenosine Receptor Antagonists 
A3-selective AR antagonists have been postulated as novel anti-
inflammatory and antiallergic agents; recent studies also indicated a 
possible employment of these derivatives as antitumor agents. In re-
cent years many efforts have been made to search for potent and 
selective hA3 AR antagonists (Table 3). 
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Table 3 
Kia values for ARs (nM) 
A3 antagonists 
A1 A2A A2B A3 
19, PSB-10126 1700b 2700b ND 0.43 
20, KF-26777127 1800 470 620 0.20 
21128 >1000 >1000 >1000 0.80 
22, OT-7999129 °°>10000 °°>10000 °°>10000 0.95 
23, MRS1097133 5930c 4770c NDe 108 
24, MRS1191133 40100c <10%c NDe 31.4 
25, MRS1334134 >100c >100c NDe 2.69 
26, MRS1523135 15600c 2050c NDe 18.9 
27, MRE-3008-F20141 1200 141 2100 0.82 
28, MRE-3005-F20143 250 60 200 0.04 
31, VUF-5574148 >10000c >10000c NDe 4.0 
a Binding experiments at recombinant hA1, A2A, A2B and A3 ARs, unless noted; b Binding experi-
ments at human cortex (A1), striatum (A2A) ARs.; c Binding experiments at rat cortex (A1), striatum 
(A2A) ARs.; d IC50 values; e ND = not determined. 
 
1.2.3. Medicinal Chemistry 
Xanthines 
Natural antagonists for ARs, such as caffeine and theophylline, show 
in general low affinity for the A3 AR subtype.124 Different positions of 
the xanthine core have been modified with the aim of improving A3 
AR affinity. A series of tricyclic imidazo[2,1-i]purinones and ring-
enlarged analogues derived from xanthine derivatives has been pre-
pared as AR antagonists. In comparison with xanthines, the tricyclic 
compounds exhibit increased water solubility due to a basic nitrogen 
atom, which can be protonated under physiological conditions.125 
Among this series PSB-10, 8(R)-ethyl-4-methyl-2-(2,3,5-
trichlorophenyl)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]purin-5-one (19, 
Figure 7), is a high-affinity ligand for A3 ARs (hA3Ki = 0.43 nM) with 
high selectivity over hA1 and hA2A ARs (Ki = 1700 and 2700 nM, re-
spectively). The compound showed inverse agonist activity in binding 
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studies in CHO cells expressing recombinant hA3 ARs (IC50 = 4 
nM).126 Another similar compound is 2-(4-bromophenyl)-7,8-dihydro-
4-propyl-1H-imidazo[2,1-i]purin-5(4H) one, also named KF-26777 
(20, Figure 7), endowed with subnanomolar affinity to hA3 ARs (Ki = 
0.20 nM) and high selectivity over A1, A2A, and A2B ARs (9000-, 
23500- and 31000-fold, respectively). It concentration-dependently 
inhibited 2-chloro-N6-(3-iodobenzyl)-N-methyl-5’-carbamoyl-
adenosine (Cl-IB-MECA) -induced [35S]guanosine 5’-O-(3-
thiotriphosphate) ([35S]-GTPγS) binding to human embryonic kidney 
293 cells (HEK293) (IC50 = 270 nM) and enhanced intracellular Ca2+ 
concentration in human promyelocytic cells (KB = 0.42 nM). This 
agent was indicated for potential interest for treatment of brain 
ischemia and inflammatory diseases such as asthma.127  
The discovery of 1-benzyl-3-propyl-1H,8H-imidazo[2,1-f]purine-2,4-
diones by cyclization between the 7- and 8- positions of the xanthine 
core lead to 21 (Figure 7), a highly potent and selective A3 adenosine 
receptor antagonist.128 This compound shows a subnanomolar affin-
ity (hA3Ki = 0.8 nM) toward the desired receptor target with a note-
worthy selectivity versus the other adenosine receptors subtypes. 
In this field of research the triazolopurine derivatives in which the 
xanthine structure is extended are also reported. One example is 
OT-7999 (22, Figure 7), which proved to be a potent and selective 
hA3 AR ligand. In receptor binding assays, OT-7999 displayed high 
affinity for the A3 AR (Ki = 0.95 nM) and >10500-fold selectivity rela-
tive to other AR subtypes. Significant reductions in intraocular pres-
sure were obtained in cynomolgus monkeys at 2-4 h following topical 
application to the eye of OT-7999 (500 mcg).129,130 
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1,4-Dihydropyridine and Pyridines 
Starting from the experimental observations that 1,4- dihydropyridi-
nes bind A1 adenosine receptors in the rat brain,131,132 Jacobson et 
al. used the 1,4-dihydropyridine nucleus as a template for probing 
the SAR profile at the A3 AR subtype.133 SAR studies of adenosine 
receptor antagonists indicated that sterically bulky groups are well 
tolerated at the 4-, 5-, and 6-positions. The combination of substitu-
tions led to the discovery of MRS 1097 (2-methyl-6-phenyl-4-styryl-
1,4-dihydro-pyridine-3,5-dicarboxylic acid diethyl ester, 23, Figure 8), 
MRS 1191, (2-methyl-6-phenyl-4-phenylethynyl-1,4-dihydro-pyridine-
3,5-dicarboxylic acid 5-benzyl ester, 24, Figure 8), and MRS 1334 (2-
methyl-6-phenyl-4-phenylethynyl-1,4-dihydro-pyridine-3,5-
dicarboxylic acid 3-ethyl ester 5-(4-nitro-benzyl) ester, 25, Figure 8) 
as the first A3 antagonists related to 1,4-dihyropyridines. 
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Figure  8. Dihydropyridine and Pyridine derivatives as A3 AR 
antagonists
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In this study, they also synthesized pyridine derivatives133,134 through 
oxidation of the corresponding 1,4-dihydropyridine. In this class of 
compounds, small groups at the 4-position were found to be essen-
tial such as in MRS 1523 (6-ethyl-5-ethylsulfanylcarbonyl-2-phenyl-4-
propyl-nicotinic acid propyl ester, 26, Figure 8), which showed fa-
vourable affinity at the hA3 AR subtype. Comparing the structural re-
quirements for the two related classes of compounds indicated that 
bulky substituents at the 4- position and a 5-benzyl ester, which are 
affinity enhancing in dihydropyridines, are not well tolerated in the 
pyridine series for A3 receptor binding. At other positions, structural 
parallels occur between corresponding dihydropyridine and pyridine 
analogues.135 
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Pyrazolo-triazolo-pyrimidines (PTPs) 
The pyrazolo-triazolo-pyrimidine nucleus, due to its strong structural 
correlation with the nonselective antagonists CGS-15943, 1, and the 
adenine nucleus present in the endogenous modulator adenosine 
(Figure 9), has been strongly investigated in the past decade as a 
prototypical template for adenosine antagonists.  
NN
N
N O
Cl
NH2 N
NN
N
NH2
O
OHHO
H
HO
N
N
NN
N
N O
1, CGS-15943 Adenosine
Figure 9. Structural correlation with CGS-15943 and the adenine nucleus 
present in the adenosine.
7
8
NH2
 
The triazolo-quinazoline derivative CGS-15943 represented the start-
ing point for searching for new potent and selective hA3 adenosine 
receptor antagonists. 
MRS-1220, a 5-N-phenylacetyl derivative of CGS-15943, in receptor 
binding studies displayed Ki values of 305 ± 51, 52.0 ± 8.8 and 0.65 
± 0.25 nM for rat A1, A2A, and hA3 receptors, respectively, being 470- 
and 80-fold selective for hA3 ARs vs rat A1 and A2A ARs, respec-
tively. MRS-1220 also antagonized the effects of an A3 agonist in 
functional assays.136,137 
An innovative series of tricyclic compounds (MRE series) reported by 
Baraldi’s group represented new selective A3 AR antagonists. In this 
class attention was focused on the N8 patterns of substitution due to 
the quite complete inactivity of the N7-substituted derivatives at the 
hA3 subtype (e.g., SCH-58261).  
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MRE-3008-F20 (27, Figure 10), one of several high affinity antago-
nists, is an A3 AR ligand (Ki = 0.29 nM against 4-aminobenzyl-5’-N-
methylcarboxamidoadenosine ([125I]-AB-MECA) binding to human 
receptors expressed in HEK293 cells) with high selectivity over rat A1 
and A2A ARs (Ki > 10000 and 1993 nM, respectively) as well as hA1 
and hA2A ARs (Ki = 1197 and 141 nM, respectively).138 The com-
pound showed antagonist activity in a functional assay being capable 
of blocking the effect of IB-MECA on cAMP production in CHO cells 
(IC50 = 4.5 nM).139-141 The tritium-labeled compound was able to bind 
hA3 ARs expressed in CHO cells with a KD value of 0.82 nM and a 
Bmax value of 297 fmol/mg protein and represents the first high-
affinity, selective radiolabeled antagonist for this subtype resulting in 
a useful tool for characterization of A3 ARs in both normal and patho-
logical conditions.142 The isosteric replacement of the phenyl with a 
4-pyridyl moiety provided higher hydrosolubility and led to the first 
water-soluble hA3 antagonist (MRE-3005-F20, 28, Figure 10) which 
is an ideal candidate for the pharmacological and clinical investiga-
tions of the hA3 AR subtype.143 
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In molecular modeling studies reported by Moro et al. on pyrazolo-
triazolo-pyrimidines, a combined target-based and ligand-based drug 
design has been carried out to define a novel pharmacophore model 
for the hA3R antagonists. A high-throughput docking strategy has 
been applied on the pyrazolo-triazolo-pyrimidine series. All low-
energy docked conformations have been superimposed and used to 
characterize the common features crucial to the recognition process. 
A novel target-based pharmacophore model has been proposed for 
human A3 AR antagonists. A CoMFA (comparative molecular field 
analysis) approach has been used as an alternative scoring function 
for prediction of ligand receptor binding affinity. The new target-
based pharmacophore model was coherent with the structure-activity 
relationships collected on the pyrazolo-triazolo-pyrimidine ana-
logues.144,145 
Moreover, very recently Botta, Martinelli and Baraldi et al. performed 
a pharmacophoric study using the software Catalyst, which yielded 
three different common feature hypotheses for antagonists of the 
hA3R. The three pharmacophores referred to a recurring scheme 
consisting of three hydrophobic interactions lying at the vertexes of a 
triangle. They seemed particularly good in handling pyrazolo-triazolo-
pyrimidine derivatives.146 These results confirm the importance of 
this tricycle as the most potent class of A3 AR antagonists. 
 
Fluorosulfonyl- and Bis(β-chloroethyl)amino-phenylamino-
pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines 
Synthesis of irreversible A3 antagonists was realized to provide use-
ful tools for structure-activity studies. Electrophilic groups, specifically 
sulfonyl fluoride and nitrogen mustard (bis-(β-chloroethyl)amino) 
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moieties, have been incorporated at the 4-position of the aryl urea 
group (compunds 29 and 30, Figure 11).147  
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Figure 11. A3 irreversible antagonists.
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Compounds containing a fluorosulfonyl moiety proved to be irre-
versible antagonists at the hA3 AR (at 100 nM, 79% of inhibition), 
while the corresponding nitrogen mustard derivatives were unable to 
covalently bind this receptor subtype. This difference in the receptor 
interaction between the 29 and 30 series has been explained on the 
basis of chemical reactivity of the two different groups: the -SO2F 
group is highly reactive versus all nucleophilic functions, while the 
nitrogen mustard reacts only with amino functions. 
 
Isoquinoline and Quinazoline Urea Analogues as Antagonists 
for the Human Adenosine A3 Receptor 
A structure-affinity analysis reported by IJzerman et al.148 indicated 
that at the 2- position of the quinazoline ring or the equivalent 3-
position of the isoquinoline ring a phenyl or heteroaryl substituent in-
creased the A3 AR affinity in comparison to unsubstituted or aliphatic 
derivatives. Combination of the optimal substituents in the two series 
led to the potent hA3 AR antagonist N-(2-methoxyphenyl)-N’-[2-(3-
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pyridyl)quinazolin-4-yl]urea (VUF5574, 31, Figure 12) with a Ki value 
of 4 nM and a selectivity of at least 2500- fold vs A1 and A2A ARs. In 
an in vitro functional assay the compound competitively antagonized 
the inhibition of cAMP production induced by the adenosine agonist 
NECA in CHO cells expressing hA3 ARs with a pA2 value of 8.1.148  
N
N
HN
O
N
31, VUF-5574
Figure 12. Quinazoline urea derivative
N
H OCH3
 
 
1.2.4. Clinical Development and Patents 
At the moment there are not A3 antagonists in clinical phases. How-
ever, in light of the plethora of biological effects attributed to A3 ARs, 
substantial efforts in medicinal chemistry have been addressed to 
develop antagonists for the A3 subtype.149 As a result a number of 
molecules are in biological testing as therapeutic agents for asthma 
and COPD, glaucoma, cancer and stroke. 
Use of A3 antagonists has been patented for inhibition of tumor 
growth.150 The pre- or coadministration of pharmaceutical composi-
tions comprising high-affinity adenosine A3 receptor antagonists, 
such as MRE-3008-F20, has been patented for synergistically ac-
centuating the response to chemotherapy consisting of taxane (e.g., 
paclitaxel), vinca alkaloid (e.g., vincristine), camptothecin (e.g., iri-
notecan), or antibiotic (e.g., doxorubicin) treatment.151 The claim fur-
ther embodies the prevention of multidrug resistance (MDR) and tar-
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geted tumors include those expressing MDRassociated protein 
(MRP), A3 ARs, or P-glycoprotein, as found in leukemia, melanoma, 
and carcinoma of the pancreas, ovary, and lung. Moreover, MRE-
3008-F20 has been also patented for the treatment of cardiac hy-
poxia, allergic diseases, cerebral ischemia, and cancers with high 
concentrations of A3 ARs.152 
Other patents of A3 antagonists also concern their use for cognitive 
disorders, multiple sclerosis, neurodegeneration, PD, stroke, trau-
matic brain injury,153 asthma and COPD,154-157 glaucoma158 and ar-
thritis.159 
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2. Design and Synthesis 
2.1. First Project: Pyrrolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines 
In the last 10 years the pyrazolo-triazolo-pyrimidine (PTP) nucleus 
has distinguished as an attractive key intermediate for obtaining 
adenosine receptor antagonists due to its strong structural correla-
tion with the non-selective AR antagonist CGS15943 (1, Fig. 2 ). A 
wide number of compounds originated from the structure-activity op-
timization work based on the systematic substitution of the N5, N7, 
N8, C2 or C9.160 
According to the literature results, a structure-activity relationship 
(SAR) profile of the pyrazolo-triazolo-pyrimidines could be deline-
ated. 
The furan ring at the 2- position of the nucleus is fundamental for the 
affinity toward all four adenosine receptor subtypes. 
The presence of the free amino group at the 5- position and an ary-
lalkyl chain at the N7 position of the PTPs are essential for both affin-
ity and selectivity at the A2A AR, whereas the concurrent presence of 
the 4-methoxy-phenyl carbamoyl moiety and small alkyl chain (such 
as methyl or ethyl) at the 5- and 8- position, respectively, play an im-
portant role in determining potency and selectivity at human A3 AR. 
Figure 13. 
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In order to identify a new series of A3 AR antagonists and with the 
aim to better investigate the role of the nitrogen at the 7- position on 
the interaction with ARs, we performed a synthetic strategy for the 
preparation of the pyrrolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidine nu-
cleus which can be considered the 7-deaza-analogue of the pyra-
zolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine core (Fig. 13).  
As depicted in scheme 1, commercially available uracil (32) has 
been employed as starting material. The 1,3-dibenzyl-1H-pyrimidine-
2,4-dione 33 was obtained via a bis-alkylation with benzylbromide.161 
Treatment of 33 with p-toluenesulphonylmethyl isocyanide (TosMIC) 
in presence of 60% NaH gave the desired 1,3-dibenzyl-1,6-dihydro-
pyrrolo[3,4-d]pyrimidine-2,4-dione 34 which was then alkylated with 
the appropriate alkyl halide to furnish 6-alkyl-derivatives (35a-d). The 
debenzylation at the 1- and 3- positions with AlCl3 in anhydrous tolu-
ene provided derivatives 36a-d. The 2,4-dichloro-6-alkyl-6H-
pyrrolo[3,4-d]pyrimidines 37a-d were obtained by treatment of 36a-d 
with POCl3 and DBU. Selective substitution of the chlorine atom at 
the 4-position with furoic acid hydrazide followed by a Dimroth rear-
rangement led to the desired pyrrolo[3,4-e][1,2,4]triazolo[1,5-
c]pyrimidine nucleus (39a-d). Compounds 40a-d were obtained 
treating derivatives 39a-d with a solution of ethanol saturated with 
ammonia. These were converted into the corresponding 4-methoxy-
phenyl urea derivatives 41a-c by reaction with 4-methoxy-
phenylisocyanate.  
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REAGENTS: i) NaOH 10%, tetrabutylammonium bromide,  benzylbromide, 
CH2Cl2, 80 °C, 18h; ii) NaH, TosMIC,  Et2O, DMSO, rt, 5h; iii) K2CO3, RX, 
DMF, 40-80 °C, 4h; iv) AlCl3, toluene, 40 °C, 1h; v) POCl3, DBU, 50 °C, 4h; 
vi) 2-Furoic acid hydrazide, TEA, 1,4-dioxane, rfx, 5h; vii) HMDS, BSA, 120 
°C, 18h; viii) EtOH sat. ammonia sol., 60 °C, 18h; ix) 4-OCH3-phenyl 
isocyanate, THF, 50 °C, 18h.
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A relevant problem of the pyrazolo-triazolo-pyrimidines was the typi-
cally low water-solubility which could limit their employment as 
pharmacological and diagnostic tools. 
Compound 5-{[(4-methoxy-phenyl)carbamoyl]amino}-(2-furan-2-yl)-8-
methyl-8H-pyrrolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidine (41a, hA1Ki = 
800 nm, hA2AKi = 500 nm, hA2BIC50 = 838 nm and hA3Ki = 15 nm) is 
characterized by good binding data but, unfortunately, by low water-
solubility, so we tried to improve the hydrophicity of this compound 
by introducing 4-pyridil moiety on the side chain at the 5- position 
(Fig.14), accordingly to a similar efficient strategy previously re-
ported.143 
 
 
 
 
 
 
 
 
Because of the reactivity and instability of the 4-pyridil isocyanate, 
this intermediate was prepared as depicted in scheme 2 , starting 
from the commercially available nicotinic acid hydrazide, which after 
reaction with sodium nitrite under acid conditions afforded the corre-
sponding acyl azide. The latter was heated at reflux for 2 hours in dry 
toluene to give the isocyanate upon Curtius rearrangement. The 
crude isocyanate was heated for 5 hours in dry toluene with com-
pound 40a to give the desired urea derivative 41e.143 
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REAGENTS: i) NaNO2, HCl acq., 1h, 0 °C; ii) Toluene, 2h, rfx; iii) Toluene, 5h, 100 °C.
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Pyrazolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines 
In order to complete the SAR studies on this class of compounds, we 
decided to synthesis a novel series of pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine derivatives which can be considered 
the structural isomers of the parent pyrazolo[4,3-e][1,2,4]triazolo[1,5-
c]pyrimidine derivatives (Fig. 15).  
Figure 15 
 
 
 
 
 
 
Starting from the data obtained from the previous series of pyrazolo-
[4,3-e]triazolo-pyrimidine, we introduced at the N8 or N9 positions, 
small alkyl chain, such as methyl or propyl, and arylalkyl chain, such 
as phenylethyl or phenylpropyl. These modifications allowed us to 
explore the interaction of this side of the molecule with the adenosine 
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receptors. In addition to the substitution at the pyrazole ring, we stud-
ied the 5- position of the PTP structure introducing a free amino 
group, the 4-methoxy-phenyl moiety, a chlorine atom, morpholine 
and substituted piperazine rings.  
For the synthesis of these new compounds we followed the synthetic 
strategy depicted in scheme 3. The 3-methyl-pyrazole (42) has been 
oxidized with KMnO4 and then nitrated at the 4 position with HNO3 
and H2SO4. The carboxylic function was converted into the corre-
sponding carboxamide via esterification and subsequent treatment 
with a solution of NH4OH.162 4-Nitro-1H-pyrazole-3-carboxylic acid 
amide 45 was alkylated with the appropriate alkyl halide and K2CO3 
in DMF to give an approximately 1:1 mixture of the two isomers a 
and b which were efficiently separated via column chromatography. 
The nitro group was then reduced with hydrogen in presence of a 
catalytic amount of C/Pd 10% and intermediates 50-53a,b were con-
verted into the corresponding 1/2-methyl-1,4-dihydro-pyrazolo[4,3-
d]pyrimidine-5,7-dione 54-57a,b by heating with an excess of urea.  
The 5,7-dichloro-1/2-methyl-1H-pyrazolo[4,3-d]pyrimidines 58-61a,b 
were obtained by treatment of 54-57a,b with POCl3 and DBU. Selec-
tive substitution of the chlorine atom at the 7- position with furoic acid 
hydrazide followed by a Dimroth rearrangement led to the desired 
pyrrolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidine nucleus (66-69a,b). 
Compounds 74-77a,b were obtained treating derivatives 66-69a,b 
with a solution of ethanol saturated with ammonia. These were con-
verted into the corresponding 4-methoxy-phenyl urea derivatives 78-
81a,b by reaction with 4-methoxy-phenylisocyanate. Compound 66a 
was also reacted with different primary and secondary amines to 
give final derivatives 70-73.  
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REAGENTS: i) KMnO4, rfx, 4hrs; ii) HNO3, H2SO4, 100 °C, 4hrs; iii) a:H2SO4, EtOH, rfx, 
10hrs; b:NH4OH 30%, 100 °C, 4hrs; iv) alkyl halide, K2CO3, DMF, rt, 10hrs; v) H2, C/Pd 
10%; vi) Urea, 250 °C; vii) POCl3, DBU, 80 °C, 8hrs; viii) 2-Furoic acid hydrazide, TEA, 
1,4-dioxane, rfx, 5h; ix) HMDS, BSA, 120 °C, 18h; x) EtOH sat. ammonia sol., 60 °C, 
18h; xi) 4-OCH3-phenyl isocyanate, THF, 50 °C, 18h; xii) Amines, 2-methoxyethanol, 
100 °C, 3hrs.
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2.2. Second Project: Imidazo[2,1-i]purin-5-ones as A3 adenosine 
receptor antagonists with improved water solubility 
The aim of the second project of this PhD thesis was to obtain A3 
adenosine receptor antagonists with high selectivity and affinity 
along with increased water-solubility. 
We focused our attention on the imidazo[2,1-i]purin-5-one scaf-
fold,126,127,163-166 obtained by the fusion of a third imidazoline ring on 
the xanthine bicycle, as an interesting tricyclic structure useful for the 
development of ARs ligands. A particular attention has been in past 
played to the substitution at the 2- position of the imidazo[2,1-
i]purinone nucleus, which theoretically corresponds to the 8-position 
of the original xanthine core. The crucial role played by the 2-
substituent in the subtype selectivity of the AR antagonists so far re-
ported has been established. Compound KF20274 (82, Fig. 16),163 
substituted at the 2- position with a 3-noradamantyl moiety can be 
structurally associated to the xanthine labelled as KW3902, (1,3-
dipropyl-8-(3-noradamantyl)xanthine). The 3-noradamantyl function 
showed to be able to induce A1 selective antagonist activity in both 
the tricycle KF20274 and the xanthine analogue KW3902. The main 
advantage claimed for the annelation approach of the xanthine core 
into the imidazo[2,1-i]purinone scaffold, is the enhancement of water 
solubility awarded by the imidazoline basic nitrogen which has been 
reported to be subject to protonation at physiological pH. Compound 
83, (Fig. 16) (R)-7,8-dihydro-8-ethyl-2-(4-bicyclo[2.2.2]octan-1-ol)-4-
propyl-1H-imidazo[2,1-i]purin-5(4H)-one,164 is a particularly potent A1 
AR antagonist with good selectivity over the other three AR subtypes 
and high water solubility (>100 mg/mL) and showed a good in vivo 
profile after oral administration in a rat diuresis model. Müller and co-
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worker explored the imidazopurinone nucleus introducing at the 2- 
position substituents previously known to promote A2A or A3 AR activ-
ity in the corresponding 8-substituted xanthine analogues.165 Com-
pound 84 (Fig. 16) has been conceived as water soluble A2A AR an-
tagonist as tricyclic congener of 8-styrylxanthines, while, derivative 
PSB11, (85, Fig. 16), (R)-4-methyl-8-ethyl-2-phenyl-4,5,7,8-
tetrahydro-1H-imidazo[2,1-i]purin-5-one, exhibited a Ki value of 2.3 
nM for A3 receptor and good selectivity vs all other adenosine recep-
tor subtypes. The radiolabelled derivative of this compound 
([3H]PSB-11) exhibited a KD value of 4.9 nM and a Bmax value of 
3500 fmol/mg of protein.166 The 2-(2,3,5-trichlorophenyl) substituted 
analogue, PSB10, showed inverse agonist activity in binding studies 
in CHO cells expressing recombinant hA3 ARs (IC50= 4 nM).126 
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In a recent study performed in Baraldi’s laboratories, a wide series of 
8-heterocyclyl-substituted xanthine derivatives has been identified as 
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very potent and selective human A2B AR antagonists.167 With this se-
ries, whose design based on the structure of the 8-phenyl-xanthine 
derivative MRS1754 (N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-
dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetamide),168 it was dem-
onstrated that the phenyl and the pyrazole rings may occasionally 
behave as bioisosters.  
Given these findings, in the present study we evaluated the effect of 
the replacement of the 2-phenyl ring of PSB11 and congeners with 
differently substituted 5-membered heterocycles, in particular 1,3- 
and 1,5- disubstituted pyrazoles or a 3- substituted isoxazole. At the 
4- position an allyl or a benzyl group have been introduced whereas, 
the 8- position has been functionalized with a methyl or an ethyl, as 
the efficacy of such substituents was suggested by previous SAR 
studies on different series of xanthine-related ARs antagonists. 
Moreover, with the aim to verify a possible enantioselective interac-
tion between the newly reported series of imidazo[2,1-i]purinones 
and ARs, for a selected number of compounds the pharmacological 
properties of the optically pure enantiomers have been compared to 
those of the corresponding racemates. 
The synthesis of the 2-heterocyclyl tricyclic purinone derivatives has 
been performed, in analogy to described procedures, as depicted in 
scheme 7.126,163,165,169 
1-Subsituted-5,6-diaminouracils 95a,b170 and the appropriate pyra-
zole/isoxazole carboxylic acids were reacted in DMF solution in 
presence of 1-ethyl-3-[3 (dimethylamino)propyl]carbodiimide hydro-
chloride (EDAC) as condensing agent, followed by ring closure with 
sodium hydroxide at reflux to afford the desired 3-allyl/benzyl-8-
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[(substituted)isoxazol/pyrazol-3/5-yl]-1H-purine-2,6(3H,7H)-dione de-
rivatives (96a-j).167 
The diamino uracils 95a,b were obtained by reduction of the corre-
sponding nitroso uracils using sodium dithionite.167 
The substituted pyrazole carboxylic acids (87a,b and 91a,b) were 
prepared according to procedures reported in literature (Scheme 4 
and 5).151 
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The 3-methoxy-isoxazole-5-carboxylic acid methyl ester (94, 
Scheme 6), obtained from dimethyl acetylenedicarboxylate172 was O-
alkylated with methyliodide in presence of K2CO3, followed by classi-
cal saponification.  
OMeO
OMeO
N
H
NH2
N
O
OMe
O
MeO
N
O
OH
O
MeO
Scheme 6
REAGENTS: i) DBU, MeOH, 30', rt; ii) CH3I, K2CO3, DMF, 6h, 60 
°C; iii) NaOH 10%, MeOH, 1h, rfx.
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ii iii
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The 8-heterocyclyl-xanthine derivatives 96a-j were treated with phos-
phorous pentasulfide in dry pyridine at reflux to give the correspond-
ing 6-thioxanthine 97a-j. The subsequent reaction with methyliodide 
in presence of sodium hydroxide furnished the S-methyl-derivatives 
98a-j with good yields. Compounds 98a-j were then treated with the 
appropriate amino alchol (2-amino-butan/propan-1-ol purchased both 
as racemic mixtures and optically active reagents), in anhydrous 
DMSO at 150 °C for 1.5 h. Final cyclizations have been performed in 
dichloromethane solution by treatment with thionyl chloride heating 
at reflux for 18 h. This kind of cyclization is known to yield final com-
pounds 119-139 with retained stereochemistry.  
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3. Results and Conclusions 
3.1. First Project: Pyrrolo/pyrazolo-triazolo pyrimidines 
All the synthesized compounds were evaluated in radioligand binding 
assays to determine their affinities at the human A1, A2A and A3 
adenosine receptors. Potency of the compounds versus hA2B adeno-
sine receptors were studied evaluating their capability to inhibit (100 
nM) NECA stimulated cAMP production. Affinity data for A1, A2A and 
A3 receptors, expressed as Ki values, and IC50 values derived from 
the cAMP assay carried out for hA2B subtypes, are listed in Table 4 
and 5. 
The biological experiments was performed by Prof. Borea and co-
workers, Dipartimento di Medicina Clinica e Sperimentale – Sezione 
di Farmacologia, Università di Ferrara. 
Derivatives 40a-d bearing a free amino group at the5- position , were 
substituted at the N8 with, respectively, methyl, propyl, phenylethyl 
and phenylpropyl chains. These compounds can be considered quite 
potent (low nanomolar range) but non selective ligands for the four 
adenosine receptors. In particular, the affinity vs A3 receptor de-
creased with the increase of the steric hindrance in fact derivative 
with phenylpropyl chain was 5-fold less potent then the compound 
with the methyl group. Derivative 40c displayed high affinity toward 
the A1 and A2A receptors (hA1Ki = 4.3 nM and hA2AKi = 3.9 nM) while 
a lower affinity has been detected at the remaining subtypes. A simi-
lar results were found with the compound bearing a phenylpropyl 
moiety 40d. Both methyl group (40a) and propyl chain (40b) showed 
a good Ki values for A2A and A3 but they also bind other two subtypes 
in the nanomolar range. 
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As previously observed, when the phenylcarbamoyl moiety is present 
at the N5 position all the synthesised derivatives 41a-c show affinities 
in the nanomolar range toward A3 receptor with different degree of 
selectivity versus the other receptor subtypes. From the biological 
data, it is evident that methyl group at the 8 position of the pyrrolo tri-
azolo pyrimidine urea (41a) produce the best compound in term of 
both affinity (hA3Ki = 15nM) and selectivity. 
The propyl derivative (41b) showed a high affinity for the human A3 
but it showed a 2- fold increase of A2A affinity with respect to the 
methyl derivative. Growing of steric hindrance at the 8- position with a 
phenyl-ethyl chain (41c) generated a remarkable loss of selectivity vs 
A1 and A2, however maintaining a good potency for A3 subtype. 
The pyridine urea derivative (41e) has been synthesised to improve 
water-solubility but unfortunately it resulted 10-fold less potent then 
the corresponding phenylcarbamoyl compound 41a toward A3 recep-
tor. 
With the aim to better investigate the role of the nitrogen at the 7- po-
sition on affinity toward A3 ARs, we synthesised a series of structural 
isomers of the pyrazolo[4,3-e]triazolo pyrimidine, obtaining a new 
class of pyrazolo[3,4-e]triazolo pyrimidine substituted at the 8- or 9- 
positions. 
The N8 alkylated amino derivatives (74-77b) showed less affinity 
compared with the corresponding N8 pyrrolo-triazolo pyrimidine (40a-
d) at the A3 receptor (125nM < Ki < 526nM) whereas they displayed a 
good affinity toward A2A (8.1nM < Ki < 17nM) and a low selectivity 
versus hA1 and hA2B ARs.  
Introduction of a methyl or propyl chain at the N8 position in combina-
tion with the 4-methoxy-phenyl-urea moiety at the 5- position yielded 
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respectively compounds 78b and 79b. The biological assays showed 
that the propyl compound 79b (hA3Ki = 50 nM) exerted 2-fold higher 
affinity at A3 AR compared to the methyl derivative 78b (hA3Ki = 110 
nM).  
The synthesis of compounds 74-81a allowed us to evaluate the effect 
of the substitution at the N9. 
The increase of the steric hindrance of the substituents at the 9- posi-
tion doesn‘t seems to affect in the same way of the pyrrolic series the 
binding profile of the ligands. Infact, compound with methyl group 
(74a, hA3Ki = 749nM) was 10-fold less active compared to the propyl 
derivative (75a, hA3Ki = 83nM). 
The free amino derivatives (74-77a) confirmed the previous data exi-
biting a good affinity toward A2A AR but, unfortunately, the ligands in-
teracted also with A1 and A2B subtypes in the same range of concen-
tration. Except for the propyl derivative 75a (hA3Ki = 83 nM), the affin-
ity of the free amino compounds toward A3 AR resulted significantly 
lower.  
It is quite difficult to delineate a SAR profile for these class of com-
pounds because the same substitution seems able to exert opposite 
effects; in fact, for example, N8 alkylated (74b, hA3Ki = 125 nM) re-
vealed a lower Ki value at the hA3 than the corresponding N9 alky-
lated (74a, hA3Ki = 749 nM) instead, analyzing the derivatives bearing 
the propyl chain at the 9- (75a, hA3Ki = 83 nM) or 8- (75b, hA3Ki = 
432 nM) position of the nucleus, the binding profile resulted opposed. 
Surprisingly the conversion of the free amino group into the 
corresponding 4-OCH3-phenyleurea derivatives (78-81a) did not 
provide the desired effect on the binding profile of the designed 
compounds. Compounds 78-81a show a slight improvement of the 
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affinity at the A3 adenosine receptor in comparison with the 
corresponding amino derivatives 74-77a but the selectivity versus A1, 
A2A and A2B subtypes resulted quite poor. 
Compound 66a, bearing a chlorine atom and a methyl function at the 
5- and 9- positions respectively, showed to be completely unable to 
bind the four investigated receptors. Among compounds 70-73, in 
which the chlorine atom has been substituted with cyclic amines such 
as cyclohexyl-amine, morpholine, methyl-piperazine and phenyl-
piperazine, only the ciclohexyl-amino derivative (70) showed some 
affinity versus ARs, in particular for A1 receptor. 
These results would confirm previously reported studies indicating the 
importance of the amino function at the 5- position to establish a hy-
drogen bond with the adenosine receptors. 
Interestingly compound 70, bearing the cyclohexyl ring which is a 
typical N6 substitution of NECA (5’-N-ethylcarboxamidoadenosine)-
related A1 AR agonists, resulted a potent A1 antagonist (hA1Ki = 12 
nM) with 12- ,75- and 42- fold selectivity vs A2A, A2B and A3 ARs re-
spectively. 
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Table 4. Binding and Functional Data of derivatives 40a-41e. 
Compd R 
[3H] DPCPX 
binding 
hA1 CHO cells 
Ki (nM) 
[3H] ZM 241385 
binding 
hA2ACHO cells 
Ki (nM) 
cAMP assay in 
hA2BCHO cells 
IC50 (nM) 
[3H] MRE 
3008F20 
binding hA3CHO 
cells Ki (nM) 
40a Me 100 (83-120) 20 (12-31) 42 (31-57) 50 (41-60) 
40b Propyl 35 (27-45) 30 (23-38) 90 (81-99) 55 (46-65) 
40c 2-Phenylethyl 4.3 (3.1-6.0) 3.9 (2.5-6.3) 46 (37-56) 124 (96-161) 
40d 3-Phenylpropyl 18 (13-23) 50 (41-60) 251 (205-306) 241 (176-330) 
41a Me 800 (701-913) 500 (420-595) 838(713-984) 15 (10-21) 
41b Propyl 743 (671-821) 200 (166-240) 906 (852-964) 10 (6-17) 
41c 2-Phenylethyl 178 (148-213) 148 (126-173) 740 (722-759) 12 (10-16) 
41e - 355 (289-437) >1000 (13%) >1000 (8%) 111 (74-167) 
 
a
 Displacement of specific [3H]DPCPX binding at human A1 receptors expressed in CHO cells.  
b
 Displacement of specific [3H]ZM241385 binding at human A2A receptors expressed in CHO cells.  
c
 Potency (IC50) of examined compounds to inhibit 100 nM NECA stimulation cAMP levels in hA2B 
CHO cells. In parentheses are reported the % of inhibition to hA1, A2A, A2B and A3 CHO cells. d Dis-
placement of specific [3H]MRE3008F20 binding at human A3 receprors expressed in CHO cells. 
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Table 5. Binding and Functional Data of derivatives 66a, 70-81a. 
Compd R 
[3H] DPCPX 
binding 
hA1 CHO cells 
Ki (nM) 
[3H] ZM241385 
binding hA2A 
CHO cells Ki 
(nM) 
cAMP assay in 
hA2BCHO cells 
IC50 (nM) 
[3H] MRE3008F20 
binding hA3CHO 
cells Ki (nM) 
66a Cl >1000 (28%) >1000 (40%) >1000 (10%) >1000 (9%) 
70 Cyclohexylamine 12 (8-18) 119 (87-162) 915 (786-1064) 507 (443-582) 
71 Morpholine >1000 (6%) >1000 (4%) >1000 (4%) >1000 (1%) 
72 4-Me-Piperazine >1000 (5%) >1000 (2%) >1000 (2%) >1000 (1%) 
73 4-Ph-Piperazine >1000 (8%) >1000 (9%) >1000 (5%) >1000 (1%) 
74a Me 10 (8-13) 3.6 (2.5-5.3) 31 (25-38) 749 (662-847) 
74b Me 30 (24-38) 8.1 (6.9-9.7) 33 (28-37) 125 (85-182) 
75a Propyl 14 (11-20) 12 (8-18) 40 (35-46) 83 (70-99) 
75b Propyl 22 (18-27) 17 (12-24) 45 (40-51) 432 (363-514) 
76a 2-Phenylethyl 33 (28-38) 42 (37-47) 319 (275-371) 603 (542-670) 
76b 2-Phenylethyl 4.9 (3.4-7.2) 9.2 (7.9-10.6) 27 (23-32) 315 (255-390) 
77a 3-Phenylpropyl 85 (68-105) 122 (86-172) 595 (502-706) 802 (719-895) 
77b 3-Phenylpropyl 7.1 (5.7-8.9) 11 (9-13) 32 (28-37) 526 (482-575) 
78a Me 129 (97-172) 68 (55-84) 122 (84-177) 61 (42-88) 
78b Me 923 (878-970) 222 (181-273) 580 (453-742) 110 (93-130) 
79a Propyl 61 (44-85) 20 (14-29) 32 (26-45) 161 (132-196) 
79b Propyl 240 (222-259) 208 (177-245) 863 (801-930) 50 (45-56) 
80a 2-Phenylethyl 524 (421-652) 626 (546-717) 772 (660-902) 208 (153-283) 
81a 3-Phenylpropyl >1000 (38%) >1000 (32%) >1000 (32%) >1000 (25%) 
 
a
 Displacement of specific [3H]DPCPX binding at human A1 receptors expressed in CHO cells.  
b
 Displacement of specific [3H]ZM241385 binding at human A2A receptors expressed in CHO cells.  
c
 Potency (IC50) of examined compounds to inhibit 100 nM NECA stimulation cAMP levels in hA2B 
CHO cells. In parentheses are reported the % of inhibition to hA1, A2A, A2B and A3 CHO cells. d Dis-
placement of specific [3H]MRE3008F20 binding at human A3 receprors expressed in CHO cells. 
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3.2. Second Project: Imidazo[2,1-i]purin-5-ones 
All the 2-heterocyclyl-imidazo[2,1-i]purin-5-one derivatives 119-138 
(Table 6 ) were evaluated in radioligand binding assays to determine 
their affinities for human A1, A2A, and A3 adenosine receptors using 
[3H]-DPCPX (1,3-[3H]-dipropyl-8-cyclopentylxanthine), [3H]-ZM 
241385 (4-(2-[7-amino-2-(2-furyl)[1,2,4]-triazolo[2,3-a][1,3,5]triazin-5-
ylamino]ethyl)phenol), [3H]-MRE3008F20 (5-N-(4-
methoxyphenylcarbamoyl)amino-8-propyl-2-(2-furyl)pyrazolo[4,3-e]-
1,2,4-triazolo[1,5-c]pyrimidine), respectively, as radioligands. Effi-
cacy of the compounds versus hA2B AR was investigated evaluating 
their capability to inhibit (100 nM) NECA stimulated cAMP produc-
tion. Antagonism of selected ligands versus hA3AR was also as-
sessed through cAMP experiments performed evaluating their capa-
bility to block the inhibitory effect mediated by Cl-IB-MECA. Affinity 
data for A1, A2A and A3 receptors (expressed as Ki values), and IC50 
values for hA2B subtypes, derived from the cAMP, are listed in Tables 
6, 7.  
The biological experiments was performed by Prof. Borea and co-
workers, Dipartimento di Medicina Clinica e Sperimentale – Sezione 
di Farmacologia, Università di Ferrara. 
Structure-Activity Relationships Analysis: hA3AR Affinity. All the 
synthesised molecules exhibited high affinity at the hA3AR subtype 
with Ki values ranging from 1.46 (compound R-124) to 44.8 nM 
(compound 129). The different kind of heterocycle introduced at the 
2- position gave various contributions to the binding profile of the ex-
amined imidazo[2,1-i]purin-5-one derivatives. The affinity at hA3AR of 
4-allyl-2-(1′,5′-dimethyl-pyrazole) derivatives (119, 120) showed to be 
about 3/4-fold higher then that of the corresponding 4-allyl-2-(1′,3′-
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dimethyl-pyrazole) isomers (131, 132 respectively), whereas, 4-
benzyl-2-(1′,5′-dimethyl-pyrazole) derivatives (121, 122) show hA3 
AR Ki binding values similar to those of the corresponding 4-benzyl-
2-(1′,3′-dimethyl-pyrazole) derivatives 133 and 134. This would indi-
cate that 1′,5′-disubstitution of the 2-pyrazole ring is equivalent or 
slightly detrimental, with regard to hA3 binding affinity, if compared 
with 1′,3′-disubstitution. The comparison between hA3 affinities of 2-
(1′-methyl-3′-methoxy-pyrazole) derivatives 123-126 and 2-(3′-
methoxy-isoxazole) derivatives 135-138 indicated a substantial bioi-
sosterism of these heterocycles as regards the interaction with hA3 
AR of the examined ligands. As indicated by the affinity values of 
compounds 119-130, the type of substitutions at the 3′-position of the 
2-pyrazole ring appreciably affects the affinity for the hA3 AR. The 
order of efficacy OMe (compounds 123-126) > Me (119-122) > OBn 
(127-130) is maintained in the whole subset of molecules. For exam-
ple the 3′-OCH3-derivative 123 (hA3Ki = 2.36 nM) appeared 2- and 
10-fold more potent in binding hA3 subtype than the analogously 
substituted 3′-CH3-derivative 119 (hA3Ki = 4.56 nM) and 3′-OBn-
derivative 127 (hA3Ki = 24.7 nM), respectively. Similarly, the 3′-
OCH3-derivative 124 (hA3Ki = 1.96 nM) resulted 1.5- and 11-fold 
more potent then the corresponding 3′-CH3-derivative 120 (hA3Ki = 
3.01 nM) and 3′-OBn-derivative 128 (hA3Ki = 21.5 nM), respectively, 
at the hA3AR. This trend led us to synthesise 3′-OCH3-isoxazole de-
rivative 135-138 which confirmed the efficacy of the introduction of a 
methoxy group at the 3′- position of the 2- heterocycle. From the set 
of molecules we analysed, it emerged that the kind of substitutions of 
the 5-membered heterocycle at the 2- position of the imidazo[2,1-
i]purin-5-one tricycle, is particularly important for hA3 AR binding af-
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finity. A steric control seems to take place around the 3′-position of 
the 2-heterocycle, as suggested by the decrease of affinities of the 
3′-OBn derivatives 127-130 (hA3Ki ranging from 21.5 nM to 44.8 nM). 
Moreover the angularity component of the 3′-OCH3, in association 
with the possibility of this function to establish a hydrogen bond, 
could contribute to favour particular ligand-receptor interactions.  
A benzyl or an allyl substituent have been introduced at the 4-
position of the imidazo[2,1-i]purin-5-one core. The pairwise compari-
son between the Ki (hA3) values of 4-allyl and 4-benzyl derivatives 
resulted in most cases in a fairly prevalent affinity of the allyl-
substituted compounds (i.e. compounds 121, 122, 126 were 3.8-, 
1.6- and 2-fold less potent then the correspondent 4-allyl derivatives 
119, 120, 124 as hA3 ligands). Nevertheless some exceptions have 
been observed (see compounds 133, 134, 137 versus 131, 132, 135, 
respectively). 
The substitution of the 8- position with a methyl or an ethyl seems to 
be essentially equivalent in terms of hA3 affinity, as it can be de-
duced from the binding equipotency between 8-methyl and 8-ethyl 
derivatives. For example, compounds 119 exhibited a binding affinity 
similar to that of the correspondent 8-ethyl derivative 120. The same 
can be observed, for example, for compounds 127, 129, 131 versus 
128, 130 and 131, respectively.  
The monosubstitution of the C8 generated an asymmetric carbon. 
For selected compounds (119, 122, 124, 125, 132) both racemic 
mixtures and optically active derivatives have been prepared in order 
to determine a stereoselective criterion for the interaction with hA3 
AR. The affinities of racemates appeared generally comparable to 
those of the respective R and S pure isomers. Only a very weak pref-
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erence for the R isomer can be noted (R-119 compared to S-119 or 
R-124 compared to S-124) with the exception of compound 132. The 
data related to the 8- position seem to suggest that this side of the 
molecule could not be involved in determining interactions with the 
hA3 receptor binding site. In fact, neither the kind of substitution nor 
the stereoisomery of the C8 seem to particularly affect the affinity of 
the ligands for the hA3 AR.   
Structure-Activity Relationships Analysis: hA3AR vs hA2A and 
hA1 ARs Selectivity. Very high level of hA3 vs hA2A selectivity has 
been obtained with all the compounds. Indeed, with the exception of 
derivatives 129 (hA2AKi = 2010 nM), 130 (hA2AKi = 2130 nM) and 136 
(hA2AKi = 1520 nM), the Ki values calculated in the binging assay at 
the hA2A AR were higher then 5 µM. Whereas, the affinity at the hA1 
AR subtype resulted occasionally relevant (lower then 1 µM for com-
pounds 120, 122, 126, 138). Comparing the type of heterocycle at 
the two position, the 1,5-disubstituted pyrazole seems to assure a 
low affinity at the hA1 AR, however, derivatives 131-134 (hA1Ki > 5 
µM), displaying from about 330- to 540-fold selectivity for the hA3 AR 
over the hA1 AR, are not the most selective of the series because of 
the concomitant small reduction of hA3 affinity. The most selective 
derivatives have been obtained with the introduction of the 2-(1′-
methyl-3′-methoxy-pyrazole) or the 2-(3′-methoxy-isoxazole) func-
tions (derivatives 123-126 and 135-138 respectively), in particular 
compounds 123 (4-allyl-7,8-dihydro-2-(3-methoxy-1-methyl-1H-
pyrazol-5-yl)-8-methyl-1H-imidazo[2,1-i]purin-5(4H)-one) and 137 (4-
benzyl-8-methyl-7,8-dihydro-2-(3-methoxyisoxazol-5-yl)-1H-
imidazo[2,1-i]purin-5(4H)-one) appeared the most selective of the se-
ries of the 2-heterocyclyl-imidazo[2,1-i]purin-5-ones herein de-
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scribed, displaying more than 2100- and 1800-fold selectivity, re-
spectively, for the hA3 AR over the other ARs subtypes. The kind of 
substituent at the 3′-position of the 2-(1′,3′-disubstituted-pyrazole) 
moiety seems somewhat to affect the selectivity of the ligands for the 
hA3 vs hA1 AR, in fact the related affinities ratios (hA1Ki / hA3Ki) 
clearly suggested that the selectivity follows the sequence  3′-OMe > 
3′-Me > 3′-OBn, for example compound 123 (3′-OMe), 129 (3′-Me) 
and 127 (3′-OBn) were 2100-, 450- and 202-fold selective for hA3 vs 
hA1, respectively. The same can be noticed in the comparison be-
tween compounds 124 (3′-OMe, hA1Ki / hA3Ki = 780), 120 (3′-Me, 
hA1Ki / hA3Ki = 170), 128 (3′-OBn, hA1Ki / hA3Ki = 56) as well as be-
tween compounds 125 (hA1Ki / hA3Ki = 610), 121 (hA1Ki / hA3Ki = 
291), 129 (hA1Ki / hA3Ki = 57) and derivatives 126 (hA1Ki / hA3Ki = 
105), 122 (hA1Ki / hA3Ki = 60), 130 (hA1 Ki/ hA3Ki = 42). 
In most of the evaluated examples the 4-allyl substitution seems 
quite more favourable for hA1Ki / hA3Ki selectivity in comparison with 
4-benzyl substitution. For example the 4-allyl derivative 119 (hA1Ki / 
hA3Ki = 450) is 1.5-fold more selective for hA3 vs hA1 then the corre-
sponding 4-benzyl derivative 121 (hA1Ki / hA3Ki = 290). The same 
behaviour can be observed for compounds 123 (hA1Ki / hA3Ki = 
2119) which is 3.5-fold more selective then the corresponding 4-
benzyl substituted 125 (hA1Ki / hA3Ki = 610), et cetera. The only ex-
ceptions to this leaning are compounds 131 (hA1Ki / hA3Ki = 359) 
compared to 133 (hA1Ki / hA3Ki = 400), in which the 4-substitution 
with a benzyl or an allyl functions seems practically equivalent, and 
compounds 135 (hA1Ki / hA3Ki = 1397) compared to 137 (hA1Ki / 
hA3Ki = 1866), in which the effect on hA3 vs hA1 selectivity of the two 
substituents at the 4- position appeared reversed.  
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While practically equivalent for the effect on hA3 affinity, the introduc-
tion of a methyl or an ethyl at the 8- position appears to sensibly in-
fluence the affinity of the examined molecules towards hA1 AR sub-
type. The choice of the substituent at this position resulted therefore 
important for the optimization of hA3 over hA1 selectivity. The general 
selectivity pattern would quite strongly suggest a preference by A1 
adenosine receptor for the 8-ethyl substitution. This effect is fairly 
evident if the 8-methyl derivative 137 (hA1Ki = > 50000, hA1Ki / hA Ki 
= 1866) was compared to the 8-ethyl analog 138 (hA1Ki = 485, hA1Ki 
/ hA3Ki = 179). With the exception of compound 134, the molecules 
exerting higher affinity at the hA1 subtype were concomitantly substi-
tuted at the 4- and 8- positions with a benzyl and an ethyl moieties, 
respectively, indicating a synergistic detrimental effect of the two 
substituents on hA3 selectivity. On the contrary, the 4-allyl-8-methyl-
imidazo[2,1-i]purin-5-one derivatives displayed the best hA1Ki / hA3Ki 
ratios of the series.  
A slight level of enantioselectivity seems to concern the interaction of 
the described ligands with the hA1AR subtype. The affinities of S iso-
mers of compounds 119, 122, 124 and 125, resulted from 1.3- to 2.3-
fold higher then those of the corresponding R isomers, thus resulting 
in a higher hA3 vs hA1 selectivity of the R isomers with reference to 
the corresponding S-configured molecules. This data resulted in 
agreement with the marks previously described by Müller and co-
workers165 and appeared to give evidence for a direct involvement of 
the additional imidazolidine ring in critical interactions between the 2-
heterocyclyl-imidazo[2,1-i]purinones and the hA1 AR binding pocket. 
This could be the reason for the responsiveness of hA1 AR binding 
affinities to the kind of substitution and/or the configuration of the C8.  
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Compound R-124 showed to be the most potent hA3 AR ligands of 
the 2-heterocyclyl-imidazo[2,1-i]purin-5-one derivatives herein de-
scribed. It also confirmed to have very high selectivity versus A2A, A2B 
and also at A1 AR with one of the heist value of hA1Ki / hA3Ki ratio of 
the series (1,729).  
 
 
 
 
Table 6. Binding and Functional Data of derivatives 119-130. 
Compd   X Y R A1 Ki (nM)a A2A Ki (nM)b A2B IC50 (nM)c A3 Ki (nM)d 
     119 
  Me Allyl Me 2040 (1710-2450)      >5000 (7%) >5000 (30%) 4.56 (3.44-6.05) 
R-119 Me Allyl Me 2510 (2050-3060) >5000 (1%) >5000 (10%) 5.04 (5.14-6.01) 
S-119 Me Allyl Me 1960 (1540-2480) >5000 (4%) >5000 (12%) 6.03 (5.64-6.38) 
120 Et Allyl Me 515 (437-608) >5000 (8%) >5000 (20%) 3.01 (2.29-3.96) 
121 Me Bn Me >5000 (20%) >5000 (1%) >5000 (8%) 17.2 (12.2-24.0) 
122 Et Bn Me 615 (536-707) >5000 (5%) >5000 (20%) 10.3 (7.9-13.4) 
R-122 Et Bn Me 803 (654-986) >5000 (3%) >5000 (10%) 12.6 (9.4-16.9) 
S-122 Et Bn Me 545 (468-635) >5000 (4%) >5000 (13%) 13.2 (9.7-17.9) 
123 Me Allyl OMe >5000 (30%) >5000 (1%) >5000 (13%) 2.36 (1.60-3.49) 
124 Et Allyl OMe 1530 (1280-1830) >5000 (1%) >5000 (16%) 1.96 (1.22-3.13) 
R-124 Et Allyl OMe 2525 (2106-3027) >5000 (13%) >5000 (21%) 1.46 (0.88-2.42) 
S-124 Et Allyl OMe 1078 (868-1340) >5000 (15%) >5000 (14%) 2.37 (1.48-3.83) 
125 Me Bn OMe 1900 (1720-2090) >5000 (1%) >5000 (11%) 3.11 (2.01-4.80) 
R-125 Me Bn OMe 2550 (2060-3170) >5000 (11%) >5000 (19%) 2.38 (1.79-3.17) 
S-125 Me Bn OMe 1730 (1470-2030) >5000 (1%) >5000 (22%) 2.52 (1.64-3.88) 
126 Et Bn OMe 405 (338-486) >5000 (9%) >5000 (22%) 3.85 (3.14-4.72) 
127 Me Allyl OBn >5000 (47%) >5000 (25%) >5000 (17%) 24.7 (17.0-35.8) 
128 Et Allyl OBn 1200 (1030-1400) >5000 (5%) >5000 (14%) 21.5 (17.0-27.3) 
129 Me Bn OBn 2560 (2300-2860) 2010 (1720-2360) >5000 (13%) 44.8 (36.5-55.0) 
130 Et Bn OBn 1680 (1380-2040) 2130 (1870-2430) >5000 (12%) 39.8 (31.6-50.1) 
 
a
 Displacement of specific [3H]-DPCPX binding to human A1 receptors expressed in CHO cells (Ki 
nM); b Displacement of specific [3H]-ZM 241385 binding to human A2A receptors expressed in CHO 
cells (Ki nM); c cAMP assay in CHO cells expressing hA2B receptors (IC50 nM); d Displacement of 
specific [3H]-MRE3008F20 binding to human A3 receptors expressed in CHO cells (Ki nM). 
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Table 7. Binding and Functional Data of derivatives 131-138. 
Compd  X Y A1 Ki (nM)a A2A Ki (nM)b A2B IC50 (nM)c A3 Ki (nM)d 
131 Me Allyl >5000 (13%) >5000 (1%) >5000 (9%) 13.9 (10.7-18.1) 
132 Et Allyl >5000 (20%) >5000 (1%) >5000 (16%) 12.5 (8.6-18.2) 
R-132 Et Allyl >5000 (12%) >5000 (3%) >5000 (14%) 12.2 (8.4-17.7) 
S-132 Et Allyl >5000 (29%) >5000 (1%) >5000 (8%) 9.20 (7.61-11.12) 
133 Me Bn >5000 (22%) >5000 (9%) >5000 (24%) 12.2 (8.4-17.7) 
134 Et Bn >5000 (28%) >5000 (13%) >5000 (27%) 15.0 (13.3-16.9) 
135 Me Allyl >5000 (26%) >5000 (11%) >5000 (13%) 3.58 (2.84-4.51) 
136 Et Allyl 3023 (2388-3827) 1520 (1126-2051) >5000 (25%) 1.93 (1.28-2.93) 
137 Me Bn >5000 (35%) >5000 (5%) >5000 (11%) 2.68 (2.11-3.41) 
138 Et Bn 485 (407-578) >5000 (12%) >5000 (18%) 2.71 (2.20-3.33) 
 
a
 Displacement of specific [3H]-DPCPX binding to human A1 receptors expressed in CHO cells (Ki 
nM); b Displacement of specific [3H]-ZM 241385 binding to human A2A receptors expressed in CHO 
cells (Ki nM); c cAMP assay in CHO cells expressing hA2B receptors (IC50 nM); d Displacement of 
specific [3H]-MRE3008F20 binding to human A3 receptors expressed in CHO cells (Ki nM). 
 
Table 8. Functional Data. 
 
As shown in Table 8, some compounds were tested in a specific 
functional model where the inhibition of cAMP generation by IB-
MECA was measured in CHO cells stably transfected with the hu-
Compd cAMP hA3 IC50 (nM) Compd cAMP hA3 IC50 (nM) 
119 34.2 (27.4-42.6) 125 27.6 (23.3-32.7) 
(R)119 35.9 (29.9-43.0) (R)125 15.9 (12.6-20.1 
(S)119 40.9 (34.9-47.9) (S)125 17.5 (13.4-22.9) 
123 14.5 (10.5-20.1) 135 24.2 (19.1-30.7) 
124 12.2 (8.4-17.7) 136 14.6 (12.0-17.8) 
131-134 135-138 
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man A3 receptor. All the tested derivatives proved to be competitive 
antagonists. Interestingly, a notable concordance between binding 
and functional experiments has been revealed. Among the examined 
compounds, the molecules showing some of the best affinities for the 
A3 AR have also proved to have very high potency in functional as-
says. In particular, derivative 124 can be consider the most potent 
compound, exhibiting an IC50 value of 12.2 nM. 
 
3.3. Conclusions 
First Project: Pyrrolo/Pyrazolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines 
Herein we evaluated the importance of the nitrogen at the 7- position 
of the pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine nucleus. From 
the biological data obtained, we can assert that N7 is fundamental for 
the selectivity of these A2A/A3 ligands versus the remaining ARs sub-
type. 
Furthermore, the substitution of the carbon atom at the 9- position 
with a nitrogen is detrimental for both affinity and selectivity, probably 
cause from a negative interaction with the receptor. 
Our results confirmed the importance of the presence of the NH at 
the 5- position of the PTPs nuclus, this could be due to the formation 
of an essential ligand-receptor hydrogen bond. 
Second Project: Imidazo[2,1-i]purin-5-ones 
We analyzed the effect of the introduction of different disubstituted 
five-membered heterocycles at the 2- position in a new series of imi-
dazo[2,1-i]-purinones. In particular, we introduced 1,3-/1,5- disubsti-
tuted pyrazoles and 3-substituted isoxazoles. All the synthesised 
molecules exhibited high affinity at the hA3AR subtype with Ki values 
ranging from 1.46 (compound R-124) to 44.8 nM (compound 129). 
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The best results were obtained with 1,3-disubstituted heterocycles. 
In particular, the concomitant presence of a methyl group at the 1- 
position and a methoxy function at the 3- position of the five mem-
bered ring afforded the most potent compounds. 
The presence of an allyl moiety at the 4- position of the imidazo[2,1-
i]purin-5-one resulted to be more effective than the benzyl group for 
the affinity toward A3 AR. 
The binding affinity of the optical isomers highlighted that the com-
pounds did not bind stereo-selectively to the A3 receptor. 
The substitution of the 8- position with a methyl or an ethyl seems to 
be essentially equivalent in terms of hA3 affinity. 
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Experimental section of pyrrolo/pyrazolo-triazolo-pyrimidines 
Chemical Materials and Methods. Starting materials were pur-
chased and used without any purification. All reactions were carried 
out under in inert atmosphere of dry nitrogen unless otherwise de-
scribed. Standard hypodermic syringe (glass/metal Luer) techniques 
were applied for transferring dry solvents. Reaction progress and 
product mixtures were monitored by thin-layer chromatography 
(TLC) on silica gel (precoated F254 Macherey-Nagel plates) and visu-
alized with aqueous potassium permanganate. 1H NMR data were 
determined in CDCl3 or DMSO-d6 solutions with a Varian VXR 200 
spectrometer or a Varian Mercury Plus 400 spectrometer. Peak posi-
tions are given in parts per million (δ) downfield from tetramethylsi-
lane as internal standard, and J values are given in hertz. All prod-
ucts reported showed 1H NMR spectra in agreement with the as-
signed structures. Light petroleum refers to the fractions boiling at 
40-60 °C. Melting points (m.p.) were determined on a Buchi-Tottoli 
instrument and are uncorrected. Electrospray Ionization Mass Spec-
trometry (ESI/MS) was performed with an Agilent 1100 Series 
LC/MSD model in positive scan mode using direct injection of the pu-
rified compound solution (MH+). Chromatography was performed on 
Merck 230-400 mesh silica gel. Organic solutions were dried over 
anhydrous sodium sulfate. 
 
1,3-Dibenzyl-1,6-dihydro-pyrrolo[3,4-d]pyrimidine-2,4-dione (34) 
was synthesized according to known procedures.161  
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General procedure for preparation of 1,3-dibenzyl-6-alkyl-1,6-
dihydro-pyrrolo[3,4-d]pyrimidine-2,4-diones (35a-d).  
N
N
O
O
N
N
O
O
Bn
Bn
NH N R
Bn
Bn
 
1,3-Dibenzyl-6-methyl-1,6-dihydro-pyrrolo[3,4-d]pyrimidine-2,4-
dione (35a) To a solution of 1,3-dibenzyl-1,6-dihydro-pyrrolo[3,4-
d]pyrimidine-2,4-dione (34, 1.5 mmol) in anhydrous DMF (5 mL) was 
added K2CO3 (4.5 mmol) and the resulting mixture was stirred at 40 
°C for 10’. After cooling at room temperature, CH3I (4.5 mmol) was 
added and the reaction heated at 40 °C for further 2 h. The solvents 
were removed in vacuo and the residue was suspended with water 
and extracted with EtOAc. The organic phase was dried over anhy-
drous Na2SO4 and the solvents removed under reduced pressure to 
obtain a crude solid which was purified by crystallization from Et2O/ 
Petroleum ether. White solid; 97% yield; mp 164-166 °C; 1H NMR 
(200MHz, CDCl3) δ ppm 7.52-7.22 (m, 10H), 7.18 (d, J = 2.2 Hz, 
1H), 6.13 (d, J = 2.4 Hz, 1H), 5.24 (s, 2H), 5.01 (s, 2H), 3.66 (s, 3H). 
MS (ESI): [MH]+ = 346.4. 
1,3-Dibenzyl-6-propyl-1,6-dihydro-pyrrolo[3,4-d]pyrimidine-2,4-
dione (35b) To a solution of 1,3-dibenzyl-1,6-dihydro-pyrrolo[3,4-
d]pyrimidine-2,4-dione (34, 1.5 mmol) in anhydrous DMF (5 mL) was 
added K2CO3 (4.5 mmol) and the resulting mixture was stirred at 40 
°C for 10’. After cooling at room temperature, CH3CH2CH2Br (4.5 
mmol) was added and the reaction heated at 40 °C for further 4 h. 
The solvents were removed in vacuo and the residue was sus-
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pended with water and extracted with EtOAc. The organic phase was 
dried over anhydrous Na2SO4 and the solvents removed under re-
duced pressure to obtain a crude solid which was purified by crystal-
lization from Et2O/ Petroleum ether. White solid; 89% yield; mp 122 
°C; 1H NMR (200MHz, CDCl3) δ ppm 7.51-7.48 (m, 2H), 7.29-7.22 
(m, 9H), 6.15 (d, J = 2.4 Hz, 1H), 5.24 (s, 2H), 5.01 (s, 2H), 3.80 (t, J 
= 7.2 Hz, 2H), 1.77-1.73 (m, J = 7.2 Hz, 2H), 0.86 (t, J = 7.4 Hz, 3H). 
1,3-Dibenzyl-6-phenethyl-1,6-dihydro-pyrrolo[3,4-d]pyrimidine-
2,4-dione (35c) To a solution of 1,3-dibenzyl-1,6-dihydro-pyrrolo[3,4-
d]pyrimidine-2,4-dione (34, 1.5 mmol) in anhydrous DMF (5 mL) was 
added K2CO3 (4.5 mmol) and the resulting mixture was stirred at 40 
°C for 10’. After cooling at room temperature, PhCH2CH2Cl (4.5 
mmol) was added and the reaction heated at 80 °C for further 4 h. 
The solvents were removed in vacuo and the residue was sus-
pended with water and extracted with EtOAc. The organic phase was 
dried over anhydrous Na2SO4 and the solvents removed under re-
duced pressure to obtain a crude solid which was purified by crystal-
lization from Et2O/ Petroleum ether. White solid; 76% yield; mp 159-
160 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 7.46 (d, J = 2 Hz, 1H), 
7.29-7.13 (m, 15H), 6.83 (d, J = 2 Hz, 1H), 5.04 (s, 2H), 4.93 (s, 2H), 
4.18 (t, J = 7.6 Hz, 2H), 3.02 (t, J = 7.2 Hz, 2H). MS (ESI): [MH]+ = 
436.8. 
1,3-Dibenzyl-6-(3-phenyl-propyl)-1,6-dihydro-pyrrolo[3,4-
d]pyrimidine-2,4-dione (35d) To a solution of 1,3-dibenzyl-1,6-
dihydro-pyrrolo[3,4-d]pyrimidine-2,4-dione (34, 1.5 mmol) in anhy-
drous DMF (5 mL) was added K2CO3 (4.5 mmol) and the resulting 
mixture was stirred at 40 °C for 10’. After cooling at room tempera-
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ture, Ph(CH2)3Cl (4.5 mmol) was added and the reaction heated at 
80 °C for further 4 h. The solvents were removed in vacuo and the 
residue was suspended with water and extracted with EtOAc. The 
organic phase was dried over anhydrous Na2SO4 and the solvents 
removed under reduced pressure to obtain a crude solid which was 
purified by column chromatography eluting with a mixture EtOAc/ Pe-
troleum ether 1:4. White solid; 82% yield; mp 129-130 °C; 1H NMR 
(400MHz, DMSO-d6) δ ppm 7.57 (d, J = 2 Hz, 1H), 7.33-7.12 (m, 
15H), 6.86 (d, J = 2 Hz, 1H), 5.08 (s, 2H), 4.99 (s, 2H), 3.97 (t, J = 
7.2 Hz, 2H), 2.51-2.44 (m, 2H), 2.03 (m, 2H). 
 
General procedure for preparation of 6-alkyl-1,6-dihydro-
pyrrolo[3,4-d]pyrimidine-2,4-diones (36a-d).  
N
N
O
O
Bn
Bn
N R HN
N
H
O
O
N R
 
To a solution of the appropriate dibenzyl derivative 35a-d (4 mmol) in 
anhydrous toluene (50 mL) was added AlCl3 (28 mmol) and the re-
sulting suspension was stirred at room temperature for 1,5-3h. The 
solvent was concentrated in vacuo and the residue treated with 
crashed ice  
6-Methyl-1,6-dihydro-pyrrolo[3,4-d]pyrimidine-2,4-dione (36a) 
White solid; 82% yield; mp >300 °C; 1H NMR (200MHz, DMSO-d6) δ 
ppm 10.36 (bs, 1H), 10.28 (bs, 1H), 7.29 (s, 1H), 6.44 (s, 1H), 3.67 
(s, 3H). MS (ESI): [MH]+ = 166.1. 
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6-Propyl-1,6-dihydro-pyrrolo[3,4-d]pyrimidine-2,4-dione (36b) 
Pale yellow solid; 87% yield; mp dec. 270 °C; 1H NMR (200MHz, 
DMSO-d6) δ ppm 10.37 (bs, 1H), 10.27 (bs, 1H), 7.35 (d, J = 2.2 Hz, 
1H), 6.47 (d, J = 2.2 Hz, 1H), 3.89 (t, J = 7 Hz, 2H), 1.77-1.66 (m, 
2H), 0.79 (t, J = 7.4 Hz, 3H). 
6-Phenethyl-1,6-dihydro-pyrrolo[3,4-d]pyrimidine-2,4-dione (36c) 
White solid; 81% yield; mp dec. 263 °C; 1H NMR (400MHz, DMSO-
d6) δ ppm 10.38 (bs, 1H), 10.28 (bs, 1H), 7.30-7.10 (m, 6H), 6.49 (d, 
J = 2.4 Hz, 1H), 4.19 (t, J = 7.6 Hz, 2H), 3.03 (t, J = 7.2 Hz, 2H). MS 
(ESI): [MH]+ = 256.3. 
6-(3-Phenyl-propyl)-1,6-dihydro-pyrrolo[3,4-d]pyrimidine-2,4-
dione (36d) White solid; 80% yield; mp dec. 225 °C; 1H NMR 
(400MHz, DMSO-d6) δ ppm 10.40 (bs, 1H), 10.30 (bs, 1H), 7.38 (d, J 
= 2 Hz, 1H), 7.30-7.17 (m,5H), 6.51 (d, J = 2 Hz, 1H), 3.96 (t, J = 6.8 
Hz, 2H), 2.52-2.48 (m, 2H), 2.051-2.00 (m, 2H). 
 
4-nitro-1H-pyrazole3-carboxylic acid amide (45) was synthesised 
according to the known procedure.162 
 
General procedure for preparation of 1-alkyl-4-nitro-1H-
pyrazole-5-carboxamide and 1-alkyl-4-nitro-1H-pyrazole-3-
carboxamide (46-49a,b) 
N N
H
NO2
NH2
O N N N N
NO2
R
NH2
O R
NO2
NH2
O
 
To a solution of nitroamide (45, 1.2 mmol) in anhydrous DMF (36 
mL) was added K2CO3 (2.3 mmol) and the resulting mixture was 
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stirred for 10’. Then, the iodomethane (1.4 mmol) was added and the 
mixture was stirred for 6 h. The solvent was removed in vacuo and 
the residue was suspended with water and extracted with EtOAc. 
The organic phase was dried over anhydrous Na2SO4 and the sol-
vents removed under reduced pressure to obtain a crude solid which 
was purified via column chromatography (gradient from EtOAc/ EtP 
1:1 to EtOAc) to obtain the desired products. 
1-Methyl-4-nitro-1H-pyrazole-5-carboxamide (46a) White solid; 
40% yield; mp 167 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 8.49 (bs, 
1H), 8.34 (bs, 1H), 8.27 (s, 1H), 3.86 (s, 3H). 
1-Methyl-4-nitro-1H-pyrazole-3-carboxamide (46b) White solid; 
38% yield; mp 166 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 8.83 (s, 
1H), 8.03 (bs, 1H), 7.79 (bs, 1H), 3.90 (s, 3H). 
To a solution of nitroamide (45, 1.2 mmol) in anhydrous DMF (36 
mL) was added K2CO3 (2.3 mmol) and the resulting mixture was 
stirred for 10’. Then, the bromopropane (1.4 mmol) was added and 
the mixture was stirred for 6 h. The solvent was removed in vacuo 
and the residue was suspended with water and extracted with 
EtOAc. The organic phase was dried over anhydrous Na2SO4 and 
the solvents removed under reduced pressure to obtain a crude solid 
which was purified via column chromatography (gradient from Etp/ 
EtOAc 7:3 to EtOAc) to obtain the desired products. 
1-Propyl-4-nitro-1H-pyrazole-5-carboxamide (47a) White solid; 
48% yield; mp 98-100 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 8.48 
(bs, 1H), 8.28-8.27 (m, 2H), 4.08 (t, J = 6.8 Hz, 2H), 1.81-1.76 (m, 
2H), 0.813 (t, J = 7.6 Hz, 3H). 
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1-Propyl-4-nitro-1H-pyrazole-3-carboxamide (47b) White solid; 
43% yield; mp 115-116 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 8.87 
(s, 1H), 7.98 (bs, 1H), 7.73 (bs, 1H), 4.10 (t, J = 6.8 Hz, 2H), 1.83-
1.78 (m, 2H), 0.83 (t, J = 7.2 Hz, 3H). 
To a solution of nitroamide (45, 1.2 mmol) in anhydrous DMF (36 
mL) was added K2CO3 (2.3 mmol) and the resulting mixture was 
stirred for 10’. Then, PhCH2CH2Cl (1.4 mmol) was added and the 
mixture was heated at 60 °C for 6 h. The solvent was removed in 
vacuo and the residue was suspended with water and extracted with 
EtOAc. The organic phase was dried over anhydrous Na2SO4 and 
the solvents removed under reduced pressure to obtain a crude solid 
which was purified via column chromatography (gradient from Etp/ 
EtOAc 4:1 to EtOAc) to obtain the desired products. 
4-Nitro-1-(2-phenylethyl)-1H-pyrazole-5-carboxamide (48a) White 
solid; 25% yield; mp 133 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 
8.45 (bs, 1H), 8.31 (bs, 1H), 8.25 (s, 1H), 7.29-7.16 (m, 5H), 4.38-
4.35 (m, 2H), 3.09 (t, J = 7.6 Hz, 2H). 
4-Nitro-1-(2-phenylethyl)-1H-pyrazole-3-carboxamide (48b) White 
solid; 50% yield; mp 158-160 °C; 1H NMR (400MHz, DMSO-d6) δ 
ppm 8.74 (s, 1H), 8.00 (bs, 1H), 7.76 (bs, 1H), 7.30-7.18 (m,5H), 
4.40 (t, J = 7.2 Hz, 2H), 3.13 (t, J = 7.6 Hz, 2H). 
To a solution of nitroamide (45, 1.2 mmol) in anhydrous DMF (36 
mL) was added K2CO3 (2.3 mmol) and the resulting mixture was 
stirred for 10’. Then, Ph(CH2)3Cl (1.4 mmol) was added and the mix-
ture was heated at 80 °C for 5 h. The solvent was removed in vacuo 
and the residue was suspended with water and extracted with 
EtOAc. The organic phase was dried over anhydrous Na2SO4 and 
Chapter 4          Experimental section of pyrrolo/pyrazolo-triazolo pyrimidines 
 74 
the solvents removed under reduced pressure to obtain a crude solid 
which was purified via column chromatography (gradient from Etp/ 
EtOAc 4:1 to EtOAc) to obtain the desired products. 
4-Nitro-1-(3-phenylpropyl)-1H-pyrazole-5-carboxamide (49a) 
White solid; 34% yield; mp 93-95 °C; 1H NMR (400MHz, DMSO-d6) δ 
ppm 8.53 (bs, 1H), 8.33-8.32 (m, 2H), 7.30-7.19 (m, 5H), 4.16 ( t, J = 
6.8 Hz, 2H), 2.57 (t, J = 7.2 Hz, 2H), 2.11-2.08 (m, 2H). 
4-Nitro-1-(3-phenylpropyl)-1H-pyrazole-3-carboxamide (49b) 
White solid; 57% yield; mp 111-113 °C; 1H NMR (400MHz, DMSO-
d6) δ ppm 8.90 (s, 1H), 8.00 (bs, 1H), 7.77 (bs, 1H), 7.31-7.19 (m, 
5H), 4.18 (t, J = 7.2 Hz, 2H), 2.59 (t, J =7.2 Hz, 2H), 2.15-2.12 (m, 
2H). 
 
General procedure for preparation of 4-amino-1-alkyl-1H-
pyrazole-5-carboxamide and 4-amino-1-alkyl-1H-pyrazole-3-
carboxamide (50-53a,b) 
N N
NO2
NH2
O N N
NH2
NH2
OR R  
1.3 g of nitroamide (46-49a,b) were dissolved in EtOH (200 mL), 
0.15 g of Pd on activated charcoal was added and the mixture was 
hydrogenated at 50 psi for 5 h at room temperature. The mixture was 
filtered on celite and then the solvent was removed under reduced 
pressure to obtain the crude product which was purified by crystalli-
zation EtOAc/ Et2O/ Petroleum ether. 
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4-Amino-1-methyl-1H pyrazole-5-carboxamide (50a) White solid; 
60% yield; mp 174-175 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 7.37 
(bs, 2H), 7.01 (s, 1H); 4,39 (bs, 2H), 3.89 (s, 3H). 
4-Amino-1-methyl-1H pyrazole-3-carboxamide (50b) White solid; 
60% yield; mp 171-172 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 7.10 
(bs, 1H), 7.06 (s, 1H), 6.95 (bs, 1H), 4.63 (bs, 2H), 3.72 (s, 3H). 
4-Amino-1-propyl-1H pyrazole-5-carboxamide (51a) White solid; 
65% yield; mp 91-92 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 7.40 
(bs, 2H), 7.04 (s, 1H), 4.33-4.24 (bm, 4H), 1.69 (m, 2H), 0.75 (t, J = 
7.6 Hz, 3H). 
4-Amino-1-propyl-1H pyrazole-3-carboxamide (51b) White solid; 
91% yield; mp 115 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 7.10 (s, 
1H), 7.07 (bs, 1H), 6.95 (bs, 1H), 4.62 (bs, 2H), 3.92 (t, J = 6.8 Hz, 
2H), 1.79-1.69 (m, 2H), 0.82 (t, J = 7.2 Hz, 3H). 
4-Amino-1-(2-phenylethyl)-1H-pyrazole-5-carboxamide (52a) 
White solid; 68% yield; mp 87-88 °C; 1H NMR (200MHz, DMSO-d6) δ 
ppm 7.40 (bs, 2H), 7.27-7.15 (m, 5H), 7.05 (s, 1H), 4.53 (t, J = 7.6 
Hz, 2H), 4.37 (bs, 2H), 2.94 (t, J = 7.8 Hz, 2H). 
4-Amino-1-(2-phenylethyl)-1H-pyrazole-3-carboxamide (52b) 
White solid; 87% yield; mp 82-83 °C; 1H NMR (200MHz, DMSO-d6) δ 
ppm 7.29-7.17 (m, 5H), 7.11 (bs, 1H), 7.04 (s, 1H), 6.97 (bs, 1H), 
4.61 (bs, 2H), 4.22 (t, J =7 Hz, 2H), 3.07 (t, J = 7.6 Hz, 2H). 
4-Amino-1-(3-phenylpropyl)-1H-pyrazole-5-carboxamide (53a) 
White solid; 87% yield; mp 78 °C; 1H NMR (200MHz, DMSO-d6) δ 
ppm 7.42 (bs, 2H), 7.26-7.15 (m, 5H), 7.07 (s, 1H), 4.38-4.31 (m, 
4H), 2.51-2.43 (m, 2H), 1.97-1.93 (m, 2H). 
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4-Amino-1-(3-phenylpropyl)-1H-pyrazole-3-carboxamide (53b) 
White solid; 90% yield; mp 111-112 °C; 1H NMR (200MHz, DMSO-
d6) δ ppm 7.32-7.11 (m, 7H), 6.97 (bs, 1H), 4.65 (bs, 2H), 3.98 (t, J = 
6.8 Hz, 2H), 2.58-2.49 (m, 2H), 2.08-2.00 (m, 2H). 
 
General procedure for preparation of 1-alkyl-1H-pyrazolo[4,3-
d]pyrimidine 5,7 (4H, 6H)-dione and 2-alkyl-2H-pyrazolo[4,3-
d]pyrimidine 5,7 (4H, 6H)-dione (54-57a,b) 
N N
NH2
NH2
O
R
HN
N
H
N
N
O
O
R
 
The urea (33.3 mmol) was added to aminoamide (50-53a,b, 7.1 
mmol) and the mixture was heated at 200 °C for 2 h. The crude 
product was purified by crystallization NaOH 10%/ Acetic acid. 
1-Methyl-1H-pyrazolo[4,3-d]pyrimidine 5,7 (4H, 6H)-dione (54a) 
White solid; quantitative yield; mp >300 °C; 1H NMR (200MHz, 
DMSO-d6) δ ppm 11.15 (bs, 1H), 10.96 (bs, 1H), 8.16 (s, 1H), 4.04 
(s, 3H). 
2-Methyl-2H-pyrazolo[4,3-d]pyrimidine 5,7 (4H, 6H)-dione (54b) 
White solid; 81% yield; mp >300 °C; 1H NMR (400MHz, DMSO-d6) δ 
ppm 10.87 (bs, 1H), 10.71 (bs, 1H), 7.64 (s, 1H), 3.94 (s, 3H). MS 
(ESI): [MH]+ = 167.1. 
1-Propyl-1H-pyrazolo[4,3-d]pyrimidine 5,7 (4H, 6H)-dione (55a) 
White solid; quantitative yield; mp >300 °C; 1H NMR (200MHz, 
DMSO-d6) δ ppm 9.34 (bs, 2H), 7.37 (s, 1H), 4.35 (t, J = 6.8 Hz, 2H), 
1.81-1.70 (m, 2H), 0.78 (t, J = 7.2 Hz, 3H). 
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2-Propyl-2H-pyrazolo[4,3-d]pyrimidine 5,7 (4H, 6H)-dione (55b) 
White solid; 74% yield; mp >300 °C; 1H NMR (200MHz, DMSO-d6) δ 
ppm 10.48 (bs, 2H), 7.68 (s, 1H), 4.14 (t, J = 6.8 Hz, 2H), 1.85-1.74 
(m, 2H), 0.80 (t, J = 7.4 Hz, 3H). 
1-(2-Phenylethyl)-1H-pyrazolo[4,3-d]pyrimidine 5,7 (4H, 6H)-
dione (56a) White solid; quantitative yield; mp >300 °C; 1H NMR 
(200MHz, DMSO-d6) δ ppm 11.08 (bs, 2H), 7.34 (s, 1H), 7.27-7.10 
(m, 5H), 4.62 (t, J = 7.2 Hz, 2H), 3.07 (t, J = 7.4 Hz, 2H). 
2-(2-Phenylethyl)-2H-pyrazolo[4,3-d]pyrimidine 5,7 (4H, 6H)-
dione (56b) White solid; 70% yield; mp >300 °C; 1H NMR (200MHz, 
DMSO-d6) δ ppm 10.91 (bs, 1H), 10.38 (bs, 1H), 7.58 (s, 1H), 7.32-
7.17 (m, 5H), 4.45 (t, J = 7.4 Hz, 2H), 3.14 (t J = 7.2 Hz, 2H). 
1-(3-Phenylpropyl)-1H-pyrazolo[4,3-d]pyrimidine 5,7 (4H, 6H)-
dione (57a) White solid; 63% yield; mp 280 °C; 1H NMR (200MHz, 
DMSO-d6) δ ppm 11.19 (bs, 1H), 10.02 (bs, 1H), 7.38 (s, 1H), 7.26-
7.154 (m, 5H), 4.43 (t, J = 6.8 Hz, 2H), 2.57-2.50 (m, 2H), 2.11-2.04 
(m, 2H). 
2-(3-Phenylpropyl)-2H-pyrazolo[4,3-d]pyrimidine 5,7 (4H, 6H)-
dione (57b) White solid; 55% yield; mp >300 °C; 1H NMR (200MHz, 
DMSO-d6) δ ppm 10.51 (bs, 2H), 7.71 (s, 1H), 7.28-7.17 (m, 5H), 
4.22 (t, J =6.8 Hz, 2H), 2.58-2.48 (m, 2H), 2.15-2.11 (m, 2H). 
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General procedure for preparation of 2,4-dichloro-6-alkyl-6H-
pyrrolo[3,4-d]pyrimidines (37a-d), 5,7-dichloro-1/2-alkyl-1/2H-
pyrazole[4,3-d]pyrimidines (58-61a,b) 
HN
N
H
N
X
O
O
N
N
N
X
Cl
Cl
R R
 
A mixture of pyrimidine-2,4-dione (37a-d and 58-61a,b, 6.1 mmol) 
and phosphoroxy chloride (60 mmol) was heated at 50 °C under ar-
gon atmosphere and DBU (36.6 mmol) was added dropwise under 
vigorous stirring then the reaction was heated for further 8 h. After 
cooling at room temperature, the reaction mixture was slowly poured 
in cold water and treated with a 50% aqueous solution of NaOH until 
pH 4. The solution was extracted with Et2O, the organic phase was 
dried over anhydrous Na2SO4 and the solvent was removed under 
reduced pressure to obtain the desired intermediate. Because these 
compounds are unstable, they were used for the next reaction step 
without further purification. The NMR analysis were performed on the 
crude product. 
2,4-Dichloro-6-methyl-6H-pyrrolo[3,4-d]pyrimidine (37a) Pale yel-
low solid; 75% yield; crude product; 1H NMR (400MHz, CDCl3) δ 
ppm 7.32 (s, 1H), 7.24 (s, 1H), 4.07 (s, 3H). MS (ESI): [MH]+ = 202.1. 
2,4-Dichloro-6-propyl-6H-pyrrolo[3,4-d]pyrimidine (37b) Pale yel-
low solid; 63% yield; crude product; 1H NMR (200MHz, CDCl3) δ 
ppm 7.34 (d, J = 2.2 Hz, 1H), 7.25 (s, 1H), 4.20 (t, J = 7 Hz, 2H), 
2.02-1.92 (m, 2H), 0.96 (t, J = 7.4 Hz, 3H). MS (ESI): [MH]+ = 230.1. 
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2,4-Dichloro-6-phenethyl-6H-pyrrolo[3,4-d]pyrimidine (37c) Pale 
yellow solid; 73% yield; crude product; 1H NMR (400MHz, DMSO-d6) 
δ ppm 7.88 (d, J = 2 Hz, 1H), 7.72 (d, J = 2 Hz, 1H), 7.29-7.19 (m, 
5H), 4.59 (t, J = 7.2 Hz, 2H), 3.21 (t, J = 7.6 Hz, 2H). 
2,4-Dichloro-6-(3-phenyl-propyl)-6H-pyrrolo[3,4-d]pyrimidine 
(37d) Pale yellow oil; 81% yield; crude product; 1H NMR (400MHz, 
CDCl3) δ ppm 7.33-7.14 (m, 7H), 4.23 (t, J = 7.2 Hz, 2H), 2.65 (t, J = 
6.8 Hz, 2H), 2.31- 2.28 (m, 2H).  
5,7-Dichloro-1-methyl-1H-pyrazolo[4,3-d]pyrimidine (58a) Pale 
yellow solid; 63% yield; crude product; 1H NMR (400MHz, CDCl3) δ 
ppm 8.17 (s, 1H), 4.41 (s, 3H). 
5,7-Dichloro-2-methyl-2H-pyrazolo[4,3-d]pyrimidine (58b) Pale 
yellow solid; 63% yield; crude product; 1H NMR (400MHz, CDCl3) δ 
ppm 8.17 (s, 1H), 4.41 (s, 3H). 
5,7-Dichloro-1-propyl-1H-pyrazolo[4,3-d]pyrimidine (59a) Pale 
yellow oil; 57% yield; crude product; 1H NMR (200MHz, CDCl3) δ 
ppm 8.20 (s, 1H), 4.69 (t, J = 7 Hz, 2H), 2.04-1.92 (m, 2H), 0.96 (t, J 
= 7.2 Hz, 3H). 
5,7-Dichloro-2-propyl-2H-pyrazolo[4,3-d]pyrimidine (59b) Pale 
yellow solid; 55% yield; crude product; 1H NMR (200MHz, CDCl3) δ 
ppm 8.16 (s, 1H), 4.49 (t, J =7.2 Hz, 2H), 2.11-2.04 (m, 2H), 0.99 (t, 
J = 7.6 Hz, 3H). 
5,7-Dichloro-1-phenethyl-1H-pyrazolo[4,3-d]pyrimidine (60a) 
Pale yellow solid; 58% yield; crude product; 1H NMR (200MHz, 
CDCl3) δ ppm 8.22 (s, 1H), 7.26-7.23 (m, 3H), 7.10-7.07 (m, 2H), 
4.94 (t, J = 7.4 Hz, 2H), 3.23 (t, J = 7.6 Hz, 2H). 
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N
N
N
X
Cl
Cl
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NH
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5,7-Dichloro-2-phenethyl-2H-pyrazolo[4,3-d]pyrimidine (60b) 
Pale yellow solid; 50% yield; crude product; 1H NMR (200MHz, 
CDCl3) δ ppm 7.83 (s, 1H), 7.29-7.26 (m, 3H), 7.08-7.04 (m, 2H), 
4.75 (t, J = 7.2 Hz, 2H), 3.34 (t, J = 7 Hz, 2H). 
5,7-Dichloro-1-(3-phenyl-propyl)-1H-pyrazolo[4,3-d]pyrimidine 
(61a) Pale yellow solid; 58% yield; crude product; 1H NMR (200MHz, 
CDCl3) δ ppm 8.19 (s, 1H), 7.27-7.14 (m, 5H), 4.73 (t, J = 7 Hz, 2H), 
2.71 (t, J = 7.4 Hz, 2H), 2.33-2.62 (m, 2H). 
5,7-Dichloro-2-(3-phenyl-propyl)-2H-pyrazolo[4,3-d]pyrimidine 
(61b) Pale yellow solid; 62% yield; crude product; 1H NMR (200MHz, 
CDCl3) δ ppm 7.77 (s, 1H), 7.30-7.14 (m, 5H), 4.55-4.35 (m, 2H), 
2.65 (t, J = 7.4 Hz, 2H), 2.45-2.30 (m, 2H). 
 
General procedure for preparation of furan-2-carboxylic acid N'-
(2-chloro-6-alkyl-6H-pyrrolo[3,4-d]pyrimidin-4-yl)-hydrazides 
(38a-d) and furan-2-carboxylic acid N'-(5-chloro-1/2-alkyl-1/2H-
pyrazolo[4,3-d]pyrimidin-7-yl)-hydrazide (62-65a,b) 
 
 
 
 
 
 
To a solution of dichloro derivative (37a-d and 58-61a,b, 0.5 mmol) 
in anhydrous THF (4 mL) were added TEA (50 mmol) and furan-2-
carboxylic acid hydrazide (69 mmol). The reaction was refluxed for 
24 h. The solvent was removed under reduced pressure to obtain a 
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crude solid which was purified via column chromatography eluting 
with a mixture CH2Cl2/ CH3OH 9:1. 
Furan-2-carboxylic acid N'-(2-chloro-6-methyl-6H-pyrrolo[3,4-
d]pyrimidin-4-yl)-hydrazide (38a) Pale yellow solid; 65% yield; mp 
250-251 °C dec.; 1H NMR (400MHz, DMSO-d6) δ ppm 11.45 (bs, 
1H), 10.40 (bs, 1H), 7.89 (s, 1H), 7.77 (t, J = 4.8 Hz, 1H), 7.40 (bs, 
1H), 7.23 (d, J = 2.8 Hz, 1H), 6.66-6.65 (m, 1H), 3.45 (s, 3H). MS 
(ESI): [MH]+ = 292.2. 
Furan-2-carboxylic acid N'-(2-chloro-6-propyl-6H-pyrrolo[3,4-
d]pyrimidin-4-yl)-hydrazide (38b) Pale yellow solid; 72% yield; mp 
202-204 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 10.60 (bs, 1H), 
9.91 (bs, 1H), 7.96 (s, 1H), 7.52 (s, 1H), 7.31-7.28 (m, 1H), 7.18 
(bs,1H), 6.72-6.71 (m, 1H), 4.17 (m, 2H), 1.81 (m, 2H), 0.88-0.80 (m, 
3H). MS (ESI): [MH]+ = 320.2. 
Furan-2-carboxylic acid N'-(2-chloro-6-phenethyl-6H-pyrrolo[3,4-
d]pyrimidin-4-yl)-hydrazide (38c) Pale yellow solid; 48% yield; mp 
209-212 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 10.58 (bs, 1H), 
10.17 (bs, 1H), 7.95 (s, 1H), 7.45 (s, 1H), 7.27-7.12 (m, 8H), 6.71 (s, 
1H), 4.47-4.41 (m, 2H), 3.15-3.12 (m, 1H). MS (ESI): [MH]+ = 382.3. 
Furan-2-carboxylic acid N'-[2-chloro-6-(3-phenyl-propyl)-6H-
pyrrolo[3,4-d]pyrimidin-4-yl]-hydrazide (38d) Pale yellow solid; 
56% yield; mp 204-206 °C dec.; 1H NMR (400MHz, DMSO-d6) δ ppm 
10.63 (bs, 1H), 9.97 (bs, 1H), 7.96 (s, 1H), 7.55 (s, 1H), 7.32-6.99 
(m, 7H), 6.71 (s, 1H), 4.22 (t, J = 6.8 Hz, 2H), 2.56 (t, J = 7.2 Hz, 
2H), 2.16- 2.12 (m, 2H).  
Furan-2-carboxylic acid N'-(5-chloro-1-methyl-1H-pyrazolo[4,3-
d]pyrimidin-7-yl)-hydrazide (62a) Pale yellow solid; 82% yield; mp 
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205 °C dec.; 1H NMR (400MHz, DMSO-d6) δ ppm 10.76 (bs, 1H), 
9.98 (bs, 1H), 8.07 (s, 1H), 7.98 (d, J = 1.2 Hz, 1H), 7.33 (d, J = 3.2 
Hz, 1H), 6.73-6.72 (m, 1H), 4.29 (s, 3H). 
Furan-2-carboxylic acid N'-(5-chloro-2-methyl-2H-pyrazolo[4,3-
d]pyrimidin-7-yl)-hydrazide (62b) White solid; 40% yield; mp 158 
°C dec.; 1H NMR (400MHz, DMSO-d6) δ ppm 10.67 (bs, 1H), 10.61 
(bs, 1H), 8.42 (s, 1H), 7.96 (d, J =1.2 Hz, 1H), 7.29 ( d, J = 3.2 Hz, 
1H), 6.72-6.70 (m, 1H), 4.19 (s, 3H). MS (ESI): [MH]+ = 293.3. 
Furan-2-carboxylic acid N'-(5-chloro-1-propyl-1H-pyrazolo[4,3-
d]pyrimidin-7-yl)-hydrazide (63a) White solid; 70% yield; mp 217 
°C dec.; 1H NMR (200MHz, DMSO-d6) δ ppm 10.77 (bs, 1H), 9.86 
(bs, 1H), 8.11 (s, 1H), 7.98-7.97 (m, 1H), 7.32 (d, J = 3.4 Hz, 1H), 
6.74-6.71 (m, 1H), 4.61 (t, J = 7Hz, 2H), 1.85-1.75 (m, 2H), 0.80 (t, J 
= 7.4 Hz, 3H). 
Furan-2-carboxylic acid N'-(5-chloro-2-propyl-2H-pyrazolo[4,3-
d]pyrimidin-7-yl)-hydrazide (63b) White solid; 50% yield; mp 164-
166 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 10.66 (bs, 2H), 8,48 (s, 
1H), 7.96 (s, 1H), 7.29 (d, J = 3.6 Hz, 1H), 6.72-6.70 (m, 1H), 4.41 (t, 
J = 7.2 Hz, 2H), 1.97-1.90 (m, 2H), 0.87 (t, J = 7.4 Hz, 3H). MS 
(ESI): [MH]+ = 321.0. 
Furan-2-carboxylic acid N'-(5-chloro-1-phenethyl-1H-
pyrazolo[4,3-d]pyrimidin-7-yl)-hydrazide (64b) White solid; 60% 
yield; mp 197-199 °C dec.; 1H NMR (200MHz, DMSO-d6) δ ppm 
10.78 (bs, 1H), 10.04 (bs, 1H), 8.03 (s, 1H), 7.98 (s, 1H), 7.33 (d, J = 
3.4 Hz, 1H), 7.24-7.20 (m, 5H), 6.74-6.72 (m, 1H), 4.94-4.87 (m, 2H), 
3.16-3.09 (m, 2H). MS (ESI): [MH]+ = 383.0. 
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Furan-2-carboxylic acid N'-(5-chloro-2-phenethyl-2H-
pyrazolo[4,3-d]pyrimidin-7-yl)-hydrazide (64b) White solid; 42% 
yield; mp 137-139 °C dec.; 1H NMR (200MHz, DMSO-d6) δ ppm 
10.66 (bs, 2H), 8.37 (s, 1H),7.96 (s, 1H), 7.32-7.17 (m, 6H), 6.72-
6.70 (m, 1H), 4.71 (t, J = 6.8 Hz, 2H), 3.36-3.24 (m, 2H). MS (ESI): 
[MH]+ = 383.0. 
Furan-2-carboxylic acid N'-[5-chloro-1-(3-phenyl-propyl)-1H-
pyrazolo[4,3-d]pyrimidin-7-yl]-hydrazide (65a) Pale yellow solid; 
50% yield; mp 115-116 °C dec.; 1H NMR (200MHz, DMSO-d6) δ ppm 
10.79 (bs, 1H), 9.98 (bs, 1H), 8.10 (s, 1H), 7.99-7.98 (m, 1H), 7.34-
7.16 (m, 6H), 6.74-6.71 (m, 1H), 4.70 (t, J = 7 Hz, 2H), 2.59-2.49 (m, 
2H), 2.13-2.05 (m, 2H). MS (ESI): [MH]+ = 397.0. 
Furan-2-carboxylic acid N'-[5-chloro-2-(3-phenyl-propyl)-2H-
pyrazolo[4,3-d]pyrimidin-7-yl]-hydrazide (65b) Pale yellow solid; 
56% yield; mp 169-171 °C dec.; 1H NMR (200MHz, DMSO-d6) δ ppm 
10.67 (bs, 2H), 8.51 (s, 1H), 7.97-7.96 (m, 1H), 7.30-7.19 (m, 6H), 
6.72-6.70 (m, 1H), 4.49-4.43 (m, 2H), 2.62-2.49 (m, 2H), 2.29-2.21 
(m, 2H). MS (ESI): [MH]+ = 397.0. 
General procedure for preparation of 5-chloro-2-furan-2-yl-8-
alkyl-8H-pyrrolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines (39a-d) 
and 5-chloro-2-furan-2-yl-8/9-alkyl-8/9H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidines (66-69a,b) 
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The pyrrolo/pyrazolepyrimidine (38a-d, 62-65a,b, 0.2 mmol) was 
suspended in a mixture of HMDS (0.5 mL) and BSA (0.5 mL) and the 
reaction was heated at 120 °C for 15 h. The excess of reagents was 
removed under reduced pressure and the residue was purified via 
column chromatography eluting with a mixture CH2Cl2/ CH3OH 
9.5:0.5. 
5-Chloro-2-furan-2-yl-8-methyl-8H-pyrrolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (39a) White solid; 75% yield; mp 
275 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 8.02- 8.01 (m, 1H), 
7.86 (d, J = 2Hz, 1H), 7.62 (d, J = 2 Hz, 1H), 7.04- 7.03 (m, 1H), 
6.76- 6.74 (m, 1H), 3.96 (s, 3H). MS (ESI): [MH]+ = 274.2. 
5-Chloro-2-furan-2-yl-8-propyl-8H-pyrrolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (39b) White solid; 63% yield; mp 
81-82 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 8.02 (d, J = 1 Hz, 
1H), 7.93 (d, J = 2 Hz, 1H), 7.68 (d, J = 2 Hz, 1H), 7.02-7.01 (m, 1H), 
6.76-6.75 (m, 1H), 4.18 (t, J = 7.4 Hz, 2H), 1.91-1.79 (m, 2H), 0.85 (t, 
J = 7.4 Hz, 3H). MS (ESI): [MH]+ = 302.1. 
5-Chloro-2-furan-2-yl-8-phenethyl-8H-pyrrolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (39c) White solid; 60% yield; mp 
182-184 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 8.02-8.01 (m, 1H), 
7.87 (d, J = 2 Hz, 1H), 7.63 (d, J = 1.6 Hz, 1H), 7.29-7.20 (m, 5H), 
7.02-7.01 (m, 1H), 6.75-6.74 (m, 1H), 4.49 (t, J = 7.2 Hz, 2H), 3.19 (t, 
J = 7.2 Hz, 2H). MS (ESI): [MH]+ = 364.0. 
5-Chloro-2-furan-2-yl-8-(3-phenyl-propyl)-8H-pyrrolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (39d) White solid; 65% yield; mp 
138 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 8.02 (t, J = 0.8 Hz, 1H), 
7.97 (d, J = 2 Hz, 1H), 7.72 (d, J = 2 Hz, 1H), 7.29-7.19 (m, 5H), 7.03 
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(d, J = 3.2 Hz, 1H), 6.76-6.74 (m, 1H), 4.26 (t, J = 6.8 Hz, 2H), 2.55 
(t, J = 8.4 Hz, 2H, 2.18 (m, 2H). MS (ESI): [MH]+ = 379.2. 
5-Chloro-2-(2-furyl)-9-methyl-9H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (66a) White solid; 43% yield; mp 
221-223 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 8.31 (s, 1H), 8.08-
8.07 (m, 1H), 7.10-7.09 (m, 1H), 6.80-6.79 (m, 1H), 4.42 (s, 3H). MS 
(ESI): [MH]+ = 275.2. 
5-Chloro-2-(2-furyl)-8-methyl-8H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (66b) White solid; 52% yield; mp 
238 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 8.70 (s, 1H), 8.06-8.05 
(m, 1H), 7.07-7.06 (m, 1H), 6.78-6.77 (m, 1H), 4.20 (s, 3H). MS 
(ESI): [MH]+ = 275.2. 
5-Chloro-2-(2-furyl)-9-propyl-9H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (67a) White solid; 76% yield; mp 
104-105 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 8.32 (s, 1H), 8.08-
8.06 (m, 1H), 7.10-7.07 (m, 1H), 6.80-6.78 (m, 1H), 4.73 (t, J = 7 Hz, 
2H), 2.02-1.99 (m, 2H), 0.88 (t, J = 7.4 Hz, 3H). MS (ESI): [MH]+ = 
303.0. 
5-Chloro-2-(2-furyl)-8-propyl-8H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (67b) White solid; 46% yield; mp 
155 °C; 1H NMR (200MHz, CDCl3) δ ppm 8.04 (s, 1H), 7.71-7.70 (m, 
1H), 7.00-6.98 (m, 1H), 6.64-6.62 (m, 1H), 4.41 (t, J = 7.2 Hz, 2H), 
2.10-2.06 (m, 2H), 0.97 (t, J = 7.6 Hz, 3H). MS (ESI): [MH]+ = 303.0. 
5-Chloro-2-(2-furyl)-9-(2-phenylethyl)-9H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (68a) White solid; 89% yield; mp 
178 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 8.30 (s, 1H), 8.08-8.07 
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(m, 1H), 7.26-7.21 (m, 5H), 7.11-7.09 (m, 1H), 6.81-6.78 (m, 1H), 
4.99 (t, J = 7.2 Hz, 2H), 3.33 (t, J = 7 Hz, 2H).  
5-Chloro-2-(2-furyl)-8-(2-phenylethyl)-8H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (68b) White solid; 57% yield; mp 
186 °C; 1H NMR (200MHz, CDCl3) δ ppm 7.71-7.70 (m, 2H), 7.25-
7.24 (m, 3H), 7.11-7.02 (m, 2H), 6.99 (m, 1H), 6.61 (m, 1H), 4.66 (t, 
J = 7.2 Hz, 2H), 3.35 (t, J = 7 Hz, 2H). 
5-Chloro-2-(2-furyl)-9-(3-phenylpropyl)-9H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (69a) White solid; 76% yield; mp 
155-157 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 8.34 (s, 1H), 8.08-
8.07 (m, 1H), 7.25-7.15 (m, 5H), 7.10-7.09 (m, 1H), 6.80-6.79 (m, 
1H), 4.81 (t, J = 6.8 Hz, 2H), 2.63 (t, J = 7.2 Hz, 2H), 2.33-2.29 (m, 
2H). MS (ESI): [MH]+ = 378.9. 
5-Chloro-2-(2-furyl)-8-(3-phenylpropyl)-8H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (69b) White solid; 62% yield; mp 
173 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 8.09 (s, 1H), 7.89-7.81 
(m, 1H), 7.35-7.22 (m, 5H), 7.01-6.99 (m, 1H), 6.75-6.67 (m, 1H), 
4.32 (t, J = 6.8 Hz, 2H), 2.54 (t, J = 7.2 Hz, 2H), 2.25-2.19 (m, 2H). 
MS (ESI): [MH]+ = 378.9. 
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General procedure for preparation of 5-amino-2-furan-2-yl-8-
alkyl-8H-pyrrolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidine (40a-d) and 
5-amino-2-furan-2-yl-8/9-alkyl-8/9H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (74-77a,b) 
 
 
 
 
 
 
130 mg of opportune pyrrolo/pyrazolo-triazolo pyrimidine (39a-d,66-
69a,b) were dissolved in 20 mL of EtOH previously saturated at 0 °C 
with ammonia. The mixture was heated in a steel bomb at 60 °C for 
24 h. The solvent was removed under reduced pressure and the 
residue was purified via column chromatography eluting with a mix-
ture CH2Cl2/ CH3OH 9.5:0.5. 
5-Amino-2-furan-2-yl-8-methyl-8H-pyrrolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (40a) White solid; 80% yield; mp 
273 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 7.92 (d, J = 1 Hz, 1H), 
7.55 (d, J = 2.2 Hz, 1H), 7.16 (t, J = 3.4 Hz, 1H), 7.01-7.00 (m, 3H), 
6.72 (m, 1H), 3.87 (s, 3H). MS (ESI): [MH]+ = 255.2. 
5-Amino-2-furan-2-yl-8-propyl-8H-pyrrolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (40b) White solid; 75% yield; mp 
176 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 7.92-7.90 (m, 1H), 7.61 
(d, J = 2.2 Hz, 1H), 7.31 (bs, 1H), 7.17-7.15 (m, 1H), 7.06 (d, J = 2.2 
Hz, 1H), 6.98 (s, 1H), 6.72-6.70 (m, 1H), 4.08 (t, J = 6.8 Hz, 2H), 
1.84-1.77 (m, 1H), 0.84 (t, J = 7.4 Hz,3H). MS (ESI): [MH]+ = 283.1. 
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5-Amino-2-furan-2-yl-8-phenethyl-8H-pyrrolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (40c) White solid; 77% yield; mp 
148-150 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 7.91-7.90 (m, 1H), 
7.53 (d, J = 2Hz, 1H), 7.29-7.20 (m, 5H), 7.16-7.15 (m, 1H), 7.05 (d, 
J = 2 Hz, 1H), 6.99 (bs, 2H), 6.71-6.70 (m, 1H), 4.38 (t, J = 7.2 Hz, 
2H), 3.15 (t, J = 7.2 Hz, 2H). MS (ESI): [MH]+ = 345.4. 
5-Amino-2-furan-2-yl-8-(3-phenyl-propyl)-8H-pyrrolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (40d) White solid; 77% yield; mp 
155-157 °C;1H NMR (400MHz, CDCl3) δ ppm 7.62 (bs, 1H), 7.44 (bs, 
1H), 7.30-7.15 (bm, 6H), 6.97 (bs, 1H), 6.59 (bs, 1H), 6.19 (bs, 2H), 
4.08 (bm, 2H), 2.61 (bm, 2H), 2.23 (bm, 2H). MS (ESI): [MH]+ = 
359.2. 
5-Amino-2-(2-furyl)-9-methyl-9H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (74a) White solid; 72% yield; mp 
270 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 7.98-7.97 (m, 1H), 7.85 
(s, 1H), 7.47 (bs, 2H), 7.27-7.26 (m, 1H), 6.76-6.75 (m, 1H), 4.28 (s, 
3H). 
5-Amino-2-(2-furyl)-8-methyl-8H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (74b) White solid; 77% yield; mp 
295 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 8.14 (s, 1H), 7.96 (d, J 
= 1.2 Hz, 1H), 7.37 (bs, 2H), 7.24 (d, J = 3.6 Hz, 1H), 6.75-6.74 (m, 
1H), 4.11 (s, 3H). 
5-Amino-2-(2-furyl)-9-propyl-9H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (75a) White solid; 82% yield; mp 
229 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 7.98 (s, 1H), 7.88 (s, 
1H), 7.47 (bs, 2H), 7.26 (d, J =3.2 Hz, 1H), 6.77-6.74 (m, 1H), 4.58 
(t, J = 7 Hz, 2H), 1.99-1.95 (m, 2H), 0.85 (t, J = 7.6 Hz, 3H). 
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5-Amino-2-(2-furyl)-8-propyl-8H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (75b) White solid; 78% yield; mp 
198 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 8.18 (s, 1H), 7.96-7.95 
(m, 1H), 7.36 (bs, 2H), 7.25-7.23 (m, 1H), 6.76-6.73 (m, 1H), 4.32 (t, 
J = 7 Hz, 2H), 1.94-1.90 (m, 2H), 0.86 (t, J = 7.4 Hz, 3H). 
5-Amino-2-(2-furyl)-9-(2-phenylethyl)-9H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (76a) White solid; 85% yield; mp 
239 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 7.99 (d, J = 1.2 Hz, 
1H), 7.85 (s, 1H), 7.47 (bs, 2H), 7.28-7.14 (m, 6H), 6.78-6.76 (m, 
1H), 4.84 (t, J = 6.8 Hz, 2H), 3.33-3.24 (m, 2H). 
5-Amine-2-(2-furyl)-8-(2-phenylethyl)-8H-pyrazolo[3,4-e] 
[1,2,4]triazolo[1,5-c]pyrimidine (76b) White solid; 82% yield; mp 
218 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 8.07 (s, 1H), 7.96 (d, J 
= 1Hz, 1H), 7.37 (bs, 2H), 7.27-7.18 (m, 6H), 6.76-6.74 (m, 1H), 4.61 
(t, J = 7 Hz, 2H), 3.35-3.25 (m, 2H). 
5-Amino-2-(2-furyl)-9-(3-phenylpropyl)-9H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (77a) White solid; 78% yield; mp 
208 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 7.99-7.98 (m, 1H), 7.89 
(s, 1H), 7.48 (bs, 2H), 7.25-7.15 (m, 6H), 6.78-6.75 (m, 1H), 4.63 (t, J 
= 7 Hz, 2H), 2.61 (t, J = 7.2 Hz, 2H), 2.32-2.24 (m, 2H). 
5-Amino-2-(2-furyl)-8-(3-phenylpropyl)-8H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (77b) White solid; 84% yield; mp 
161-163 °C; 1H NMR (200MHz, CDCl3) δ ppm 7.78 (s, 1H), 7.65-7.63 
(m, 1H), 7.37-7.16 (m, 6H), 6.62-6.60 (m, 1H), 6.21 (bs, 2H), 4.37 (t, 
J = 7.2 Hz, 2H), 2.66 (t, J = 7.8 Hz, 2H), 2.41-2.37 (m, 2H). 
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General procedure for preparation of 5-alkyl-2-(2-furyl)-9-methyl-
9H-pyrazolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidine (70-73) 
 
 
 
 
 
 
50 mg of pyrazolo-triazolo pyrimidine (66a) were dissolved in 2 mL of 
2-methoxyethanol and 1 mL of the opportune amine was added to 
the solution. The mixture was heated in a steel bomb at 100 °C for 4-
5 h. The solvent was removed under reduced pressure and the resi-
due was purified via column chromatography eluting with a mixture 
EtP/ EtOAc 1:4. 
N-cyclohexyl-2-(2-furyl)-9-methyl-9H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (70) White solid; 76% yield; mp 
175 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 7.98 (m, 1H), 7.94 (s, 
1H), 7.37 (d, J = 8 Hz, 1H), 7.29-7.28 (m, 1H), 6.76-6.75 (m, 1H), 
4.28 (s, 3H), 4.12-3.82 (m, 1H), 1.95-1.13 (m, 10H). 
2-(2-furyl)-9-methyl-5-morpholin-4-yl-9H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (71) White solid; 68% yield; mp 
193 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 8.15 (s, 1H), 8.08 (m, 
1H), 7.14-7.13 (m, 1H), 6.83-6.82 (m, 1H), 4.38 (s, 3H), 3.33 (m, 4H), 
2.98 (m, 4H). 
2-(2-furyl)-9-methyl-5-(4-methylpiperazin-1-yl)-9H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (72) White solid; 73% yield; mp 
159-160 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 8.13 (s, 1H), 8.05-
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8.04 (m, 1H), 7.11-7.10 (m, 1H), 6.81-6.80 (m, 1H), 4.37 (s, 3H), 
3.33 (m, 4H), 3.01 (m, 4H), 2.10 (s, 3H). 
2-(2-furyl)-9-methyl-5-(4-phenylpiperazin-1-yl)-9H-pyrazolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (73) White solid; 67% yield; mp 
105-106 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 8.16 (s, 1H),8.03-
8.02 (m, 1H), 7.23-7.19 (m, 2H), 7.15-7.14 (m, 1H), 6.91-6.89 (m, 
2H), 6.80-6.77 (m, 2H), 4.39 (s, 3H), 3.58 (m, 4H), 3.15 (m, 4H). 
 
General procedure for preparation of 5-{[(4-methoxy-
phenyl)carbamoyl]amino}-8-alkyl-(2-furan-2-yl)-8H-pyrrolo[3,4-
e][1,2,4]triazolo[1,5-c]pyrimidine (41a-c) and 5-{[(4-methoxy-
phenyl)carbamoyl]amino}-8/9-alkyl-(2-furan-2-yl)-8/9H-
pyrazolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidine (78-81a, 78-79b) 
N
N
N
X
N
N
O
H2N
N
N
N
X
N
N
O
N
H
N
H
OOR R
 
To a solution of the free amino derivative (40a-c, 78-81a, 78-79b, 
0.27 mmol) in anhydrous THF (5 mL) was added 4-methoxy-phenyl-
isocyanate (53.4 mmol) and the mixture was heated at 50 °C for 12h. 
The solvent was removed under reduced pressure and the residue 
was purified via column chromatography eluting with CH2Cl2. The 
crude solid was purified by crystallization from CH3OH. 
5-{[(4-methoxy-phenyl)carbamoyl]amino}-(2-furan-2-yl)-8-
methyl-8H-pyrrolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidine (41a) 
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White solid; 37% yield; mp 214-216 °C; 1H NMR (200MHz, DMSO-
d6) δ ppm 10.68 (bs, 1H), 9.18 (bs, 1H), 7.96-7.95 (m, 1H), 7.74 (d, J 
= 2Hz, 1H), 7.52 (dd, J = 9.2 Hz, 2H), 7.45 (bs, 1H), 7.26 (d, J = 3.2 
Hz, 1H), 6.81 (dd, J = 9 Hz, 2H), 6.75-6.73 (m, 1H), 3.95 (s, 3H), 
3.76 (s, 3H). MS (ESI): [MH]+ = 404.3. 
5-{[(4-methoxy-phenyl)carbamoyl]amino}-(2-furan-2-yl)-8-propyl-
8H-pyrrolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidine (41b) White solid; 
40% yield; mp 198-199°C; 1H NMR (200MHz, DMSO-d6) δ ppm 
10.72 (bs, 1H), 9.16 (bs, 1H), 7.97-7.96 (m, 1H), 7.55-7.50 (m, 3H), 
7.26 (d, J = 3.4 Hz, 1H), 6.95 (d, J = 9.2 Hz, 2H), 6.76-6.73 (m, 1H), 
4.18 (t, J = 7.4 Hz, 2H), 3.75 (s, 3H), 1.89-1.85 (m, 2H), 0.86 (t, J = 
7.4 Hz, 3H). MS (ESI): [MH]+ = 432.1. 
5-{[(4-methoxy-phenyl)carbamoyl]amino}-(2-furan-2-yl)-8-
phenylethyl-8H-pyrrolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidine 
(41c) White solid; 35% yield; mp 181-183 °C; 1H NMR (200MHz, 
DMSO-d6) δ ppm 10.66 (bs, 1H), 9.14 (bs, 1H), 7.96 (s, 1H), 7.74 (d, 
J = 2Hz, 1H), 7.54 (d, J = 2Hz, 1H), 7.51 (dd, J = 9Hz, 2H), 7.28-7.21 
(m, 6H), 6.95 (dd, J = 9Hz, 2H), 6.76-6.73 (m, 1H), 4.49 (t, J = 7.2 
Hz, 2H), 3.76 (s, 3H), 3.20 (t, J = 7.2 Hz, 2H). MS (ESI): [MH]+ = 
494.2. 
5-{[(4-pyridinyl)-carbamoyl]amino}-2-(2-furyl)-8-methyl-8H-
pyrrolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidine (41e) White solid; 
45% yield; mp 205-207 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 10.8 
(bs, 1H), 9.69 (bs, 1H),8.45-8.44 (m, 2H), 7.96-7.95 (m, 1H), 7.75 
(m, 1H), 7.60-7.58 (m, 2H), 7.48 (m, 1H), 7.25-7.24 (m, 1H), 6.75-
6.73 (m, 1H), 3.96 (s, 3H). 
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5-{[(4-methoxy-phenyl)carbamoyl]amino}-2-(2-furyl)-9-methyl-
9H-pyrazolo[3,4-e][1,2,4]triazolo[1,5c]pyrimidine (78a) White 
solid; 55% yield; mp 223 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 
10.35 (bs, 1H), 9.62 (bs, 1H), 8.24 (s, 1H), 8.03-8.02 (m, 1H), 7.51 
(dd, J = 8.8 Hz, 2H), 7.37 (d, J = 3.2 Hz, 1H), 6.95 (dd, J = 8.8 Hz, 
2H), 6.78-6.78 (m, 1H), 4.36 (s, 3H), 3.75 (s, 3H). MS (ESI): [MH]+ = 
405.0. 
5-{[(4-methoxy-phenyl)carbamoyl]amino}-2-(2-furyl)-8-methyl-
8H-pyrazolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidine (78b) White 
solid; 61% yield; mp 253-255 °C; 1H NMR (400MHz, DMSO-d6) δ 
ppm 10.38 (bs, 1H), 9.50 (bs, 1H), 8.56 (s, 1H), 8.01-8.00 (m, 1H), 
7.50 (dd, J = 9.2 Hz, 2H), 7.34 (d, J = 2.8 Hz, 1H), 6.95 (dd, J = 9.2 
Hz, 2H), 6.78-6.77 (m, 1H), 4.20 (s, 3H), 3.75 (s, 3H). MS (ESI): 
[MH]+ = 405.0. 
5-{[(4-methoxy-phenyl)carbamoyl]amino}-2-(2-furyl)-9-propyl-
9H-pyrazolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidine (79a) White 
solid; 50% yield; mp 202 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 
10.37 (bs, 1H), 9.61 (bs, 1H), 8.26 (s, 1H), 8.02 ( d, J =1 Hz, 
1H),7.52 (dd, J = 8.8 Hz, 2H), 7.36 (d, J = 2.6 Hz, 1H), 6.95 (d, J = 
9Hz, 2H), 6.78-6.77 (m, 1H), 4.66 (t, J = 6.6 Hz, 2H), 3.75 (s, 3H), 
2.08-1.99 (m, 2H), 0.87 (t, J = 7.4 Hz, 3H). MS (ESI): [MH]+ = 433.0. 
5-{[(4-methoxy-phenyl)carbamoyl]amino}-2-(2-furyl)-8-propyl-
8H-pyrazolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidine (79b) White 
solid; 40% yield; mp 238 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 
10.43 (bs, 1H), 9.58 (bs, 1H), 8.60 (s, 1H), 8.01 (s, 1H), 7.51 (dd, J = 
8.8 Hz, 2H), 7.33 (d, J =3.4 Hz, 1H), 6.95 (dd, J = 9 Hz, 2H), 6.79-
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6.76 (m, 1H), 4.41 (t, J =6.8 Hz, 2H), 3.75 (s, 3H), 1.98-1.94 (m, 2H), 
0.88 (t, J = 7.4 Hz, 3H). MS (ESI): [MH]+ = 433.1. 
5-{[(4-methoxy-phenyl)carbamoyl]amino}-2-(2-furyl)-9-(2-
phenylethyl)-9H-pyrazolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidine 
(80a) White solid; 27% yield; mp 199 °C; 1H NMR (400MHz, DMSO-
d6) δ ppm 10.39 (bs, 1H), 9.55 (bs, 1H), 8.23 (s, 1H), 8.04 (s, 1H), 
7.51 (dd, J =8.8 Hz, 2H), 7.37 (d, J = 3.6 Hz, 1H), 7.24-7.23 (m, 5H), 
6.95 (dd, J = 8.8 Hz, 2H), 6.80 (d, J = 1.2 Hz, 1H), 4.92 (t, J = 7 Hz, 
2H), 3.75 (s, 3H), 3.34-3.27 (m, 2H).  
5-{[(4-methoxy-phenyl)carbamoyl]amino}-2-(2-furyl)-9-(3-
phenylpropyl)-9H-pyrazolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidine 
(81a) White solid; 32% yield; mp 205-207 °C; 1H NMR (200MHz, 
DMSO-d6) δ ppm 10.39 (bs, 1H), 9.68 (bs, 1H), 8.26 (s, 1H), 8.03-
8.02 (m, 1H), 7.52 (dd, J =9 Hz, 2H), 7.33-7.31 (m, 1H), 7.22-7.19 
(m, 5H), 6.95 (dd, J = 9 Hz, 2H), 6.81-6.78 (m, 1H), 4.72 (t, J = 7 Hz, 
2H), 3.75 (s, 3H), 2.62 (t, J = 7.2 Hz, 2H), 2.39-2.21 (m, 2H).  
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Experimental section of imidazo[2,1-i]purin-5-one derivatives 
Chemical Material and Methods Reaction progress and product 
mixtures were monitored by thin-layer chromatography (TLC) on sil-
ica gel (precoated F254 Merck plates) and visualized with aqueous 
potassium permanganate. 1H NMR data were determined in CDCl3 
or DMSO-d6 solutions with a Varian VXR 200 spectrometer or a Var-
ian Mercury Plus 400 spectrometer. Peak positions are given in parts 
per million (δ) downfield from tetramethylsilane as internal standard, 
and J values are given in hertz. Light petroleum refers to the frac-
tions boiling at 40-60 °C. Melting points were determined on a Buchi-
Tottoli instrument and are uncorrected. Chromatography was per-
formed on Merck 230-400 mesh silica gel. Organic solutions were 
dried over anhydrous sodium sulfate. Chiral amino alcohols were 
purchased from Alfa Aesar or Aldrich in the highest available purity 
grade. The mass spectra were obtained on a ESI Micromass ZMD 
2000 mass spectrometer.  
All final compounds revealed a purity of not less then 95%. 
 
General procedure for the synthesis of 3-allyl/benzyl-8-
[(substituted)isoxazol/pyrazol-3/5-yl]-1H-purine-2,6(3H,7H)-dione 
derivatives (96a-j).  
HN
N
O
O
R
NH2
NH2
HN
N N
H
N
O
O
R
Het
 
To a solution of the appropriately substituted isoxazol/pyrazol-
carboxylic acid (87a,b, 91a,b, 94, 2.5 mmol) in DMF (7 mL), 
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EDC·HCl (2.5 mmol, N-Ethyl-N'-(3-dimethylamino-propyl)-
carbodiimide hydrochloride) and HOBt (2.5 mmol, hydroxybenzotria-
zole) were added. The mixture was stirred at room temperature for 
10’ then, 5,6-diamino-1-allyl/benzyl-1H-pyrimidine-2,4-dione (95a,b, 
2.5 mmol) was added. The mixture was stirred for further 24 h then 
the solvent was evaporated and the residue was suspended with 
H2O (30 mL) to favor the precipitation of a solid which was subse-
quently filtrated and washed with cold H2O. The solid was suspended 
with a 10% aqueous solution of NaOH and the mixture was refluxed 
for 1.5 h. The reaction was cooled at 0°C and acidified with a 10% 
aqueous solution of HCl to obtain a precipitate which was filtered, 
washed with cold water and finally crystallized from DMF-H2O. 
3-Allyl-8-(1,3-dimethyl-1H-pyrazol-5-yl)-1H-purine-2,6(3H,7H)-
dione (96a) Pale white solid; 65% yield; mp >300 °C; 1H NMR 
(200MHz, DMSO-d6) δ ppm 13.83 (bs, 1H), 11.24 (bs, 1H), 6.77 
(s,1H), 5.97-5.88 (m, 1H), 5.22-5.14 (m, 2H), 4.56 (m, 2H), 4.11 (s, 
3H), 2.18 (s, 3H). 
3-Benzyl-8-(1,3-dimethyl-1H-pyrazol-5-yl)-1H-purine-2,6(3H,7H)-
dione (96b) White solid; 57% yield; mp >300 °C; 1H NMR (200MHz, 
DMSO-d6) δ ppm 13.90 (bs, 1H), 11.25 (s, 1H), 7.32 (m, 5H), 6.75 (s, 
1H), 5.15 (s, 2H), 4.10 (s, 3H), 2.17 (s, 3H). 
3-Allyl-8-(3-methoxy-1-methyl-1H-pyrazol-5-yl)-1H-purine-
2,6(3H,7H)-dione (96c) White solid; 81% yield; mp >300 °C; 1H 
NMR (200MHz, DMSO-d6) δ ppm 13.93 (bs, 1H), 11.27 (s, 1H), 6.45 
(s, 1H), 6.11-5.92 (m, 1H), 5.22-5.13 (m, 2H), 4.57 (d, J = 5 Hz, 2H), 
4.06 (s, 3H), 3.79 (s, 3H). 
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3-Benzyl-8-(3-methoxy-1-methyl-1H-pyrazol-5-yl)-1H-purine-
2,6(3H,7H)-dione (96d) White solid; 60% yield; mp >300 °C; 1H 
NMR (200MHz, DMSO-d6) δ ppm 13.89 (bs, 1H), 11.32 (s, 1H), 7.43-
7.22 (m, 5H), 6.41 (s, 1H), 5.15 (s, 2H), 4.05 (s, 3H), 3.79 (s, 3H). 
3-Allyl-8-(3-(benzyloxy)-1-methyl-1H-pyrazol-5-yl)-1H-purine-
2,6(3H,7H)-dione (96e) White solid; 57% yield; mp 296 °C dec.; 1H 
NMR (200MHz, DMSO-d6) δ ppm 13.87 (bs, 1H), 11.27 (s, 1H), 7.43-
7.36 (m, 5H), 6.46 (s, 1H), 6.02-5.87 (m, 1H), 5.16-5.13 (m, 4H), 
4.57 (d, J = 5 Hz, 2H), 4.07 (s, 3H). 
3-Benzyl-8-(3-(benzyloxy)-1-methyl-1H-pyrazol-5-yl)-1H-purine-
2,6(3H,7H)-dione (96f) White solid; 58% yield; mp >300 °C; 1H NMR 
(200MHz, DMSO-d6) δ ppm 13.94 (bs, 1H), 11.32 (s, 1H), 7.43-7.29 
(m, 10H), 6.45 (s, 1H), 5.16 (s, 4H), 4.06 (s, 3H). 
3-Allyl-8-(1,5-dimethyl-1H-pyrazol-3-yl)-1H-purine-2,6(3H,7H)-
dione(96g) White solid; 66% yield; mp >300 °C; 1H NMR (200MHz, 
DMSO-d6) δ ppm 13.61 (bs, 1H), 11.08 (s, 1H), 6.65 (s, 1H), 5.87 (m, 
1H), 5.15-5.04 (m, 2H), 4.56 (m, 2H), 3.80 (s, 3H), 2.29 (s, 3H). 
3-Benzyl-8-(1,5-dimethyl-1H-pyrazol-3-yl)-1H-purine-2,6(3H,7H)-
dione (96h) White solid; 77% yield; mp >300 °C; 1H NMR (200MHz, 
DMSO-d6) δ ppm 13.45 (bs, 1H), 11.14 (s, 1H), 7.33-7.10 (m, 5H), 
6.65 (s, 1H), 5.15 (s, 2H), 3.79 (s, 3H), 2.29 (s, 3H). 
3-Allyl-8-(3-methoxyisoxazol-5-yl)-1H-purine-2,6(3H,7H)-dione 
(96i) Pale white solid; 45% yield; mp 297 °C; 1H NMR (200MHz, 
DMSO-d6) δ ppm 14.55 (bs, 1H), 11.37 (s, 1H), 6.84 (s, 1H), 6.01-
5.87 (m, 1H), 5.16-5.06 (m, 2H), 4.56 (m, 2H), 3.96 (s, 3H). 
3-Benzyl-8-(3-methoxyisoxazol-5-yl)-1H-purine-2,6(3H,7H)-dione 
(96j) Pale yellow solid; 40% yield; mp 284 °C dec.; 1H NMR 
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(200MHz, DMSO-d6) δ ppm 14.45 (bs, 1H),11.41 (bs, 1H), 7.34-7.22 
(m, 5H), 6.84 (s, 1H), 5.15 (s, 2H), 3.96 (s, 3H). 
 
General procedure for the synthesis of 3-allyl/benzyl-1,6-
dihydro-8-[(substituted)isoxazol/pyrazol-3/5-yl]-6-thioxo-3H-
purin-2(7H)-one derivatives (97a-j)165 
HN
N N
H
N
O
O
R
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The appropriate 3-allyl/benzyl-8-[(substituted)isoxazol/pyrazol-3/5-
yl]-1H-purine-2,6(3H,7H)-dione derivative (96a-j, 1.5 mmol) was dis-
solved with pyridine (10 mL) and 2.55 mmol of P2S5 were added. The 
reaction was vigorously stirred at 140°C for 5h then cooled at 0°C. 
After the addition of water (30 mL) a pale green solid precipitated 
which was filtered, washed with cold water and crystallized from 
DMF/H2O. 
3-Allyl-1,6-dihydro-8-(1,3-dimethyl-1H-pyrazol-5-yl)-6-thioxo-3H-
purin-2(7H)-one (97a) Pale yellow solid; 95% yield; mp 272 °C; 1H 
NMR (200MHz, DMSO-d6) δ ppm 13.80 (bs, 1H), 12.40 (s, 1H), 7.01 
(s, 1H), 6.10-5.80 (m, 1H), 5.25-5.16 (m, 2H), 4.59 (d, 2H, J = 5.8), 
4.12 (s, 3H), 2.19 (s, 3H). 
3-Benzyl-1,6-dihydro-8-(1,3-dimethyl-1H-pyrazol-5-yl)-6-thioxo-
3H-purin-2(7H)-one (97b) Yellow solid; 87% yield; mp 265 °C; 1H 
NMR (200MHz, DMSO-d6) δ ppm 13.66 (bs, 1H), 12.28 (bs, 1H), 
7.32 (m, 5H), 6.86 (s, 1H), 5.17 (s, 2H), 3.81 (s, 3H), 2.30 (s, 3H). 
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3-Allyl-1,6-dihydro-8-(3-methoxy-1-methyl-1H-pyrazol-5-yl)-6-
thioxo-3H-purin-2(7H)-one (97c) Pale yellow; 82% yield; mp 272 °C 
dec; 1H NMR (200MHz, DMSO-d6) δ ppm 13.81 (bs, 1H), 12.43 (bs, 
1H), 6.68 (s, 1H), 6.11-5.97 (m, 1H), 5.25-5.16 (m, 2H), 4.60 (d, J = 
4.6 Hz, 2 H), 4.07 (s, 3H), 3.80 (s, 3H). 
3-Benzyl-1,6-dihydro-8-(3-methoxy-1-methyl-1H-pyrazol-5-yl)-6-
thioxo-3H-purin-2(7H)-one (97d) Pale yellow solid; 84% yield; mp 
293-295 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 13.92 (bs, 1H), 
12.48 (bs, 1H), 7.40-7.30 (m, 5H), 6.68 (s, 1H), 5.18 (s, 2H), 4.06 (s, 
3H), 3.80 (s, 3H). 
3-Allyl-8-(3-(benzyloxy)-1-methyl-1H-pyrazol-5-yl)-1,6-dihydro-6-
thioxo-3H-purin-2(7H)-one (97e) Pale yellow solid; 71% yield; mp 
241 °C dec.; 1H NMR (200MHz, DMSO-d6) δ ppm 13.82 (bs, 1H), 
12.43 (bs, 1H), 7.44-7.36 (m, 5H), 6.71 (s, 1H), 6.15-5.82 (m, 1H), 
5.25-5.16 (m, 2H), 4.60 (d, J = 4 Hz, 2H), 4.08 (s, 3H). 
3-Benzyl-8-(3-(benzyloxy)-1-methyl-1H-pyrazol-5-yl)-1,6-dihydro-
6-thioxo-3H-purin-2(7H)-one (97f) Pale yellow solid; 96% yield; mp 
244 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 13.89 (bs, 1H), 12.50 
(s, 1H), 7.47-7.30 (m, 10H), 6.72 (s, 1H), 5.19 (s, 2H), 5.17 (s, 2H), 
4.08 (s, 3H). 
3-Allyl-1,6-dihydro-8-(1,5-dimethyl-1H-pyrazol-3-yl)-6-thioxo-3H-
purin-2(7H)-one (97g) Yellow solid; yield 83%; mp 280-282 °C; 1H 
NMR (200MHz, DMSO-d6) δ ppm 13.60 (bs, 1H), 12.23 (bs, 1H), 
6.86 (s, 1H), 5.97-5.89 (m, 1H), 5.18-5.06 (m, 2H), 4.58 (d, J = 4.6 
Hz, 2H), 3.82 (s, 3H), 2.31 (s, 3H). 
3-Benzyl-1,6-dihydro-8-(1,5-dimethyl-1H-pyrazol-3-yl)-6-thioxo-
3H-purin-2(7H)-one (97h) Yellow solid; yield 87 %; mp 288 °C; 1H 
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NMR (200MHz, DMSO-d6) δ ppm 13.63 (bs, 1H), 12.26 (bs, 1H), 
7.30 (m, 5H), 6.84 (s, 1H), 5.15 (s, 2H), 3.78 (s, 3H), 2.28 (s, 3H). 
3-Allyl-1,6-dihydro-8-(3-methoxyisoxazol-5-yl)-6-thioxo-3H-purin-
2(7H)-one (97i) Pale yellow solid; 75% yield; mp 254 °C dec.; 1H 
NMR (200MHz, DMSO-d6) δ ppm 14.51 (bs, 1H), 12.61 (bs, 1H), 
8.63 (s, 1H), 6.12-5.82 (m, 1H), 5.21 (m, 2H), 4.62 (m, 2H), 4.02 (s, 
3H). 
3-Benzyl-1,6-dihydro-8-(3-methoxyisoxazol-5-yl)-6-thioxo-3H-
purin-2(7H)-one (97j) Pale green solid; 96 % yield; mp 205 °C dec. ; 
1H NMR (200MHz, DMSO-d6) δ ppm 14.45 (bs, 1H), 12.62 (bs, 1H), 
8.59 (s, 1H), 7.43-7.19 (m, 5H), 5.17 (s, 2H), 3.97 (s, 3H). 
 
General procedure for the synthesis of 3-allyl/benzyl-8-
[(substituted)isoxazol/pyrazol-3/5-yl]-6-(methylthio)-3H-purin-
2(7H)-one derivatives (98a-j)  
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The appropriate 3-allyl/benzyl-1,6-dihydro-8-
[(substituted)isoxazol/pyrazol-3/5-yl]-6-thioxo-3H-purin-2(7H)-one de-
rivative (97a-j, 1 mmol) was dissolved in 10 mL of NaOH 0.5N and 
EtOH (5 mL). After cooling at 0°C, CH3I (1.5 mmol) was added and 
the reaction was stirred at room temperature for 3h. The mixture was 
acidified with HCl 5% to obtain a precipitate which was collected by 
filtration, washed with cold H2O and dried under vacuum.  
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3-Allyl-8-(1,3-dimethyl-1H-pyrazol-5-yl)-6-(methylthio)-3H-purin-
2(7H)-one (98a) Pale white solid; 68% yield; mp 250-252 °C; 1H 
NMR (200MHz, DMSO-d6) δ ppm 13.63 (bs, 1H), 6.82 (s 1H), 6.17-
5.85 (m, 1H), 5.19 (m, 2H), 4.68 (d, J =5.2 Hz, 2H), 4.14 (s, 3H), 2.63 
(s, 3H), 2.21 (s, 3H). 
3-Benzyl-8-(1,3-dimethyl-1H-pyrazol-5-yl)-6-(methylthio)-3H-
purin-2(7H)-one (98b) Yellow solid; 93% yield; mp 163-165 °C; 1H 
NMR (200MHz, DMSO-d6) δ ppm 13.76 (bs, 1H), 7.30-7.26 (m, 5H), 
6.69 (s, 1H), 5.25 (s, 2H), 3.83 (s, 3H), 2.56 (s, 3H), 2.32 (s, 3H). 
3-Allyl-8-(3-methoxy-1-methyl-1H-pyrazol-5-yl)-6-(methylthio)-
3H-purin-2(7H)-one (98c) Pale yellow solid; 78% yield; mp 243 °C 
dec. ; 1H NMR (200MHz, DMSO-d6) δ ppm 13.63 (bs, 1H), 6.39 (s, 
1H), 6.15-5.86 (m, 1H), 5.17-5.11 (m, 2H), 4.66 (d, J = 4.8 Hz, 2H), 
4.07 (s, 3H), 3.80 (s, 3H), 2.62 (s, 3H). 
3-Benzyl-8-(3-methoxy-1-methyl-1H-pyrazol-5-yl)-6-(methylthio)-
3H-purin-2(7H)-one (98d) White solid; 48% yield; mp 268-270 °C; 
1H NMR (200MHz, DMSO-d6) δ ppm 13.73 (bs, 1H), 7.39-7.27 (m, 
5H), 6.46 (s, 1H), 5.25 (s, 2H), 4.08 (s, 3H), 3.81 (s, 3H), 2.63 (s, 
3H). 
3-Allyl-8-(3-(benzyloxy)-1-methyl-1H-pyrazol-5-yl)-6-(methylthio)-
3H-purin-2(7H)-one (98e) Pale yellow solid; 85% yield; mp 224 °C; 
1H NMR (200MHz, DMSO-d6) δ ppm 13.79 (bs, 1H), 7.4-7.34 (m, 
5H), 6.53 (s, 1H), 6.15-5.87 (m, 1H), 5.19-5.11 (m, 4H), 4.68 (d, J = 
4.4 Hz, 2H), 4.09 (s, 3H), 2.62 (s, 3H). 
3-Benzyl-8-(3-(benzyloxy)-1-methyl-1H-pyrazol-5-yl)-6-
(methylthio)-3H-purin-2(7H)-one (98f) White solid; 87% yield; mp 
228 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 13.79 (bs, 1H), 7.43-
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7.27 (m, 5H), 6.47 (s, 1H), 5.26 (s, 2H), 5.18 (s, 2H), 4.10 (s, 3H), 
2.63 (s, 3H). 
3-Allyl-8-(1,5-dimethyl-1H-pyrazol-3-yl)-6-(methylthio)-3H-purin-
2(7H)-one (98fg) White solid; 95% yield; mp 242-244 °C; 1H NMR 
(200MHz, DMSO-d6) δ ppm 13.99 (bs, 1H),  6.71 (s, 1H), 6.11-5.85 
(m, 1H), 5.16-5.03 (m, 2H), 4.67 (d, J = 4.6 Hz, 2H), 3.84 (s, 3H), 
2.61 (s, 3H), 2.32 (s, 3H). 
3-Allyl-8-(1,5-dimethyl-1H-pyrazol-3-yl)-6-(methylthio)-3H-purin-
2(7H)-one (98h) White solid; 82% yield; mp 183 °C; 1H NMR 
(200MHz, DMSO-d6) δ ppm 13.80 (bs, 1H), 7.30 (m, 5H), 6.69 (s, 
1H), 5.25 (s, 2H), 3.83 (s, 3H), 2.56 (s, 3H), 2.31 (s, 3H). 
3-Allyl-8-(3-methoxyisoxazol-5-yl)-6-(methylthio)-3H-purin-2(7H)-
one (98i) Pale yellow solid; 73% yield; mp 271 °C dec.; 1H NMR 
(200MHz, DMSO-d6) δ ppm 14.38 (bs, 1H), 6.90 (s, 1H), 6.09-5.80 
(m, 1H), 5.11 (m, 2H), 4.65 (m, 2H), 3.97 (s, 3H), 2.67 (s, 3H). 
3-Benzyl-8-(3-methoxyisoxazol-5-yl)-6-(methylthio)-3H-purin-
2(7H)-one (98j) Pale yellow solid; 75% yield; mp 249-251 °C dec.; 1H 
NMR (200MHz, DMSO-d6) δ ppm 14.62 (bs, 1H),7.35-7.28 (m, 5H), 
6.91 (s, 1H), 5.25 (s, 2H), 3.97 (s, 3H), 2.68 (s, 3H).  
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General procedure for the synthesis of 6-(1-
hydroxybutan/propan-2-ylamino)-3-allyl/benzyl-8-
[(substituted)isoxazol/pyrazol-3/5-yl]-3H-purin-2(7H)-one deriva-
tives (99-118) 
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The appropriate 3-allyl/benzyl-8-[(substituted)isoxazol/pyrazol-3/5-
yl]-6-(methylthio)-3H-purin-2(7H)-one derivative (98a-j, 0.3 mmol) 
was suspended in anhydrous DMSO (0.3 mL) and, after cooling at 
0°C, the opportune (R/S/R,S)-2-amino-butan/propan-1-ol (1.5 mmol) 
was added. The reaction was heated at 150 °C for 1h. The solvent 
was evaporated under vacuum and the product was precipitated 
from CH2Cl2-Et2O, filtered, washed with Et2O and finally purified via 
column chromatography on silica gel eluting with EtOAc/CH3OH 
9.5:0.5.  
(R,S)-3-allyl-8-(1,3-dimethyl-1H-pyrazol-5-yl)-6-[(2-hydroxy-1-
methylethyl)amino]-3,7-dihydro-2H-purin-2-one (99) White solid; 
56 % yield; mp 255-256 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 
12.98 (bs, 1H), 7.43 (bs, 1H), 6.45 (s, 1H), 6.18-5.83 (m, 1H), 5.18-
5.03 (m, 3H), 4.59 (d, J = 3 Hz, 2H), 4.22 (m, 1H), 4.13 (s, 3H), 3.58 
(m, 2H), 2.18 (s, 3H), 1.22 (m, 3H); MS (ESI): [MH]+ = 344.3. 
(R)-3-allyl-8-(1,3-dimethyl-1H-pyrazol-5-yl)-6-[(2-hydroxy-1-
methylethyl)amino]-3,7-dihydro-2H-purin-2-one ((R)99) White 
solid; 66% yield; mp 253-254 °C, dec.; 1H NMR (200MHz, DMSO-d6) 
Chapter 4          Experimental section of imidazo[2,1-i]purin-5-one derivatives 
 104 
δ ppm 12.38 (bs, 1H), 7.43 (bs, 1H), 6.45 (s, 1H), 6.03-5.84 (m, 1H), 
5.14-5.08 (m, 3H), 4.57 (d, J = 4.8 Hz, 2H), 4.21 (m, 1H), 4.11 (s, 
3H), 3.51 (m, 2H), 2.17 (s, 3H), 1.22-1.16 (m, 3H). MS (ESI): [MH]+ = 
344.3. 
(S)-3-allyl-8-(1,3-dimethyl-1H-pyrazol-5-yl)-6-[(2-hydroxy-1-
methylethyl)amino]-3,7-dihydro-2H-purin-2-one ((S)99) White 
solid; 52% yield; mp 253-254 °C dec.; 1H NMR (200MHz, DMSO-d6) 
δ ppm 12.80 (bs, 1H), 7.42 (bs, 1H), 6.48 (s, 1H), 6.05-5.82 (m, 1H), 
5.15-4.92 (m, 3H), 4.58 (d, J = 5.0 Hz, 2H), 4.22 (m, 1H), 4.12 (s, 
3H), 3.51 (m, 2H), 2.19 (s, 3H), 1.22-1.17 (m, 3H). MS (ESI): [MH]+ = 
344.3. 
(R,S)-3-allyl-8-(1,3-dimethyl-1H-pyrazol-5-yl)-6-{[1-
(hydroxymethyl)propyl]amino}-3,7-dihydro-2H-purin-2-one (100) 
White solid; 62% yield; mp 253-255 °C dec.; 1H NMR (200MHz, 
DMSO-d6) δ ppm 12.47 (bs, 1H), 7.52 (bs, 1H), 6.45 (s, 1H), 6.10-
5.85 (m, 1H), 5.20-5.10 (m, 2H), 5.00-4.80 (bs, 1H), 4.57 (d, J = 4.6 
Hz, 2H), 4.12 (m, 4H), 4.75-4.67 (m, 2H), 2.16 (m, 3H), 1.80-1.60 (m, 
2H), 1.12-0.80 (m, 3H). MS (ESI): [MH]+ = 357.5. 
(R,S)-3-benzyl-8-(1,3-dimethyl-1H-pyrazol-5-yl)-6-[(2-hydroxy-1-
methylethyl)amino]-3,7-dihydro-2H-purin-2-one (101) White solid; 
46% yield; mp 230-233 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 
12.70 (bs, 1H), 7.31-7.20 (m, 6H), 6.55 (s, 1H), 5.14 (s, 2H), 4.95 
(bs, 1H), 4.19 (m, 1H), 3.82 (s, 3H), 3.47 (m, 2H), 2.30 (s, 3H), 1.18 
(d, 3H, J = 6.6 Hz). MS (ESI): [MH]+ = 394.5. 
(R,S)-3-benzyl-8-(1,3-dimethyl-1H-pyrazol-5-yl)-6-{[1-
(hydroxymethyl)propyl]amino}-3,7-dihydro-2H-purin-2-one (102) 
White solid; 72% yield; mp 171-172 °C; 1H NMR (200MHz, DMSO-
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d6) δ ppm 12.65 (bs, 1H), 7.40-7.26 (m, 6H), 6.56 (s, 1H), 5.16 (s, 
2H), 4.89-4.81 (m, 1H), 4.12 (m, 4H), 3.60-3.40 (m, 2H), 2.19-2.15 
(m, 3H), 1.80-1.67 (m, 2H), 0.87 (t, J = 7.2 Hz, 3H). MS (ESI): [MH]+ 
= 408.2. 
(R)-3-benzyl-8-(1,3-dimethyl-1H-pyrazol-5-yl)-6-{[1-
(hydroxymethyl)propyl]amino}-3,7-dihydro-2H-purin-2-one 
((R)102) White solid; 45% yield; mp 170-172 °C; 1H NMR (400MHz, 
DMSO-d6) δ ppm 12.70 (bs, 1H), 7.31-7.26 (m, 6H), 6.56 (s, 1H), 
5.16 (s, 2H), 4.88-4.79 (m, 1H), 4.06-4.04 (m, 1H), 3.82 (s, 3H), 
3.532-3.43 (m, 1H), 2.31 (s, 3H), 1.69-1.67 (m, 1H), 1.52-1.49 (m, 
1H), 0.92 (t, J = 7.2 Hz, 3H). MS (ESI): [MH]+ = 408.2. 
(S)-3-benzyl-8-(1,3-dimethyl-1H-pyrazol-5-yl)-6-{[1-
(hydroxymethyl)propyl]amino}-3,7-dihydro-2H-purin-2-one 
((S)102) White solid; 48% yield; mp 174 °C; 1H NMR (200MHz, 
DMSO-d6) δ ppm 12.61 (bs, 1H), 7.28-7.19 (m, 6H), 6.53 (s, 1H), 
5.11 (s, 2H), 4.83 (m, 1H), 4.20-4.10 (m, 1H), 3.79 (s, 3H), 3.47 (m, 
2H), 2.28 (s, 3H), 1.81-1.42 (m, 2H), 0.90 (t, J = 7.2 Hz, 3H). MS 
(ESI): [MH]+ = 408.2. 
(R,S)-3-allyl-6-[(2-hydroxy-1-methylethyl)amino]-8-(3-methoxy-1-
methyl-1H-pyrazol-5-yl)-3,7-dihydro-2H-purin-2-one (103) White 
solid; 58% yield; mp 225 °C dec.; 1H NMR (200MHz, DMSO-d6) δ 
ppm 12.72 (bs, 1H), 7.53 (bs, 1H), 6.12-5.83 (m, 2H), 5.19-5.02 (m, 
3H), 4.62.4.55 (m, 2H), 4.21 (m, 1H), 4.07 (s, 3H), 3.78 (s, 3H), 3.56-
3.44 (m, 2H), 1.35-1.19 (m, 3H); MS (ESI): [MH]+ = 360.4 
(R,S)-3-allyl-6-{[1-(hydroxymethyl)propyl]amino}-8-(3-methoxy-1-
methyl-1H-pyrazol-5-yl)-3,7-dihydro-2H-purin-2-one (104) White 
solid; 52% yield; mp 231 °C dec.; 1H NMR (200MHz, DMSO-d6) δ 
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ppm 12.89 (bs, 1H), 7.51 (bs, 1H), 6.11-5.82 (m, 2H), 5.19-5.02 (m, 
2H), 4.99-4.80 (m, 1H), 4.59 (m, 2H), 4.07 (m, 4H), 3.77 (s, 3H), 
3.62-3.41 (m, 2H),1.79-1.52 (m, 2H), 0.98-0.82 (m, 3H). MS (ESI): 
[MH]+ = 374.4 
(R)-3-allyl-6-{[1-(hydroxymethyl)propyl]amino}-8-(3-methoxy-1-
methyl-1H-pyrazol-5-yl)-3,7-dihydro-2H-purin-2-one ((R)104) 
White solid; 55% yield; mp 230 °C dec.; 1H NMR (200MHz, CDCl3) δ 
ppm 12.12 (bs, 1H), 7.53 (bs, 1H), 6.14 (s, 1H), 6.07-5.95 (m, 1H), 
5.26-5.14 (m, 2H), 4.81-4.79 (m, 2H), 4.15 (s, 3H), 3.87 (s, 3H), 
3.87-3.75 (m, 1H), 3.44 (m, 2H), 1.40-1.20 (m, 2H), 0.69-0.65 (m, 
3H). MS (ESI): [MH]+ = 374.4 
(S)-3-allyl-6-{[1-(hydroxymethyl)propyl]amino}-8-(3-methoxy-1-
methyl-1H-pyrazol-5-yl)-3,7-dihydro-2H-purin-2-one ((S)104 
White solid; 43% yield; mp 230 °C dec.; 1H NMR (200MHz, CDCl3) δ 
ppm 12.13 (bs, 1H), 7.55 (bs, 1H), 6.13 (s, 1H), 6.07-5.85 (m, 1H), 
5.26-5.14 (m, 2H), 4.81-4.79 (m, 2H), 4.15 (m, 3H), 3.87 (s, 3H), 
3.87-3.75 (m, 1H), 3.41 (m, 2H), 1.40-1.20 (m, 2H), 0.69-0.65 (m, 
3H). MS (ESI): [MH]+ = 374.4 
(R,S)-3-benzyl-6-[(2-hydroxy-1-methylethyl)amino]-8-(3-methoxy-
1-methyl-1H-pyrazol-5-yl)-3,7-dihydro-2H-purin-2-one (105) White 
solid; 53% yield; mp 258-260 °C; 1H NMR (400MHz, DMSO-d6) δ 
ppm 13.88 (bs, 1H), 7.51 (bs, 1H), 7.39-7.25 (m, 5H), 6.02 (s, 1H), 
5.16 (s, 2H), 5.08 (s, 1H), 4.24 (m, 1H), 4.07 (s, 3H), 3.78 (s, 3H), 
3.49 (m, 2H), 1.26-1.17 (m, 3H). MS (ESI): [MH]+ = 410.3. 
(R)-3-benzyl-6-[(2-hydroxy-1-methylethyl)amino]-8-(3-methoxy-1-
methyl-1H-pyrazol-5-yl)-3,7-dihydro-2H-purin-2-one ((R)105) 
White solid; 57% yield; mp 257-259 °C; 1H NMR (400MHz, DMSO-
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d6) δ ppm 12.83 (bs, 1H), 7.56 (bs, 1H), 7.39-7.25 (m, 5H), 6.02 (s, 
1H), 5.16 (s, 2H), 5.06 (bs, 1H), 4.23 (m, 1H), 4.07 (s, 3H), 3.77 (s, 
3H), 3.50 (m, 2H), 1.26-1.19 (m, 3H). MS (ESI): [MH]+ = 410.3. 
(S)-3-benzyl-6-[(2-hydroxy-1-methylethyl)amino]-8-(3-methoxy-1-
methyl-1H-pyrazol-5-yl)-3,7-dihydro-2H-purin-2-one ((S)105) 
White solid; 71% yield; mp 259 °C; 1H NMR (400MHz, DMSO-d6) δ 
ppm 12.93 (bs, 1H), 7.56 (bs, 1H), 7.39-7.25 (m, 5H), 6.02 (s, 1H), 
5.16 (s, 2H), 5.09 (bs, 1H), 4.23 (m, 1H), 4.07 (s, 3H), 3.78 (s, 3H), 
3.50 (m, 2H), 1.26-1.19 (m, 3H). MS (ESI): [MH]+ = 410.3. 
(R,S)-3-benzyl-6-{[1-(hydroxymethyl)propyl]amino}-8-(3-
methoxy-1-methyl-1H-pyrazol-5-yl)-3,7-dihydro-2H-purin-2-one 
(106) White solid; 60% yield; mp 259-260 °C; 1H NMR (400MHz, 
DMSO-d6) δ ppm 12.85 (bs, 1H), 7.67 (bs, 1H), 7.40-7.30 (m, 5H), 
6.02 (s, 1H), 5.17 (s, 2H), 5.02 (bs, 1H), 4.07 (m, 4H), 3.77 (s, 3H), 
3.61 (m, 2H), 1.79-1.45 (m, 2H), 0.93 (m, 3H). MS (ESI): [MH]+ = 
424.3. 
(R,S)-3-allyl-8-[3-(benzyloxy)-1-methyl-1H-pyrazol-5-yl]-6-[(2-
hydroxy-1-methylethyl)amino]-3,7-dihydro-2H-purin-2-one (107) 
White solid; 56% yield; mp 180-182 °C; 1H NMR (200MHz, DMSO-
d6) δ ppm 12.89 (bs, 1H), 7.43-7.35 (m, 6H), 6.02-5.87 (m, 2H), 5.16-
5.10 (m, 5H), 4.58 (d, J = 4.4 Hz, 2H), 4.22 (m, 1H), 4.08 (s, 3H), 
3.56-3.43 (m, 2H), 1.23 (m, 3H). MS (ESI): [MH]+ = 436.5. 
(R,S)-3-allyl-8-[3-(benzyloxy)-1-methyl-1H-pyrazol-5-yl]-6-{[1-
(hydroxymethyl)propyl]amino}-3,7-dihydro-2H-purin-2-one (108) 
White solid; 54% yield; mp 224-225 °C; 1H NMR (200MHz, DMSO-
d6) δ ppm 12.91 (bs, 1H), 7.43-7.36 (m, 6H), 6.19-5.76 (m, 2H), 5.16-
5.00 (m, 4H), 4.92 (bs, 1H), 4.59 (m, 2H), 4.08 (m, 4H), 3.51-3.42 
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(m, 2H), 1.79-1.46 (m, 2H), 1.08-0.86 (m, 3H). MS (ESI): [MH]+ = 
450.5. 
(R,S)-3-benzyl-8-[3-(benzyloxy)-1-methyl-1H-pyrazol-5-yl]-6-[(2-
hydroxy-1-methylethyl)amino]-3,7-dihydro-2H-purin-2-one (109) 
White solid; 63% yield; mp 121 °C; 1H NMR (400MHz, DMSO-d6) δ 
ppm 12.83 (bs, 1H), 7.61 (bs, 1H), 7.45-7.25 (m, 10H), 6.10 (s, 1H), 
5.16 (s, 4H), 5.01 (bs, 1H), 4.22 (m, 1H), 4.08 (s, 3H), 3.50 (m, 2H), 
1.26-1.19 (m, 3H). MS (ESI): [MH]+ = 486.3. 
(R,S)-3-benzyl-8-[3-(benzyloxy)-1-methyl-1H-pyrazol-5-yl]-6-{[1-
(hydroxymethyl)propyl]amino}-3,7-dihydro-2H-purin-2-one (110) 
White solid; 61% yield; mp 248 °C; 1H NMR (400MHz, DMSO-d6) δ 
ppm 12.98 (bs, 1H), 7.56 (bs, 1H), 7.44-7.30 (m, 10H), 6.08 (s, 1H), 
5.17 (s, 2H), 5.14 (s, 2H), 5.02 (m, 1H), 4.86 (m, 1H), 4.08 (s, 3H), 
3.61-3.45 (m, 2H), 1.79-1.47 (m, 2H), 0.95-9.91 (m, 3H). MS (ESI): 
[MH]+ = 500.4. 
(R,S)-3-allyl-8-(1,5-dimethyl-1H-pyrazol-3-yl)-6-[(2-hydroxy-1-
methylethyl)amino]-3,7-dihydro-2H-purin-2-one (111) Pale yellow 
solid; 57% yield; mp 177-180 °C; 1H NMR (200MHz, DMSO-d6) δ 
ppm 12.53 (bs, 1H), 7.26 (d, J = 7.4 Hz, 1H), 6.55 (s, 1H), 5.93-5.85 
(m, 1H), 5.09-4.97 (m, 3H), 4.54 (d, J = 4.8 Hz, 2H), 4.19 (m, 1H), 
3.82 (s, 3H), 3.47 (m, 2H), 2.31 (s, 3H), 1.18 (d, J = 6.8 Hz, 3H). MS 
(ESI): [MH]+ = 344.4. 
(R,S)-3-allyl-8-(1,5-dimethyl-1H-pyrazol-3-yl)-6-{[1-
(hydroxymethyl)propyl]amino}-3,7-dihydro-2H-purin-2-one. (112) 
White solid; 52% yield; mp 169-170 °C; 1H NMR (200MHz, DMSO-
d6) δ ppm 12.61 (bs, 1H), 7.25 (d, J = 8 Hz, 1H), 6.56 (s, 1H), 6.02-
5.81 (m, 1H), 5.10-4.98 (m, 3H), 4.54 (d, J = 4.8 Hz, 2H), 4.17-3.99 
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(m, 1H), 3.82 (s, 3H), 3.50- 3.48 (m, 2H), 2.31 (s, 3H), 2.79-2.61 (m, 
2H), 0.92 (t, J = 7.4 Hz, 3H). MS (ESI): [MH]+ = 358.4. 
(R)-3-allyl-8-(1,5-dimethyl-1H-pyrazol-3-yl)-6-{[1-
(hydroxymethyl)propyl]amino}-3,7-dihydro-2H-purin-2-one 
((R)112) White solid; 62% yield; mp 168-170 °C; 1H NMR (400MHz, 
DMSO-d6) δ ppm 12.66 (bs, 1H), 7.21 (bs, 1H), 6.55 (s, 1H), 5.95-
5.88 (m, 1H), 5.08-5.05 (m, 2H), 4.89 (bs, 1H), 4.54 (d, J = 4.8 Hz, 
2H), 4.05-4.04 (m, 1H), 3.82 (s, 3H), 3.51 (m, 2H), 2.31 (s, 3H), 1.72-
1.66 (m, 1H), 1.54-1.47 (m, 1H), 0.92 (t, 7.6 Hz, 3H). MS (ESI): [MH]+ 
= 358.6. 
(S)-3-allyl-8-(1,5-dimethyl-1H-pyrazol-3-yl)-6-{[1-
(hydroxymethyl)propyl]amino}-3,7-dihydro-2H-purin-2-one 
((S)112) White solid; 59% yield; mp 167-169 °C; 1H NMR (200MHz, 
DMSO-d6) δ ppm 12.63 (bs, 1H), 7.21-7.18 (bd, J = 7.4, Hz 1H), 6.54 
(s, 1H), 5.98-5.84 (m, 1H), 5.14-4.82 (m, 3H), 4.54 (d, 2H), 4.15-3.93 
(m, 1H), 3.80 (s, 3H), 3.49 (m, 2H), 2.92 (s, 3H), 1.79-1.43 (m, 2H), 
0.9 (t, J = 7 Hz, 3H). MS (ESI): [MH]+ = 358.6. 
(R,S)-3-benzyl-8-(1,5-dimethyl-1H-pyrazol-3-yl)-6-[(2-hydroxy-1-
methylethyl)amino]-3,7-dihydro-2H-purin-2-one (113) White solid; 
56% yield; mp 212 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 12.84 
(bs, 1H), 7.30-7.22 (m, 6H), 6.55 (s, 1H), 5.13 (s, 2H), 5.00 (bs, 1H), 
4.20 (m, 1H), 3.81 (s, 3H), 3.45 (m, 2H), 2.30 (s, 3H), 1.18 (d, 3H, J 
= 6.6). MS (ESI): [MH]+ = 394.7. 
(R,S)-3-benzyl-8-(1,5-dimethyl-1H-pyrazol-3-yl)-6-{[1-
(hydroxymethyl)propyl]amino}-3,7-dihydro-2H-purin-2-one (114) 
White solid; 47% yield; mp 199-201 °C dec.; 1H NMR (200MHz, 
DMSO-d6) δ ppm 12.78 (bs, 1H), 7.31-7.24 (m, 6H), 6.56 (s, 1H), 
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5.14 (s, 2H), 4.90 (bs, 1H), 4.10 (m, 1H), 3.82 (s, 3H), 3.45 (m, 2H), 
2.30 (s, 3H), 1.8-1.6 (m, 2H), 0.92 (t, 3H, J = 7.6); MS (ESI): [MH]+ = 
408.7. 
(R,S)-3-allyl-6-[(2-hydroxy-1-methylethyl)amino]-8-(3-
methoxyisoxazol-5-yl)-3,7-dihydro-2H-purin-2-one (115) White 
solid; 64% yield; mp 289-290 °C; 1H NMR (200MHz, DMSO-d6) δ 
ppm 8.52 (bs, 1H), 7.78 (bs, 1H), 6.44 (s, 1H), 6.03-5.84 (m, 1H), 
5.15-5.10 (m, 3H), 4.58 (d, J = 4.8 Hz, 2H), 4.22 (m, 1H), 3.92 (s, 
3H), 3.50 (m, 2H), 1.24-1.19 (m, 3H); MS (ESI): [MH]+ = 347.2. 
(R,S)-3-allyl-6-{[1-(hydroxymethyl)propyl]amino}-8-(3-
methoxyisoxazol-5-yl)-3,7-dihydro-2H-purin-2-one (116) White 
solid; 54% yield; mp 270-271 °C; 1H NMR (200MHz, DMSO-d6) δ 
ppm 8.58 (bs, 1H), 7.71 (bs, 1H), 6.42 (s, 1H), 6.02-5.88 (m, 1H), 
5.16-4.91 (m, 3H), 4.58 (d, J = 4.6 Hz, 2H), 4.11 (m, 1H), 3.93 (s, 
3H), 3.61-3.52 (m, 2H), 1.62-1.59 (m, 2H), 0.97-0.86 (m, 3H). MS 
(ESI): [MH]+ = 361.5. 
(R,S)-3-benzyl-6-[(2-hydroxy-1-methylethyl)amino]-8-(3-
methoxyisoxazol-5-yl)-3,7-dihydro-2H-purin-2-one (117) White 
solid; 40% yield; mp 292-293 °C; 1H NMR (200MHz, DMSO-d6) δ 
ppm 8.68 (bs, 1H), 7.78 (bs, 1H), 7.31 (m, 5H), 6.43 (s, 1H), 5.17 (s, 
2H), 5.16-5.00 (m, 1H), 4.22 (m, 1H), 3.92 (s, 3H), (m, 2H), 1.35-1.24 
(m, 3H). MS (ESI): [MH]+ = 397.5. 
(R,S)-3-benzyl-6-{[1-(hydroxymethyl)propyl]amino}-8-(3-
methoxyisoxazol-5-yl)-3,7-dihydro-2H-purin-2-one (118) White 
solid; 67% yield; mp 284-286 °C dec.; 1H NMR (200MHz, DMSO-d6) 
δ ppm 12.91 (bs, 1H), 7.80 (bs, 1H), 7.31 (m, 5H), 6.44 (s, 1H), 5.15 
(s, 2H), 4.90-5.00 (s, 1H), 4.22 (m, 1H), 3.20 (s, 3H), 3.60-3.50 (m, 
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2H), 1.75-1.55 (m, 2H), 0.91 (t, 3H, J = 7.6). MS (ESI): [MH]+ = 
411.5. 
 
General procedure for the preparation of 4-allyl/benzyl-7,8-
dihydro-8-methyl/ethyl-2-[(substituted)isoxazol/pyrazol-3/5-yl]-
1H-imidazo[2,1-i]purin-5(4H)-one derivatives (119-138) 
N
N N
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N N
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The opportune 6-(1-hydroxybutan/propan-2-ylamino)-3-allyl/benzyl-
8-[(substituted)isoxazol/pyrazol-3/5-yl]-3H-purin-2(7H)-one derivative 
(99-118, 0.2 mmol) was dissolved in freshly distilled CH2Cl2 (7 mL) 
and, after cooling at 0°C, 0.3 mL of SOCl2 were added to the mixture. 
The reaction was stirred for further 10’ at room temperature, then 
heated at reflux for 18h. The solvent and the excess of SOCl2 were 
removed under vacuum and the residue was purified via column 
chromatography on silica gel eluting with EtOAc/CH3OH 9:1.  
(R,S)-4-allyl-2-(1,3-dimethyl-1H-pyrazol-5-yl)-8-methyl-1,4,7,8-
tetrahydro-5H-imidazo[2,1-i]purin-5-one (119) White solid; 64% 
yield; mp 232 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 10.17 (bs, 
1H), 6.40 (s, 1H), 6.05-5.83 (m, 1H), 5.22-5.13 (m, 2H), 4.62 (d, J = 5 
Hz, 2H), 4.32 (m, 2H), 4.15 (s, 3H), 3.78 (m, 1H), 2.14 (s, 3H), 1.34 
(d, J = 5.6 Hz, 3H). MS (ESI): [MH]+ = 326.3. 
(R)-4-allyl-2-(1,3-dimethyl-1H-pyrazol-5-yl)-8-methyl-1,4,7,8-
tetrahydro-5H-imidazo[2,1-i]purin-5-one ((R)119) White solid; 64% 
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yield; mp 233 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 10.17 (bs, 
1H), 6.40 (s, 1H), 5.97-5.88 (m, 1H), 5.23-5.13 (m, 2H), 4.62 (d, J = 
5.2 Hz, 2H), 4.37-4.22 (m, 2H), 4.15 (s, 3H), 3.75-3.67 (m, 1H), 2.14 
(s, 3H), 1.34 (d, J = 5.8 Hz, 3H). MS (ESI): [MH]+ = 325.8. 
(S)-4-allyl-2-(1,3-dimethyl-1H-pyrazol-5-yl)-8-methyl-1,4,7,8-
tetrahydro-5H-imidazo[2,1-i]purin-5-one ((S)119) White solid; 48% 
yield; mp 233 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 10.17 (bs, 
1H), 6.40 (s, 1H), 6.02-5.88 (m, 1H), 5.22-5.13 (m, 2H), 4.62 (d, J = 
5.2 Hz, 2H), 4.39-4.22 (m, 1H), 4.15 (s, 3H), 3.75-3.67 (m, 1H), 2.14 
(s, 3H), 1.34 (d, J = 5.8 Hz, 3H). MS (ESI): [MH]+ = 325.8. 
(R,S)-4-allyl-2-(1,3-dimethyl-1H-pyrazol-5-yl)-8-ethyl-1,4,7,8-
tetrahydro-5H-imidazo[2,1-i]purin-5-one (120) White solid; 51% 
yield; mp 188 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 10.17 (bs, 
1H), 6.40 (s, 1H), 6.02-5.88 (m, 1H), 5.22-5.13 (m, 2H), 4.62 (d, J = 
5.2 Hz, 2H), 4.25-4.22 (m, 2H), 4.15 (s, 3H), 3.75-3.67 (m, 1H), 2.14 
(s, 3H), 1.68 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H). MS (ESI): [MH]+ = 
340.8. 
(R,S)-4-benzyl-2-(1,3-dimethyl-1H-pyrazol-5-yl)-8-methyl-1,4,7,8-
tetrahydro-5H-imidazo[2,1-i]purin-5-one (121) White solid; 57% 
yield; mp 244 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 1.07 (bs, 1H), 
7.38-7.24 (m, 5H), 6.41 (s, 1H), 5.19 (s, 2H), 4.38-4.17 (m, 2H), 3.73 
(s, 3H), 3.69-3.60 (m, 1H), 2.26 (s, 3H), 1.32 (d, J = 6.4 Hz, 3H). MS 
(ESI): [MH]+ = 376.6. 
(R,S)-4-benzyl-2-(1,3-dimethyl-1H-pyrazol-5-yl)-8-ethyl-1,4,7,8-
tetrahydro-5H-imidazo[2,1-i]purin-5-one (122) White solid; 48% 
yield; mp 295 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 10.12 (bs, 
1H), 7.42-7.28 (m, 5H), 6.68 (s, 1H), 5.19 (s, 2H), 4.20-4.00 (m, 5H), 
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3.80 (m, 1H), 2.15 (s, 3H), 1.65 (m, 2H), 0.95 (t, J = 7.2 Hz, 3H). MS 
(ESI): [MH]+ = 390.2. 
(R)-4-benzyl-2-(1,3-dimethyl-1H-pyrazol-5-yl)-8-ethyl-1,4,7,8-
tetrahydro-5H-imidazo[2,1-i]purin-5-one ((R)122) White solid; 48% 
yield; mp 294 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 10.12 (bs, 
1H), 7.39-7.27 (m, 5H), 6.42 (s, 1H), 5.20 (s, 2H), 4.20-4.18 (m, 2H), 
3.73 (m, 4H), 2.26 (s, 3H), 1.65 (m, 2H), 0.94 (t, J = 7.2 Hz, 3H). MS 
(ESI): [MH]+ = 390.2. 
(S)-4-benzyl-2-(1,3-dimethyl-1H-pyrazol-5-yl)-8-ethyl-1,4,7,8-
tetrahydro-5H-imidazo[2,1-i]purin-5-one ((S)122) White solid; 43% 
yield; mp 295 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 10.21 (bs, 
1H), 7.35-7.27 (m, 5H), 6.42 (s, 1H), 5.20 (s, 2H), 4.17 (m, 2H), 3.73 
(m, 4H), 2.26 (s, 3H), 1.79-1.62 (m, 2H), 0.94 (t, J = 7.2 Hz, 3H). MS 
(ESI): [MH]+ = 390.2. 
(R,S)-4-allyl-2-(3-methoxy-1-methyl-1H-pyrazol-5-yl)-8-methyl-
1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purin-5-one (123) White solid; 
55% yield; mp 121 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 10.17 
(bs, 1H), 5.99 (s, 1H), 5.95-5.91 (m, 1H), 5.20-5.14 (m, 2H), 4.62 (d, 
J = 5.2 Hz, 2H), 4.4.38-4.25 (m, 2H), 4.10 (s, 3H), 3.77 (s, 3H), 3.75-
3.70 (m, 1H), 1.34 (d, J = 6 Hz, 3H). MS (ESI): [MH]+ = 342.4. 
(R,S)-4-allyl-2-(3-methoxy-1-methyl-1H-pyrazol-5-yl)-8-ethyl-
1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purin-5-one (124) White solid; 
47% yield; mp 133 °C ; 1H NMR (400MHz, DMSO-d6) δ ppm 10.23 
(bs, 1H), 6.00 (s, 1H), 5.98-5.89 (m, 1H), 5.20-5.14 (m, 2H), 4.62 (d, 
J = 5.2 Hz, 2H), 4.26-4.24 (m, 2H), 4.10 (s, 3H), 3.83-3.78 (m, 1H), 
3.77 (s, 3H), 1.68 (m, 2H), 0.95 (t, J = 7.2 Hz, 3H). MS (ESI): [MH]+ = 
356.2. 
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(R)-4-allyl-8-ethyl-2-(3-methoxy-1-methyl-1H-pyrazol-5-yl)-
1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purin-5-one ((R)124) White 
solid; 54% yield; mp 133 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 
10.23 (bs, 1H), 6.00 (s, 1H), 5.98-5.89 (m, 1H), 5.22-5.13 (m, 2H), 
4.62 (d, J = 5.2 Hz, 2H), 4.26-4.24 (m, 2H), 4.10 (s, 3H), 3.83-3.78 
(m, 1H), 3.77 (s, 3H), 1.68 (m, 2H), 0.95 (t, J = 7.2 Hz, 3H). MS 
(ESI): [MH]+ = 356.2. 
(S)-4-allyl-8-ethyl-2-(3-methoxy-1-methyl-1H-pyrazol-5-yl)-1,4,7,8-
tetrahydro-5H-imidazo[2,1-i]purin-5-one ((S)124) White solid; 51% 
yield; mp 133 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 10.23 (bs, 
1H), 6.02 (s, 1H), 5.98-5.89 (m, 1H), 5.18-5.13 (m, 2H), 4.62 (d, J = 
5.2 Hz, 2H), 4.26-4.24 (m, 2H), 4.10 (s, 3H), 3.83-3.78 (m, 1H), 3.77 
(s, 3H), 1.68 (m, 2H), 0.95 (t, J = 7.2 Hz, 3H). MS (ESI): [MH]+ = 
356.2. 
(R,S)-4-benzyl-2-(3-methoxy-1-methyl-1H-pyrazol-5-yl)-8-methyl-
1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purin-5-one (125) White solid; 
57% yield; mp 243 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 10.21 
(bs, 1H), 7.44-7.25 (m, 5H), 5.98 (s, 1H), 5.19 (s, 2H), 4.35-4.22 (m, 
2H), 4.10 (s, 3H), 3.76 (s, 3H), 3.70-3.66 (m, 1H), 1.32 (d, J = 6.4 Hz, 
3H). MS (ESI): [MH]+ = 392.2. 
(R)-4-benzyl-2-(3-methoxy-1-methyl-1H-pyrazol-5-yl)-8-methyl-
1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purin-5-one ((R)125) White 
solid; 67% yield; mp 242 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 
10.19 (bs, 1H), 7.42-7.23 (m, 5H), 5.98 (s, 1H), 5.18 (s, 2H), 4.35-
4.24 (m, 2H), 4.08 (s, 3H), 3.75 (s, 3H), 3.73-3.68 (m, 1H), 1.32 (d, J 
= 6 Hz, 3H). MS (ESI): [MH]+ = 392.2. 
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(S)-4-benzyl-2-(3-methoxy-1-methyl-1H-pyrazol-5-yl)-8-methyl-
1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purin-5-one ((S)125) White 
solid; 60% yield; mp 244 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 
10.23 (bs, 1H), 7.43-7.24 (m, 5H), 6.06 (s, 1H), 5.20 (s, 2H), 4.39-
4.26 (m, 2H), 4.08 (s, 3H), 3.76 (s, 3H), 3.73-3.71 (m, 1H), 1.34 (d, J 
= 6.4 Hz, 3H). MS (ESI): [MH]+ = 392.2. 
(R,S)-4-benzyl-8-ethyl-2-(3-methoxy-1-methyl-1H-pyrazol-5-yl)-
1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purin-5-one (126) White solid; 
53% yield; mp 140 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 10.38 
(bs, 1H), 7.43-7.25 (m, 5H), 6.08 (s, 1H), 5.21 (s, 2H), 4.27-4.23 (m, 
2H), 4.08 (s, 3H), 3.81-3.80 (m, 1H), 3.76 (s, 3H), 1.70-1.66 (m, 2H), 
0.93 (t, J = 7.2 Hz, 3H). MS (ESI): [MH]+ = 406.2. 
(R,S)-4-allyl-2-[3-(benzyloxy)-1-methyl-1H-pyrazol-5-yl]-8-methyl-
1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purin-5-one (127) White solid; 
59% yield; mp 214 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 10.18 
(bs, 1H), 7.45-7.38 (m, 5H), 6.03 (s, 1H), 5.98-5.84 (m, 1H), 5.20-
5.14 (m, 4H), 4.62 (d, J = 5.2 Hz, 2H), 4.37-4.25 (m, 2H), 4.11 (s, 
3H), 3.74-3.70 (m, 1H), 1.34 (d, J = 6.4 Hz, 3H). MS (ESI): [MH]+ = 
418.2. 
(R,S)-4-allyl-2-[3-(benzyloxy)-1-methyl-1H-pyrazol-5-yl]-8-ethyl-
1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purin-5-one (128) White solid; 
60% yield; mp 223 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 10.25 
(bs, 1H), 7.43-7.38 (m, 5H), 6.03 (s, 1H), 5.98-5.91 (m, 1H), 5-20-
5.14 (m, 4H), 4.62 (d, J = 5.6 Hz, 2H), 4.28-4.21 (m, 2H), 4.11 (s, 
3H), 3.81-3.78 (m, 1H), 1.70-1.66 (m, 2H), 0.94 (t, J = 7.2 HZ, 3H). 
MS (ESI): [MH]+ = 432.2. 
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(R,S)-4-benzyl-2-[3-(benzyloxy)-1-methyl-1H-pyrazol-5-yl]-8-
methyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purin-5-one (129) 
White solid; 42% yield; mp 143 °C; 1H NMR (400MHz, DMSO-d6) δ 
ppm 10.22 (bs, 1H), 7.45-7.31 (m, 10H), 6.05 (s, 1H), 5.20 (s, 2H), 
5.14 (s, 2H), 4.37-4.26 (m, 2H); 4.11 (s, 3H), 3.75-3.71 (m, 1H), 1.34 
(d, J = 6 Hz, 3H). MS (ESI): [MH]+ = 468.2. 
(R,S)-4-benzyl-2-[3-(benzyloxy)-1-methyl-1H-pyrazol-5-yl]-8-
ethyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purin-5-one (130) White 
solid; 49% yield; mp 120 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 
10.22 (bs, 1H), 7.45-7.29 (m, 10H), 6.05 (s, 1H), 5.20 (s, 2H), 5.14 
(s, 2H), 4.26-4.20 (m, 2H), 3.82-3.78 (m, 2H), 4.11 (s, 1H), 3.82-3.78 
(m,1H), 1.70-1.66 (m, 2H), 0.94 (t, J = 7.2 Hz, 3H). MS (ESI): [MH]+ = 
482.2. 
(R,S)-4-allyl-2-(1,5-dimethyl-1H-pyrazol-3-yl)-8-methyl-1,4,7,8-
tetrahydro-5H-imidazo[2,1-i]purin-5-one (131) White solid; 49% 
yield; mp 214 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 10.43 (bs, 
1H), 6.41 (s, 1H), 5.98-5.91 (m, 1H), 5.14-5.11 (m, 2H), 4.60 (d, J = 
5.2 Hz, 2H), 4.39-4.18 (m, 2H), 3.74 (s, 3H), 3.67-3.62 (m, 1H), 2.26 
(s, 3H), 1.31 (d, J = 6 Hz, 3H). MS (ESI): [MH]+ = 326.2. 
(R,S)-4-allyl-2-(1,5-dimethyl-1H-pyrazol-3-yl)-8-ethyl-1,4,7,8-
tetrahydro-5H-imidazo[2,1-i]purin-5-one (132) White solid; 46% 
yield; mp 249 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 10.43 (bs, 
1H), 6.45 (s, 1H), 5.98-5.91 (m, 1H), 5.15-5.11 (m, 2H), 4.61 (d, J = 
5.2 Hz, 2H), 4.22-4.20 (m, 2H), 3.76 (m, 4H), 2.27 (s, 3H), 1.68-1.65 
(m, 2H), 0.95 (t, J = 7.2 Hz, 3H). MS (ESI): [MH]+ = 340.2. 
(R)-4-allyl-2-(1,5-dimethyl-1H-pyrazol-3-yl)-8-ethyl-1,4,7,8-
tetrahydro-5H-imidazo[2,1-i]purin-5-one ((R)132) White solid; 48% 
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yield; mp 249 °C; 1H NMR (400MHz, DMSO-d6) δ ppm 10.11 (bs, 
1H), 6.41 (s, 1H), 5.99-5.87 (m, 1H), 5.14-5.09 (m, 2H), 4.60 (d, J = 
4.8 Hz, 2H), 4.17-4.60 (m, 2H), 3.80-3.70 (m, 4H), 2.26 (s, 3H), 1.65 
(m, 2H), 0.94 (t, J = 7.2 Hz, 3H). MS (ESI): [MH]+ = 339.9. 
(S)-4-allyl-2-(1,5-dimethyl-1H-pyrazol-3-yl)-8-ethyl-1,4,7,8-
tetrahydro-5H-imidazo[2,1-i]purin-5-one ((S)132) White solid; 47% 
yield; mp 249 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 10.08 (bs, 
1H), 6.41 (s, 1H), 6.00-5.88 (m, 1H), 5.16-5.07 (m, 2H), 4.60 (d, J = 
4.8 Hz, 2H), 4.20-4.17 (m, 2H), 3.74 (s, 3H), 3.70 (m, 1H), 2.26 (s, 
3H), 1.68-1.62 (m, 2H), 0.94 (t, J = 7.2 Hz, 3H). MS (ESI): [MH]+ = 
340.2. 
(R,S)-4-benzyl-2-(1,5-dimethyl-1H-pyrazol-3-yl)-8-methyl-1,4,7,8-
tetrahydro-5H-imidazo[2,1-i]purin-5-one (133) White solid; 65% 
yield; mp 245 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 10.20 (bs, 
1H), 7.35-7.27 (m, 5H), 6.42 (s, 1H), 5.20 (s, 2H), 4.40-4.20 (m, 2H), 
3.80-3.60 (m, 4H), 2.26 (s, 3H), 1.31 (d, J = 5.8 Hz, 3H). MS (ESI): 
[MH]+ = 376.9. 
(R,S)-4-benzyl-2-(1,5-dimethyl-1H-pyrazol-3-yl)-8-ethyl-1,4,7,8-
tetrahydro-5H-imidazo[2,1-i]purin-5-one (134) White solid; 61% 
yield; mp 275 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 10.20 (bs, 
1H), 7.35-7.27 (m, 5H), 6.42 (s, 1H), 5.20 (s, 2H), 4.20-4.10 (m, 2H), 
3.80-3.60 (m, 4H), 2.26 (s, 3H), 1.70-1.60 (m, 2H), 0.94 (t, J = 7.2 
Hz, 3H). MS (ESI): [MH]+ = 390.9. 
(R,S)-4-allyl-2-(3-methoxyisoxazol-5-yl)-8-methyl-1,4,7,8-
tetrahydro-5H-imidazo[2,1-i]purin-5-one (135) White solid; 57% 
yield; mp 169 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 10.74 (bs, 
1H), 6.53 (s, 1H), 5.93-5.88 (m, 1H), 5.21-5.13 (m, 2H), 4.63 (d, J = 
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4.8 Hz, 2H), 4.45-4.26 (m, 2H), 3.94 (s, 3H), 3.80-3.72 (m, 1H), 1.36 
(d, J = 6 Hz, 3H). MS (ESI): [MH]+ = 329.2. 
(R,S)-4-allyl-8-ethyl-2-(3-methoxyisoxazol-5-yl)-1,4,7,8-
tetrahydro-5H-imidazo[2,1-i]purin-5-one (136) White solid; 51% 
yield; mp 171 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 10.79 (bs, 
1H), 6.50 (s, 1H), 6.02-5.88 (m, 1H), 5.20-5.12 (m, 2H), 4.63 (d, J = 
4.8 Hz, 2H), 4.30-4.27 (m, 2H), 3.94 (s, 3H), 3.84-3.82 (m, 1H), 1.74-
1.67 (m, 2H), 0.95 (t, J = 7.2 Hz, 3H). MS (ESI): [MH]+ = 343.3. 
(R,S)-4-benzyl-2-(3-methoxyisoxazol-5-yl)-8-methyl-1,4,7,8-
tetrahydro-5H-imidazo[2,1-i]purin-5-one (137) White solid; 38% 
yield; mp 111 °C; 1H NMR (200MHz, DMSO-d6) δ ppm 10.64 (bs, 
1H), 7.41-7.21 (m, 5H), 6.47 (s, 1H), 5.22 (s, 2H), 4.43-4.26 (m, 2H), 
3.94 (m, 4H), 1.36 (d, J = 5.6 Hz, 3H). MS (ESI): [MH]+ = 379.1. 
(R,S)-4-benzyl-8-ethyl-2-(3-methoxyisoxazol-5-yl)-1,4,7,8-
tetrahydro-5H-imidazo[2,1-i]purin-5-one (138) White solid; 39% 
yield; mp 157 °C; 1H NMR (200MHz, CDCl3) δ ppm 10.64 (bs, 1H), 
7.60-7.56 (m, 2H), 7.32-7.28 (m, 3H), 6.46 (s, 1H), 5.35 (s, 2H), 
4.63-4.31 (m, 2H), 4.01 (s, 3H), 3.90-3.85 (m, 1H), 1.60-1.40 (m, 
2H), 0.74 (t, J = 7.6 Hz, 3H). MS (ESI): [MH]+ = 393.1. 
  
 
 
 
References 
References 
 
120 
References 
(1) Newby, A. C. Trends Biol. Sci. 1981, 9, 42. 
(2) Zimmermann, H. Naunyn Schmied. Arch. Pharmacol. 2000, 362, 299. 
(3) Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Kloz, K.-N.; Linden, J. 
Pharmacol. ReV. 2001, 53, 527. 
(4) Decking, U. K.; Schlieper, G.; Kroll, K.; Schrader, J. Circ. Res. 1997, 81, 
154. 
(5) Sattin, A.; Rall, T. W. Mol. Pharmacol. 1970, 6, 13. 
(6) Libert, F.; Parmentier, M.; Lefort, A.; Dinsart, C.; Van Sande, J.; 
Maenhaut, C.; Simons, M. J.; Dumont, J. E.; Vassart, G. Science 1989, 244, 
569. 
(7) Chern, Y.; King, K.; Lai, H. L.; Lai, H. T. Biochem. Biophys. Res. 
Commun. 1992, 185, 304. 
(8) Fink, J. S.; Weaver, D. R.; Rivkees, S. A.; Peterfreund, R. A.; Pollack, A. 
E.; Adler, E. M.; Reppert, S. M. Mol. Brain Res. 1992, 14, 186. 
(9) Furlong, T. J.; Pierce, K. D.; Selbie, L. A.; Shine, J. Mol. Brain Res. 1992, 
15, 62. 
(10) Meng, F.; Xie, G. X.; Chalmers, D.; Morgan, C.; Watson, S. J.; Akil, H. 
Neurochem. Res. 1994, 19, 613. 
(11) Marquardt, D. L.; Walker, L. L.; Heinemann, S. J. Immunol. 1994, 152, 
4508. 
(12) Ralevic, V.; Burnstock, G. Pharmacol. ReV. 1998, 50, 413. 
(13) Svenningsson, P.; Lindskog, M.; Rognoni, F.; Fredholm, B. B.; 
Greengard, P.; Fisone, G. Neuroscience 1998, 84, 223. 
(14) Kull, B.; Ferre`, S.; Arslan, G.; Svenningsson, P.; Fuxe, K.; Owman, C.; 
Fredholm, B. B. Biochem. Pharmacol. 1999, 58, 1035. 
(15) Lindskog, M.; Svenningsson, P.; Pozzi, L.; Kim, Y.; Fienberg, A. A.; 
Bibb, J. A.; Fredholm, B. B.; Nairn, A. C.; Greengard, P.; Fisone, G. Nature 
2002, 418, 774. 
(16) Huang, N. K.; Lin, Y. W.; Huang, C. L.; Messing, R. O.; Chern, Y. J. 
Biol. Chem. 2001, 276, 13838. 
References 
 
121 
(17) Kull, B.; Svenningsson, P.; Fredholm, B. B. Mol. Pharmacol. 2000, 58, 
771. 
(18) Gubitz, A. K.; Widdowson, L.; Kurokawa, M.; Kirkpatrick, K. A.; 
Richardson, P. J. J. Neurochem. 1996, 67, 374. 
(19) Stella, S. L., Jr.; Bryson, E. J.; Thoreson, W. B. J. Neurophysiol. 2002, 
87, 351. 
(20) Schulte, G.; Fredholm, B. B. Cell Signal. 2003, 15, 813. 
(21) Fuxe, K.; Ferre, S.; Canals, M.; Torvinen, M.; Terasmaa, A.; Marcellino, 
D.; Goldberg, S. R.; Staines, W.; Jacobsen, K. X.; Lluis, C.; Woods, A. S.; 
Agnati, L. F.; Franco, R. J. Mol. Neurosci. 2005, 26, 209. 
(22) Burgueno, J.; Blake, D. J.; Benson, M. A.; Tinsley, C. L.; Esapa, C. T.; 
Canela, E. I.; Penela, P.; Mallol, J.; Mayor, F., Jr.; Lluis, C.; Franco, R.; 
Ciruela, F. J. Biol. Chem. 2003, 278, 37545. 
(23) Gsandtner, I.; Charalambous, C.; Stefan, E.; Ogris, E.; Freissmuth, M.; 
Zezula, J. J. Biol. Chem. 2005, 280, 31898. 
(24) Milojevic, T.; Reiterer, V.; Stefan, E.; Korkhov, V. M.; Dorostkar, M. M.; 
Ducza, E.; Ogris, E.; Boehm, S.; Freissmuth, M.; Nanoff, C. Mol. Pharmacol. 
2006, 69, 1083. 
(25) Sun, C. N.; Cheng, H. C.; Chou, J. L.; Lee, S. Y.; Lin, Y. W.; Lai, H. L.; 
Chen, H. M.; Chern, Y. Mol. Pharmacol. 2006, 70, 454. 
(26) Gsandtner, I.; Freissmuth, M. Mol. Pharmacol. 2006, 70, 447. 
(27) Xu, K.; Bastia, E.; Schwarzschild, M. Pharmacol. Ther. 2005, 105, 267. 
(28) Chen, J. F.; Xu, K.; Petzer, J. P.; Staal, R.; Xu, Y. H.; Beilstein, M.; 
Sonsall, P. K.; Castagnoli, K.; Castagnoli, N., Jr.; Swchwarzschild, M. A. J. 
Neurosci. 2001, 21, RC143. 
(29) Ross, G. W.; Abbott, R. D.; Petrovitch, H.; Morens, D. M.; Grandinetti, 
A.; Tung, K. H.; Tanner, C. M.; Masaki, K. H.; Blanchette, P. L.; Curb, J. D.; 
Popper, J. S.; White, L. R. JAMA 2000, 283, 2674. 
(30) Ascherio, A.; Zhang, S. M.; Hernan, M. A.; Kawachi, I.; Colditz, G. A.; 
Speizer, F. E.; Willet, W. C. Ann. Neurol. 2001, 50, 56. 
References 
 
122 
(31) Fuxe, K.; Agnati, L. F.; Jacobsen, K.; Hillion, J.; Canals, M.; Torvinen, 
M.; Tinner-Staines, B.; Staines, W.; Rosin, D.; Terasmaa, P.; Popoli, P.; Leo, 
G.; Vergoni, V.; Lluis, C.; Ciruela, F.; Franco, R.; Ferre, S. Neurology 2003, 
61, S10. 
(32) Agnati, L. F.; Ferre`, S.; Lluis, C.; Franco, R.; Fuxe, K. Pharmacol. ReV. 
2003, 55, 509. 
(33) Schwarzschild, M. A.; Agnati, L.; Fuxe, K.; Chen, J.-F.; Morelli, M. 
Trends Neurosci. 2006, 29, 647. 
(34) Morelli, M.; Di Paolo, T.; Wardas, J.; Calon, F.; Xiao, D.; Schwarzschild, 
M. A. Progress in Neurobiology 2007, 83 293. 
(35) Kalda, A.; Yu, L.; Oztas, E.; Chen, J. F. J. Neurol. Sci. 2006, 248, 9. 
(36) Stone, T. W.; Jones, P. A.; Smith, R. A. Drug DeV. Res. 2001, 52, 323. 
(37) Chen, J. F.; Huang, Z.; Ma, J.; Zhu, J.; Moratalla, R.; Standaert, D. J. 
Neurosci. 1999, 19, 9192. 
(38) Yu, L.; Huang, Z.; Mariani, J.; Wang, Y.; Moskowitz, M.; Chen, J.F. Nat. 
Med. 2004, 10, 1081. 
(39) Mayne, M.; Fotheringham, J.; Yan, H. J.; Power, C.; Del Bigio, M. R.; 
Peeling, J.; Geiger, J. D. Ann. Neurol. 2001, 49, 727. 
(40) Cassada, D. C.; Tribble, C. G.; Young, J. S.; Gangemi, J. J.; Gohari, A. 
R.; Butler, P. D.; Rieger, J. M.; Kron, I. L.; Linden, J.; Kern, J. A. J. Trauma 
2002, 53, 225. 
(41) Day, Y. J.; Marshall, M. A.; Huang, L.; McDuffie, M. J.; Okusa, M.; 
Linden, J. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 286, G285. 
(42) Day, Y. J.; Huang, L.; Linden, J.; Okusa, M. D. Am. J. Physiol. Renal 
Physiol. 2005, 288, F722. 
(43) Li, L.; Okusa, M. D. Nat. Clin. Practice Nephrol. 2006, 2, 432. 
(44) Rivo, J.; Zeira, E.; Galun, E.; Einav, S.; Linden, J.; Matot, I. Shock 2007, 
27, 266. 
(45) Sitkovsky, M. V.; Ohta, A. Trends Immunol. 2005, 26, 299. 
(46) Ohta, A.; Sitkovsky, M. Nature 2001, 414, 916.  
References 
 
123 
(47) Montesinos, M. C.; Shaw, J. P.; Yee, H.; Shamamian, P.; Cronstein, B. 
N. Am. J. Pathol. 2004, 164, 1887. 
(48) Adair, T. H. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 289, 
R283. 
(49) Chan, E. S.; Fernandez, P.; Merchant, A. A.; Montesinos, M. C.; 
Trzaska, S.; Desai, A.; Tung, C. F.; Khoa, D. N.; Pillinger, M. H.; Reiss, A. 
B.; Tomic-Canic, M.; Chen, J. F.; Schwarzschild, M. A.; Crontein, B. N. 
Arthritis Rheum. 2006, 54, 2632. 
(50) Francis, J. E.; Cash, W. D.; Psychoyos, S.; Ghai, G.; Wenk, P.; 
Friedmann, R. C.; Atkins, C.; Warren, V.; Furness, P.;. Hyun, J. L.; Stone, G. 
A.; Desai, M.; Williams, M. J. Med. Chem. 1988, 31, 1014. 
(51) Gatta, F.; Del Giudice, M. R.; Borioni, A.; Borea, P. A.; Dionisotti, S.; 
Ongini, E. Eur. J. Med. Chem. 1993, 28, 569. 
(52) Zocchi, C.; Ongini, E.; Conti, A.; Monopoli, A.; Negretti, A.; Baraldi, P. 
G.; Dionisotti, S. J. Pharmacol. Exp. Ther. 1996, 276, 398. 
(53) Baraldi, P. G.; Cacciari, B.; Spalluto, G. P.; Bergonzoni, E.; Dionisotti, 
S.; Ongini, E.; Varani, K.; Borea, P. A. J. Med. Chem. 1998, 41, 2126. 
(54) Todde, S.; Moresco, R. M.; Simonelli, P.; Baraldi, P. G.; Cacciari, B.; 
Spalluto, G.; Varani, K.; Monopoli, A.; Matarrese, M.; Carpinelli, A.; Magni, 
F.; Galli, Kienle, M.; Fazio, F. J. Med. Chem. 2000, 43, 4359. 
(55) Baraldi, P. G.; Cacciari, B.; Romagnoli, R.; Spalluto, G.; Monopoli, A.; 
Ongini, E.; Varani, K.; Borea, P. A. J. Med. Chem. 2002, 45, 115. 
(56) Pinna, A.; Wardas, J.; Simola, N.; Morelli, M. Life Sci. 2005, 77, 3259. 
(57) Carta, A. R.; Tabrizi, M. A.; Baraldi, P. G.; Pinna, A.; Pala, P.; Morelli, 
M. Exp. Neurol. 2003, 184, 679. 
(58) Simola, N.; Fenu, S.; Baraldi, P. G.; Tabrizi, M. A.; Morelli, M. Exp. 
Neurol. 2006, 202, 255. 
(59) Silverman, L. S.; Caldwell, J. P.; Greenlee, W. J.; Kiselgof, E.; Matasi, J. 
J.; Tulshian, D. B.; Arik, L.; Foster, C.; Bertorelli, R.; Monopoli, A.; Ongini, E. 
Bioorg. Med. Chem. Lett. 2007, 17, 1659. 
References 
 
124 
(60) Neustadt, B. R.; Hao, J.; Lindo, N.; Greenlee, W. J.; Stamford, A. W.; 
Tulshian, D.; Ongini, E.; Hunter, J.; Monopoli, A.; Bertorelli, R.; Foster, C.; 
Arik, L.; Lachowicz, J.; Ng, K.; Feng, K.-I. Bioorg. Med. Chem. Lett. 2007, 
17, 1376. 
(61) Shimada, J.; Suzuki, F.; Nonaka, H.; Ishii, A.; Ichikawa, S. J. Med. 
Chem. 1992, 35, 2342. 
(62) Harada, H.; Asano, O.; Hoshino, Y. J. Med. Chem. 2001, 44, 170. 
(63) Jacobson, K. A.; Kim, H. O.; Siddiqi, S. M.; Olah, M. E.; Stiles, G. L., 
von Lubitz, D. K. J. E. Drugs Fut. 1995, 20, 689. 
(64) Jacobson, K. A.; Gallo-Rodriguez, C.; Melman, N.; Fischer, B.; Maillard, 
M.; van Bergen, A.; van Galen, P. J. M.; Karton, Y. J. J. Med. Chem. 1993, 
36, 1333. 
(65) Müller, C. E.; Geis, U.; Hipp, J.; Schober, U.; Frobeniu, W.; Pawlowski, 
M.; Suzuki, F.; Sandoval-Ramirez, J. J. Med. Chem. 1997, 40, 4396. 
(66) Weiss, S. M.; Benwell, K.; Cliffe, I. A.; Gillespie, R. J.; Knight, A. R.; 
Lerpiniere, J.; Misra, A.; Pratt, R. M.; Revell, D.; Upton, R.; Dourish, C. T. 
Neurology 2003, 61, S101. 
(67) Knutsen, L. J. S.; Weiss, S. M. Curr. Opin. InVestig. Drugs 2001, 2, 668. 
(68) Hirani, E.; Gillies, J.; Karasawa, A.; Shimada, J.; Kase, H.; Opacka- 
Juffry, J.; Osman, S.; Luthra, S. K.; Hume, S. P.; Brooks, D. J. Synapse 
2001, 42, 164. 
(69) Minetti, P.; Tinti, M. O.; Carminati, P.; Castorina, M.; Di Cesare, M. A.; 
Di Serio, S.; Gallo, G.; Ghirardi, O.; Giorgi, F.; Giorgi, L.; Piersanti, G.; 
Bartoccini, F.; Tarzia, G. J. Med. Chem. 2005, 48, 6887. 
(70) Schapira, A. H. V.; Bezard, E.; Brotchie, J.; Calon, F.; Collingridge, G. 
L.; Ferger, B.; Hengerer, B.; Hirsch, E.; Jenner, P.; Le Novere, N.; Obeso, J. 
A.; Schwarzschild, M. A.; Spampinato, U.; Davidai, G. Nat. ReV. Drug 
DiscoV. 2006, 5, 845. 
(71) Shiozaki, S.; Ichikawa, S.; Nakamura, J.; Kitamura, S.; Yamada, K.; 
Kuwana, Y. Psychopharmacology 1999, 147, 90. 
References 
 
125 
(72) Koga, K.; Kurokawa, M.; Ochi, M.; Nakamura, J.; Kuwana, Y. Eur. J. 
Pharmacol. 2000, 408, 249. 
(73) Aojama, S.; Kase, H.; Borrelli, Eur. J. Neurosci. 2000, 20, 5848. 
(74) Grondin, R.; Bedard, P. J.; Hadj Tahar, A.; Gregoire, L.; Mori, A.; Kase, 
H. Neurology 1999, 52, 1673. 
(75) Jenner, P. Expert Opin. InVestig. Drugs 2005, 14, 729. 
(76) Xiao, D.; Bastia, E.; Xu, Y.; Benn, C. L.; Cha, J. J.; Peterson, T. S.; 
Chen, J.; Schwarzschild, M. J. Neurosci. 2006, 26, 13548. 
(77) Shiozaki, S.; Scindo, M.; Kase, H.; Shimada, J. A method of treating 
behavioral disorders. WO Patent 2004058139, Jul 15, 2004. 
(78) Kase, H.; Seno, N.; Kase, J.; Kobayashi, M.; Shiozaki, S. A method of 
treating an anxiety disorder. WO Patent 2004108137, Dec 16, 2004. 
(79) Kase, H.; Nagakawa, Y.; Shiozaki, S.; Kobayashi, M.; Toki, S.; Seno, 
N.; Ikeda, K. Preventive and/or therapeutic agent for higher brain 
dysfunction. WO Patent 2005056016, Jun 23, 2005. 
(80) Kase, H.; Kobayashi, M.; Imoo, N.; Mori, A.; Shiozaki, S. Medicinal 
compositions. JP Patent 2005060370, Mar 10, 2005. 
(81) Kase, H.; Seno, N.; Mori, A.; Shiozaki, S. Medicinal compositions. WO 
Patent 2005009444, Feb 3, 2005. 
(82) Kase, H.; Takahashi, I.; Kunori, S.; Kobayashi, M.; Shiozaki, S.; 
Shirakura, S. Preventive and/or therapeutic agent for disease accompanied 
by chronic muscle/skeleton pain. WO Patent 2005094885, Oct 13, 2005. 
(83) Kase, J.; Kurokawa, M.; Shiozaki, S.; Seno, N. Preventive and/or 
therapeutic agent for drug dependence. WO Patent 2006059713, Jun 8, 
2006. 
(84) Neustadt, B. R.; Lindo, N. A.; Greenlee, W. J.; Chackalamannil, S.; 
Silverman, L. S.; Xia, Y.; Boyle, C. D.; Tulshian, D. Adenosine A2A receptor 
antagonists. WO Patent 2001092264, Dec 6, 2001. 
(85) Kadiwaki, T.; Kobayashi, M.; Shiozaki, S.; Seno, N. Prophylactic and/or 
therapeutic agent for motor disorder. WO Patent 2006132275, Dec 14, 2006. 
References 
 
126 
(86) Di Cesare, M. A.; Castorina, M.; Giorgi, F. Eur. Neuropsychopharmacol. 
2003, 13 (Suppl. 4), S397 
(87) Rose, S.; Jackson, M. J.; Smith, L. A.; Stockwell, K.; Johnson, L.; 
Carminati, P.; Jenner, P. Eur. J. Pharmacol. 2006, 546, 82. 
(88) Rose, S.; Ramsay Croft, N.; Jenner, P. Brain Res. 2007, 1133, 110. 
(89) Stasi, M. A.; Borsini, F.; Varani, K.; Vincenzi, F.; Di Cesare, M. A.; 
Minetti, P.; Ghirardi, O.; Carminati, P. Int. J. Neuropsychopharmacol. 2006, 
9, 575. 
(90) Tronci, E.; Simola, N.; Borsini, F.; Schintu, N.; Frau, L.; Carminati, P.; 
Morelli, M. Eur. J. Pharmacol. 2007, 566, 94. 
(91) Tarzia, G.; Piersanti, G.; Minetti, P.; Giorni, L.; Gallo, G.; Giorni, F.; Di 
Cesare, M. A. Derivatives of triazolyl-imidazopyridine and of the 
triazolylpurines useful as ligands of the adenosine A2a receptor and their 
use as medicaments. WO Patent 2003011864, Feb 13, 2003. 
(92) Zhou, Q. Y.; Li, C.; Olah, M. E.; Johnson, R. A.; Stiles, G. L.; Civelli, O. 
Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 7432. 
(93) Meyerhof, W.; Mu¨ller-Brechlin, R.; Richter, D. FEBS Lett. 1991, 284, 
155. 
(94) Palmer, T. M.; Stiles, G. L. Neuropharmacology 1995, 34, 683. 
(95) Ramkumar, V.; Stiles, G. L.; Beaven, M. A.; Ali, H. J. Biol. Chem. 1993, 
268, 16887. 
(96) Abbracchio, M. P.; Brambilla, R.; Ceruti, S.; Kim, H. O.; Von Lubitz, D. 
K.; Jacobson, K. A.; Cattabeni, F. Mol. Pharmacol. 1995, 64, 445. 
(97) Salvatore, C. A.; Jacobson, M. A.; Taylor, H. E.; Linden, J.; Johnson, R. 
G. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 10365. 
(98) Linden, J. Trends Pharmacol. Sci. 1994, 15, 298. 
(99) Rivkees, S. A. Endocrinology 1994, 135, 2307. 
(100) Dixon, A. K.; Gubitz, A. K.; Sirinathsinghji, D. J. S.; Richardson, P. J.; 
Freeman, T. C. Br. J. Pharmacol. 1996, 118, 1461. 
(101) Tabella delia 
(102) Tabella delia 
References 
 
127 
(103)Fedorova, I. M.; Jacobson, M. A.; Basile, Q. A.; Jacobson, K. A. Cell. 
Mol. Neurobiol. 2003, 23, 431. 
(104) Headrick, J. P.; Peart, J. Vasc. Pharmacol. 2005, 42, 271. 
(105) Ge, Z.-D.; Peart, J. N.; Kreckler, L. M.; Wan, T. C.; Jacobson, M. A.; 
Gross, G. J.; Auchampach, J. A. J. Pharm. Exp. Ther. 2006, 319, 1200. 
(106) Black, R. G., Jr.; Guo, Y.; Ge, Z.-D.; Murphree, S. S.; Prabhu, S. 
D.; Jones, W. K.; Bolli, R.; Auchampach, J. A. Circ. Res. 2002, 91, 165. 
(107) Funakoshi, H.; Chan, T. O.; Good, J. C.; Libonati, J. R.; Piuhola, J.; 
Chen, X.; MacDonnel, S. M.; Lee, L. L.; Herrmann, D. E.; Zhang, J.; Martini, 
J.; Palmer, T. M.; Sanbe, A.; Robbins, J.; Houser, S. R.; Koch, W. J.; 
Feldman, A. M. Circulation 2006, 114, 2240. 
(108) Gessi, S.; Varani, K.; Merighi, S.; Cattabriga, E.; Iannotta, V.; Leung, 
E.; Baraldi, P. G.; Borea, P. A. Mol. Pharmacol. 2002, 61, 415. 
(109) Le Vraux, V.; Chen, Y. L.; Masson, I.; De Sousa, M.; Giroud, J. P.; 
Florentin, I.; Chauvelot-Moachon, L. Life Sci. 1993, 52, 1917. 
(110) Ezeamuzie, C. I.; Philips, E. Br. J. Pharm. 1999, 127, 188. 
(111) Young, H. W.; Molina, J. G.; Dimina, D.; Zhong, H.; Jacobson, M.; 
Chan, L. N.; Chan, T. S.; Lee, J. J.; Blackburn, M. R. J. Immunol. 2004, 173, 
1380. 
(112) Merighi, S.; Mirandola, P.; Varani, K.; Gessi, S.; Leung, E.; Baraldi, P. 
G.; Tabrizi, M. A.; Borea, P. A. Pharmacol. Ther. 2003, 100, 31. 
(113) Jacobson, K. A. Trends Pharmacol. Sci. 1998, 19, 184. 
(114) Yao, Y.; Sei, Y.; Abbracchio, M. P.; Jiang, J. L.; Kim, Y. C.; Jacobson, 
K. A. Biochem. Biophys. Res. Commun. 1997, 232, 317. 
(115) Gao, Z.; Li, B. S.; Day, Y. J.; Linden, J. Mol. Pharmacol. 2001, 59, 76. 
(116) Merighi, S.; Benini, A.; Mirandola, P.; Gessi, S.; Varani, K.; Leung, E.; 
Maclennan, S.; Borea, P. A. J. Biol. Chem. 2005, 280, 19516. 
(117) Fishman, P.; Bar-Yehuda, S.; Ohana, G.; Barer, F.; Ochaion, A.; 
Erlanger, A.; Madi, L. Oncogene 2004, 23, 2465. 
(118) Merighi, S.; Benini, A.; Mirandola, P.; Gessi, S.; Varani, K.; Leung, E.; 
Maclennan, S.; Borea, P. A. Biochem. Pharmacol. 2006, 72, 19. 
References 
 
128 
(119) Gessi, S.; Cattabriga, E.; Avitabile, A.; Gafa’, R.; Lanza, G.; Cavazzini, 
L.; Bianchi, N.; Gambari, R.; Feo, C.; Liboni, A.; Gullini, S.; Leung, E.; Mac-
Lennan, S.; Borea, P. A. Clin. Cancer Res. 2004, 10, 5895. 
(120) Baharav, E.; Bar-Yehuda, S.; Madi, L.; Silberman, D.; Rath-Wolfson, 
L.; Halpren, M.; Ochaion, A.; Weinberger, A.; Fishman, P. J. Rheumatol. 
2005, 32, 469. 
(121) Fishman, P.; Bar-Yehuda, S.; Madi, L.; Rath-Wolfson, L.; Ochaion, A.; 
Cohen, S.; Baharav, E. Arthritis Res. Ther. 2006, 8, R33. 
(122) Avila, M. Y.; Stone, R. A.; Civan, M. M. InVest. Ophtalmol. Vis. Sci. 
2002, 43, 3021. 
(123) Yang, H.; Avila, M. Y.; Peterson-Yantorno, K.; Coca-Prados, M.; 
Stone, R. A.; Jacobson, K. A.; Civan, M. M. Curr. Eye Res. 2005, 30, 747. 
(124) Baraldi, P. G.; Cacciari, B.; Romagnoli, R.; Merighi, S.; Varani, K.; 
Borea, P. A.; Spalluto, G. Med. Res. ReV. 2000, 20, 103. 
(125) Priego, E. M.; von Frijtag Drabbe Kuenzel, J.; IJzerman, A. P.; 
Camarasa, M. J.; Maria-Perez-Perez, M. J. J. Med. Chem. 2002, 45, 3440. 
(126) Ozola, V.; Thorand, M.; Diekmann, M.; Qurishi, R.; Schumacher, B.; 
Jacobson, K. A.; Müller, C. E. Bioorg. Med. Chem. 2003, 11, 347. 
(127) Saki, M.; Tsumuki, H.; Nonaka, H.; Shimada, J.; Ichimura, M. Eur. J. 
Pharmacol. 2002, 444, 133. 
(128) Baraldi, P. G.; Preti, D.; Aghazadeh Tabrizi, M.; Fruttarolo, F.; 
Romagnoli, R.; Abdel Zaid, N.; Moorman, A. R.; Merighi, S.; Varani, K.; 
Borea, P. A. J. Med. Chem. 2005, 48, 4697. 
(129) Okamura, T.; Kurogi, Y.; Nishikawa, H.; Hashimoto, K.; Fujiwara, H.; 
Nagao, Y. J. Med. Chem.; 2002; 45, 3703. 
(130) Okamura, T.; Kurogi, Y.; Hashimoto, K.; Nishikawa, H.; Nagao, Y. 
Bioorg. Med. Chem. Lett. 2004, 14, 2443. 
(131) Hu, P. S.; Lindgren, E.; Jacobson, K. A.; Fredholm, B. B. Pharmacol. 
Toxicol. 1987, 61, 121. 
(132) Ismail, N. A.; Shaheen, A. A.; El-Sawalhi, M. M.; Megahed, Y. M. 
Arzneim.-Forsch./Drug Res. 1995, 45, 865. 
References 
 
129 
(133) Van Rhee, A. M.; Jiang, J.-L.; Melman, N.; Olah, M. E.; Stiles, G. L.; 
Jacobson, K. A. J. Med. Chem. 1996, 39, 2980. 
(134) Jiang, J. L.; van Rhee, A. M.; Cheng, L.; Patchornik, A.; Ji, X.-D.; 
Evans, P.; Melman, N.; Jacobson, K. A. J. Med. Chem. 1997, 40, 2596. 
(135) Li, A. H.; Moro, S.; Melman, N.; Ji, X.-D.; Jacobson, K. A. J. Med. 
Chem. 1998, 41, 3186. 
(136) Daly, J. W.; Jacobson, K. A. Drug DeV. Res. 1994, 31, Abst 1339. 
(137) Kim, Y.-C.; Ji, X.-D.; Jacobson, K. A. J. Med. Chem. 1996, 39, 4142. 
(138) Varani, K.; Merighi, S.; Gessi, S.; Klotz, K. N.; Leung, E.; Baraldi, P. 
G.; Cacciari, B.; Romagnoli, R.; Spalluto, G.; Borea, P. A. Mol. Pharmacol. 
2000, 57, 968. 
(139) Baraldi, P. G.; Cacciari, B.; Moro, S.; Spalluto, G.; Pastorin, G.; Da 
Ros, T.; Klotz, K. N.; Varani, K.; Gessi, S.; Borea, P. A. J. Med. Chem. 2002, 
45, 770. 
(140) Baraldi, P. G.; Cacciari, B.; Romagnoli, R.; Spalluto, G.; Klotz, K. N.; 
Leung, E.; Varani, K.; Gessi, S.; Merighi, S.; Borea, P. A. J. Med. Chem. 
1999, 42, 4474. 
(141) Baraldi, P. G.; Cacciari, B.; Romagnoli, R.; Spalluto, G.; Moro, S.; 
Klotz, K.-N.; Leung, E.; Varani, K.; Gessi, S.; Merighi, S.; Borea, P. A. J. 
Med. Chem. 2000, 43, 4768. 
(142) Baraldi, P. G.; Cacciari, B.; Romagnoli, R.; Varani, K.; Gessi, S.; 
Merighi, S.; Borea, P. A.; Leung, E.; Hickey, S. L.; Spallato, G. Bioorg. Med. 
Chem. Lett. 2000, 10, 209. 
(143) Maconi, A.; Pastorin, G.; Da Ros, T.; Spalluto, G.; Gao, Z.-G.; 
Jacobson, K. A.; Baraldi, P. G.; Cacciari, B.; Varani, K.; Moro, S.; Borea, P. 
A. J. Med. Chem. 2002, 45, 3579. 
(144) Moro, S.; Braiuca, P.; Deflorian, F.; Ferrari, C.; Pastorin, G.; Cacciari, 
B.; Baraldi, P. G.; Varani, K.; Borea, P. A.; Spalluto, G. J. Med. Chem. 2005, 
48, 152. 
(145) Moro, S.; Deflorian, F.; Bacilieri1, M.; Spalluto, G. Curr. Med. Chem. 
2006, 13, 639. 
References 
 
130 
(146) Tafi, A.; Bernardini, C.; Botta, M.; Corelli, F.; Andreini, M.; Martinelli, 
A.; Ortore, G.; Baraldi, P. G.; Fruttarolo, F.; Borea, P. A.; Tuccinardi, T. J. 
Med. Chem. 2006, 49, 4085. 
(147) Baraldi, P. G.; Cacciari, B.; Romagnoli, R.; Ji, X.-D.; Jacobson, K. A.; 
Gessi, S.; Borea, P. A.; Spalluto, G. J. Med. Chem. 2001, 44, 2735. 
(148) van Muijlwijk-Koezen, J. E.; Timmerman, H.; van der Goot, H.; Menge 
Wiro, M. P. B.; Frijtag von Drabbe Ku¨nzel, J.; de Groote, M.; IJzerman, A. P. 
J. Med. Chem. 2000, 43, 2227. 
(149) Baraldi, P. G.; Borea, P. A. Trends Pharmacol. Sci. 2000, 21, 456. 
(150) Leung, E. The use of adenosine A3 receptor antagonists to inhibit 
tumor growth. WO Patent 2000010391, Mar 2, 2000. 
(151) Borea, P. A.; Leung, E.; Chen, S. F.; Baraldi, P. G. Enhancing 
treatment of MDR cancer with adenosine A3 antagonists. WO Patent 
2004000224, Dec 31, 2003. 
(152) Baraldi, P. G.; Borea, P. A. Adenosine A3 receptor modulators. WO 
Patent 2003095457, Nov 20, 2003. 
(153) Urbahns, K.; Heine, H.-G.; Junge, B.; Mauler, F.; Glaser, T.; Wittka, R.; 
De Vry, J.-M.-V. Substituted 4H-pyrans with a modulating effect on 
potassium channels. CA Patent 2183048, Feb 15, 1997. 
(154) Tsumuki, H.; Saki, M.; Nonaka, H.; Ichimura, M.; Shimada, J.; Suzuki, 
F.; Ichikawa, S.; Kosaka, N. Fused purine derivatives. WO Patent 
1998015555, Apr 16, 1998. 
(155) Kuefner-Muehl, U.; Scheuplein, S. W.; Pohl, G.; Meade, C. J. M.; Lehr, 
E.; Mierau, J.; Gaida, W. Triazines with an adenosine antagonistic effect. 
WO Patent 1999011633, Mar 11, 1999. 
(156) Ohkawa, S.; Miwatashi, S.; Kanzaki, N. 5-Pyridyl-1,3-azole 
compounds, process for producing the same and use thereof. WO Patent 
2000064894, Nov 2, 2000. 
(157) Okamura, T.; Nishikawa, H.; Kurogi, Y. Triazolopurine derivatives, 
medicinal composition containing the derivatives, adenosine A3 receptor 
References 
 
131 
compatibilizing agent, and asthmatic remedy. WO Patent 1999051606, Oct 
14, 1999. 
(158) Castelhano, A. L.; Witter, D. J.; McKibben, B. Compounds specific 
to adenosine A1, A2A, and A3 receptor and uses thereof. WO Patent 
2001039777, Jun 7, 2001. 
(159) Heng, R.; Press, N. J.; Keller, T. H. Aryl pyridinyl thiazoles. WO Patent 
1999064418, Dec 16, 1999. 
(160) Baraldi, P. G.; Tabrizi M. A.; Romagnoli, R.; El-Kashef, H.; Preti, D.; 
Bovero, A.; Fruttarolo, F.; Gordaliza, M.; Borea, P. A. Cur. Org. Chem. 2006, 
10, 259. 
(161) Zimmerman, M. N.; Nemeroff, N. H.; Bock, C. W.: Bhat, K. L. 
Heterocycles. 2000, 53, 205. 
(162) Seneci, P.; Nicola, M.; Inglesi, M.; Vanotti, E.; Resnati, G. Synth. 
Commun. 1999, 29, 311. 
(163) Suzuki, F; Shimada, J.; Nonaka, H.; Ishii, A.; Shiozaki, S.; Ichikawa, 
S.; Ono, E. J. Med. Chem., 1992, 35, 3578.  
(164) Vu, C. B.; Kiesman, W. F.; Colon, P. R.; Lin, K. C.; Tam, M.; Setter, R. 
C.; Smits, G.; Lutterodt, F.; Jin, X.; Chen, L.; Zhang, J. J Med Chem. 2006, 
49, 7132. 
(165) Müller, C. E.; Thorand, M.; Qurishi, R.; Diekmann, M.; Jacobson, K. A.; 
Padgett, W. L.; Daly, J. W. J. Med. Chem. 2002, 45, 3440. 
(166) Müller, C. E.; Diekmann, M.; Thorand, M.; Ozola, V. Bioorg. Med. 
Chem. Lett. 2002, 12, 501. 
(167) Baraldi, P. G.; Tabrizi, M. A.; Preti, D.; Bovero, A.; Romagnoli, R.; 
Fruttarolo, F.; Zaid, N. A.; Moorman, A. R.; Varani, K.; Gessi, S.; Merighi, S.; 
Borea, P. A. J. Med. Chem. 2004, 47, 1434. 
(168) Kim, Y. C.; Ji, X.; Melman, N.; Linden, J.; Jacobson, K. A. J. Med. 
Chem. 2000, 43, 1165. 
(169) Shimada, J.; Kuroda, T.; Suzuki, F. J. Heterocycl. Chem. 1993, 30, 
241. 
(170) Papesch, V.; Schroeder, E. F. J. Org. Chem. 1951, 16, 1879. 
References 
 
132 
(171) Schmidt, A.; Habeck, T.; Kindermann, M. K.; Nieger, M. J. Org. Chem. 
2003, 68, 5977. 
(172) Frey, M.; Jäger, V. Synthesis, 1985, 12, 1100. 
 
